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Executive summary 
Introduction 
Health problem 
This systematic review focuses on the treatment of chondral and osteochondral 
lesions in the knee and ankle joint. 
Articular (chondral) cartilage is a thin layer of connective tissue. It provides 
a smooth surface for articulation and facilitates the transmission of forces to 
the underlying subchondral bone.  
A damage of the cartilage can occur due to traumatic events or degeneration 
of the joint or due to osteochondritis dissecans (OCD). The damage can also 
affect the underlying bone (i.e., osteochondral lesion). 
Description of technology 
AMIC 
In the single-step scaffold-based treatment (AMIC) of cartilage defects, a ma-
trix is implanted in the area of the damaged cartilage. The used matrix acts 
as a temporary structure to allow the cells to be seeded and establish a three-
dimensional structure. The matrix decomposes over time. 
MACI 
In the two-step scaffold-based treatment (MACI) of cartilage defects, firstly, 
intact cartilage is sampled arthroscopically from a non-weight-bearing area 
of the affected cartilage. The generated cells are then cultured in vitro until 
there are enough cells to be re-implanted into the cartilage lesion. Chondro-
cytes are pre-seeded in a scaffold matrix (e.g., collagen matrix, hyaluronan 
matrix), which is then implanted in the defect. 
Research question 
In this report, we analysed whether the single- or the two-step scaffold-based 
cartilage repair (AMIC/MACI) is more effective and safe in comparison to 
microfracturing (MFx) or as effective but safer in comparison to autologous 
chondrocyte implantation (ACI). 
 
Methods 
Answering the research questions regarding efficacy and safety-related out-
comes was based on a systematic literature search from different databases 
and an additional hand search. The study selection, data extraction and assess-
ing the methodological quality of the studies was performed by two review 
authors, independently from each other. 
Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a re-
commendation: mobility/joint functionality, quality of life, pain and necessity 
of total joint replacement. 
focus: defects in the 
knee & ankle joint 
cartilage is a thin layer 
of connective tissue 
cartilage damages  
due to traumatic events 
or degeneration 
single-step scaffold-
based treatment in 
combination with 
microfracturing (MFx) 
two-step scaffold based 
treatment: cell-free 
matrix as support for 
settlement of cells 
MFx & autologous 
chondrocyte 
implantation (ACI)  
as comparator 
systematic literature 
search, selection, 
extraction, and quality 
appraisal by at least  
two authors 
mobility/joint 
functionality, quality of 
life, pain and necessity 
for joint replacement 
for effectiveness 
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Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: severe adverse events, procedure-related complications, device-
related complications and re-operation rate. 
 
Results 
Available evidence 
We could not identify any controlled trials comparing the single- or the two-
step scaffold-assisted treatment of (osteo)chondral defects in the ankle joint. 
The only studies that met our inclusion criteria were five randomised con-
trolled trials (RCTs) and one non-randomised controlled trial (NRCT) of 
the single-step scaffold-assisted treatment (AMIC) in the knee joint (scaffold 
groups) in combination with MFx (187 patients), compared to MFx alone 
(127 patients) (MFx groups). For the evaluation of the efficacy of the two-
step scaffold-assisted treatment (MACI), five RCTs with a total of 330 pa-
tients (184 vs. 146 [92 with MFx, 54 with ACI]) were included. For the safety 
assessment nearly the same five RCTs with a total of 346 patients (191 vs. 
155 [101 with MFx, 54 with ACI]) were included. 
Clinical effectiveness 
AMIC 
Different scores measuring the effect of AMIC on mobility/joint functionality, 
quality of life and pain in comparison to MFx were reported in the included 
studies. With regard to mobility/joint functionality, inconsistent results were 
reported across the scores. For quality of life, the intervention groups showed 
an improvement; however, this improvement was not statistically significant. 
For pain, similar improvements were reported between the study groups across 
the studies. 
Furthermore, in only one study, the necessity of a total joint replacement was 
addressed. In this study, one total knee arthroplasty was reported after 12 
months. 
MACI 
Different scores measuring the effect of MACI on mobility/joint functionali-
ty, quality of life and pain were reported in the included studies. For the 
comparison, MACI versus MFx, some statistically significant improvements 
in joint functionality, quality of life and pain were reported for the interven-
tion groups across scores and studies. 
Moreover, in only one study, the necessity of a total joint replacement was 
addressed. In this study, one total knee arthroplasty was reported after 12 
months. 
For the comparison, MACI versus ACI, inconsistent results regarding im-
provements in joint functionality were reported across scores and studies. 
For pain, no statistically significant differences between the study groups 
could be identified. There was no evidence available regarding the outcomes 
quality of life and necessity of a total joint replacement. 
severe adverse events, 
complications and re-
operation rate for safety 
no controlled evidence 
for ankle joint 
5 RCTs & 1 NRCT for 
AMIC (187 vs. 127 pts.),  
5 RCTs for efficacy of 
MACI (184 vs. 146),  
5 RCTs for safety of 
MACI (191 vs. 155) 
no statistically 
significant differences 
between study groups 
for functionality,  
quality of life and pain 
1 necessity of total joint 
replacement reported in 
1 study 
MACI vs. MFx: partly 
statistically significant 
improvements in 
intervention groups 
1 necessity of total joint 
replacement reported in 
1 study 
MACI vs. ACI: 
inconsistent results 
regarding functionality, 
no significant results  
for pain 
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Safety 
AMIC 
Complications were reported in all extracted studies. Severe adverse event 
rates ranged from 0-12.2% in the intervention groups and from 0-3.8% in the 
control groups of three studies. Procedure-related adverse events occurred in 
0-93.0% of the patients in the intervention groups (0-77.0% in the control 
groups) across four studies. The rates for device-related complications differed 
from 3.0 to 22.0% across three studies. 
MACI 
Complications were reported in all three studies comparing MACI to MFx. 
Severe adverse event rates ranged from 4.8-15.3% in the intervention groups 
and from 11.1-26.4% in the control groups across the three studies. Proce-
dure-related adverse events occurred in 0-34.7% of the patients in the scaf-
fold groups (0-38.9% in the control groups) across three studies. No evidence 
was available for device-related complications. In addition, re-operation rates 
were reported in three RCTs ranging from 2.5-8.3% versus 0-9.7%. 
Furthermore, complications were reported in both studies comparing MACI 
to ACI. Severe adverse event rates ranged from 0-9.0% in the intervention 
groups, while zero events occurred in the control groups of the studies. No 
procedure-related adverse events were reported in the two RCTs. The rates 
for device-related complications differed from 12.5-36.4% in the intervention 
groups and from 9.0-140% in the control groups. The reported re-operation 
rates ranged from 6.4-27.3% versus 6.8-10.0% between the study groups. 
Upcoming evidence 
Currently, there are six registered ongoing RCTs of the single-step/two-step 
scaffold-based cartilage repair (AMIC/MACI) versus MFx. However, the ma-
jority of these studies will not provide long-term follow-up of more than 24 
months, and thus, will not fill the gap of long-term evidence exceeding 24 
months. 
No ongoing RCTs or NRCTs investigating the clinical efficacy and safety of 
AMIC/MACI compared to ACI could be identified. Further, no ongoing 
RCTs or NRCTs for the assessment of both interventions for the ankle joint 
could be identified. 
Reimbursement 
At this point in time, the single-step repair (AMIC) of cartilage defects or os-
teochondritis dissecans (OCD) or (osteo)chondral lesions in the knee or an-
kle joint is not reimbursed by the Austrian health care system. The two-step 
matrix-induced procedure (MACI) can be billed with the code for the culti-
vation of autologous chondrocytes and therefore, it is included in the Austri-
an hospital benefit catalogue. 
  
AMIC vs. MFx:  
severe adverse events: 
0-12.2% vs. 0-3.8%, 
procedure-related:  
0-93.0% vs.  
0-77.0%, device-related: 
3.0-22.0% in 
intervention group 
MACI vs. MFx:  
severe adverse events: 
4.8-15.3% vs. 11.1-26.4%, 
procedure-related:  
0-34.7% vs. 0-38.9%,  
re-operation:  
2.5-8.3% vs. 0-9.7% 
 
MACI vs. ACI:  
severe adverse events: 
0-9.0% vs. 0%,  
device-related:  
12.5-36.4% vs. 9.0-140%, 
re-operation:  
6.4-27.3% vs. 6.8-10.0% 
6 ongoing RCTs for 
AMIC/MACI vs. MFx 
no ongoing RCTs or 
NRCTs for AMIC/MACI 
vs. ACI, or the ankle 
joint 
AMIC not reimbursed in 
Austria, MACI included 
in hospital benefit 
catalogue 
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Discussion 
Overall, the strength of evidence for the efficacy and safety of the single-step 
scaffold-based cartilage repair (AMIC) of the knee in combination with MFx 
compared to MFx alone is moderate and low, respectively. The strength of 
evidence for the efficacy and safety of the two-step scaffold-assisted cartilage 
repair (MACI) of the knee in compared to MFx or ACI is low and very low, 
respectively. 
Regarding the evidence of AMIC versus MFx alone, major limitations of the 
identified trials were the low number of patients of each study and the short 
follow-up periods (below five years) in the majority of the studies. Only two 
out of five studies had a follow-up of at least five years. 
With reference to the evidence of MACI versus MFx or ACI, similar to the 
AMIC studies, a major issue of the identified studies was the low number of 
patients. Furthermore, only one study (in comparison to MFx) had a follow-
up longer than 24 months. Therefore, long-term evidence is lacking. 
The majority of the efficacy outcomes (mobility/joint functionality, quality 
of life, pain and activities of daily living) were patient-reported outcomes, 
and thus, might be confounded. Therefore, the level of subjectiveness was 
taken into account within the risk of bias assessment. 
Moreover, due to the incomprehensive or inconsistent screening, recording 
and/or reporting of adverse events across the majority of included studies for 
all comparisons aggregated statements on the safety were barely possible. 
Overall, reliable data of long-term efficacy and safety-related outcomes are 
missing. 
 
Conclusion 
The current evidence is not sufficient to conclude that the single- or the two-
step matrix-assisted cartilage repair is more effective and safer than MFx or 
as effective, but safer than ACI. 
As no controlled evidence could be identified for the cartilage repair of the 
ankle joint, it was not possible to give a recommendation about whether AMIC 
and/or MACI should be considered for the inclusion into the Austrian hos-
pital benefit catalogue for the ankle joint. 
Due to inconsistent outcome reporting, the included studies showed partly 
poor quality of evidence and high risk of bias. Hence, it is not possible to 
draw a reliable conclusion on the clinical effectiveness and safety for both 
interventions investigated. As a result, AMIC and MACI are currently not 
recommended for the inclusion in the Austrian hospital benefit catalogue. 
New study results, especially from studies with larger patient numbers and 
longer follow-up periods (e.g., ten years), will potentially influence the effect 
estimate considerably. 
A re-evaluation for AMIC is recommended not before 2022 since there are 
still ongoing RCTs. For MACI a re-evaluation might be reasonable not be-
fore 2021, as the technique seems to be promising compared to MFx. 
 
  
quality of evidence 
AMIC: moderate 
efficacy and low safety,  
quality of evidence 
MACI: low efficacy and 
very low safety 
AMIC vs. MFx alone: 
few pts. and short 
follow-ups 
MACI vs. MFx/ACI:  
few pts. and short 
follow-ups 
patient-reported 
efficacy outcomes – 
level of subjectiveness 
in addition, inconsistent 
adverse event reporting 
lacking long-term 
efficacy and safety 
results 
evidence not sufficient 
 reliable conclusion 
not possible 
no evidence for  
the ankle joint  
 no recommendation 
poor quality of evidence 
 AMIC & MACI 
currently not 
recommended for 
reimbursement 
studies with larger 
patient numbers & 
longer follow-up needed 
re-evaluation AMIC 
after 2022; 
re-evaluation MACI 
after 2021 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
In der vorliegenden systematischen Übersichtsarbeit liegt der Fokus auf der 
Behandlung von chondralen und osteochondralen Läsionen im Knie- und 
Sprunggelenk. 
Der Gelenksknorpel ist eine dünne Bindegewebsschicht. Diese bietet eine 
glatte Oberfläche für die Artikulation und erleichtert die Kraftübertragung 
auf den darunterliegenden (subchondralen) Knochen. 
Eine Schädigung des Knorpels kann durch traumatische Ereignisse, einer 
Degeneration des Gelenks oder durch Osteochondritis dissecans (OCD) ent-
stehen. Die Schädigung kann auch den darunterliegenden Knochen beein-
flussen (osteochondrale Läsion). 
Beschreibung der Technologie 
Einzeitiges Verfahren (AMIC) 
Bei der einzeitigen Matrix-basierten Behandlung von Knorpeldefekten (AMIC) 
wird nach einer durchgeführten Mikrofrakturierung (MFx) im Bereich des 
geschädigten Knorpels eine Matrix implantiert. Die verwendete Matrix fun-
giert als temporäre Struktur, um das Keimen der Zellen zu unterstützen und 
dadurch eine dreidimensionale Struktur aufzubauen. Die Matrix zersetzt sich 
im Laufe der Zeit. 
Zweizeitiges Verfahren (MACI) 
Bei der zweizeitigen Matrix-unterstützten Behandlung von Knorpeldefekten 
(MACI) wird in einem ersten Schritt intakter Knorpel arthroskopisch aus 
einem nicht belasteten Bereich des betroffenen Knorpels entnommen. In ei-
nem zweiten Schritt werden die Zellen (Chondrozyten) in vitro auf einer Ma-
trix (z. B. Kollagenmatrix, Hyaluronmatrix) kultiviert, bis genügend Zellen 
vorhanden sind, um anschließend in den geschädigten Knorpel re-implan-
tiert zu werden. 
Forschungsfrage 
Ziel des Berichtes war es, zu untersuchen, ob die ein- oder zweizeitige Ma-
trix-unterstützte Knorpelreparatur (AMIC bzw. MACI) im Vergleich zur 
Mikrofrakturierung (MFx) effektiver und sicherer bzw. im Vergleich zur 
autologen Chondrozytenimplantation (ACI) zumindest gleich wirksam und 
sicherer ist. 
 
Methode 
Die Beantwortung der Forschungsfragen bezüglich der Wirksamkeit und Si-
cherheit von AMIC bzw. MACI beruhte auf einer systematischen Literatur-
recherche in verschiedenen Datenbanken und einer zusätzlichen Handsu-
che. Die Auswahl der Studien, die Datenextraktion und die Bewertung der 
Qualität der Studien wurden von zwei Autorinnen unabhängig voneinander 
durchgeführt. 
Fokus: Defekte im  
Knie- und Sprunggelenk 
Knorpel ist eine  
dünne Schicht aus 
Bindegewebe 
Knorpelschäden durch 
traumatische Ereignisse 
oder Degeneration 
einzeitige Behandlung 
mit Hilfe einer Matrix  
in Kombination mit 
Mikrofrakturierung 
zweistufige Behandlung 
mit Hilfe einer zellfreien 
Matrix als Unterstützung 
für die Zell-ansiedlung 
AMIC bzw. MACI  
versus MFx bzw. ACI 
systematische 
Literaturrecherche,  
-auswahl, -extraktion 
und -bewertung von 
mindestens zwei 
Autorinnen 
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Klinische Wirksamkeit 
Die folgenden entscheidungsrelevanten Endpunkte wurden für die Bewertung 
der Wirksamkeit herangezogen: Mobilität/Gelenksfunktionalität, Lebensqua-
lität, Schmerz und Notwendigkeit eines totalen Gelenkersatzes. 
Sicherheit 
Die folgenden entscheidungsrelevanten Endpunkte wurden für die Bewertung 
der Sicherheit berücksichtigt: schwerwiegende unerwünschte Ereignisse, ein-
griffsbezogene Komplikationen, Komplikationen im Zusammenhang mit der 
Matrix (implantatsbezogen) und Re-operationsraten. 
 
Ergebnisse 
Verfügbare Evidenz 
Es konnten keine kontrollierten Studien identifiziert werden, in denen die 
ein- oder zweizeitige Matrix-gestützte Behandlung von (osteo)chondralen De-
fekten im Sprunggelenk untersucht wurde. 
In Bezug auf die einzeitige Matrix-unterstützte Knorpelreparatur (AMIC) 
im Kniegelenk erfüllten lediglich fünf randomisierte kontrollierte Studien 
(RCTs) und eine nicht randomisierte kontrollierte Studie (NRCT) die Ein-
schlusskriterien. Insgesamt umfassten die sechs Studien 187 PatientInnen, 
die dem einzeitigen Verfahren unterzogen wurden, und 127 PatientInnen, die 
lediglich die alleinige MFx erhielten. Bezüglich der zweizeitigen Matrix-un-
terstützten Behandlung (MACI) im Kniegelenk erfüllten jeweils fünf RCTs 
die Einschlusskriterien. Insgesamt umfassten die fünf RCTs zur Bewertung 
der Wirksamkeit 330 PatientInnen (184 vs. 146 [92 mit MFx, 54 mit ACI]). 
Die fünf RCTs zur Bewertung der Sicherheit umfassten 346 PatientInnen 
(191 vs. 155 [101 mit MFx, 54 mit ACI]). 
Klinische Wirksamkeit 
Einzeitiges Verfahren (AMIC) 
In den sechs eingeschlossenen Studien wurden unterschiedliche Scores zur 
Messung der Wirksamkeit von AMIC im Vergleich zur alleinigen MFx be-
richtet: In Bezug auf den Wirksamkeitsendpunkt „Mobilität/Gelenkfunktio-
nalität“ resultierte die Auswertung der Scores in inkonsistenten Ergebnissen. 
Bezüglich des Endpunktes „Lebensqualität“ konnte für die Interventions-
gruppen eine Verbesserung festgestellt werden. Diese Verbesserung war je-
doch nicht statistisch signifikant. In Bezug auf den Endpunkt „Schmerz“ wur-
den über die Studien hinweg ähnliche Verbesserungen zwischen den Studi-
engruppen berichtet. 
In einer der sechs eingeschlossenen Studien wurde der Endpunkt „Notwen-
digkeit eines vollständigen Gelenkersatzes“ berichtet. In dieser Studie wur-
de ein totaler Kniegelenksersatz nach 12 Monaten gemeldet (Studiengruppe 
unklar). 
 
entscheidungsrelevante 
Endpunkte für 
Wirksamkeit 
entscheidungsrelevante 
Endpunkte für 
Sicherheit 
keine kontrollierten 
Studien zum 
Sprunggelenk 
5 RCTs & 1 NRCT  
für AMIC (187 vs. 127 
PatientInnen),  
5 RCTs für Wirksamkeit 
von MACI (184 vs. 146 
PatientInnen),  
5 RCTs für Sicherheit 
von MACI (191 vs. 155 
PatientInnen) 
keine statistisch 
signifikanten 
Unterschiede zwischen 
den Studiengruppen 
hinsichtlich 
Funktionalität, 
Lebensqualität und 
Schmerzen 
1 totaler Gelenkersatz  
in einer Studie 
Zusammenfassung 
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Zweizeitiges Verfahren (MACI) 
In den fünf eingeschlossenen Studien wurden unterschiedliche Scores zur 
Messung der Wirksamkeit von MACI bezüglich der Mobilität/Gelenksfunk-
tionalität, der Lebensqualität und der Schmerzen herangezogen. Für den Ver-
gleich, MACI versus MFx, wurden für die Interventionsgruppen teilweise 
statistisch signifikante Verbesserungen der Gelenkfunktionalität, der Lebens-
qualität und der Schmerzen berichtet. 
In nur einer Studie (MACI vs. MFx) wurde der Endpunkt „Notwendigkeit 
eines vollständigen Gelenkersatzes“ berichtet. In dieser Studie wurde nach 
12 Monaten ein Fall eines totalen Kniegelenksersatzes in der Interventions-
gruppe gemeldet. 
Für den Vergleich, MACI versus ACI, wurden über die unterschiedlichen 
Scores und Studien hinweg inkonsistente Ergebnisse in Bezug auf Verbes-
serungen der Gelenkfunktionalität berichtet. In Bezug auf den Endpunkt 
„Schmerz“ konnten keine statistisch signifikanten Unterschiede zwischen den 
Studiengruppen festgestellt werden. Für die Wirksamkeitsendpunkte „Le-
bensqualität“ und „Notwendigkeit eines totalen Gelenkersatzes“ lag keine 
Evidenz vor. 
Sicherheit 
Einzeitiges Verfahren (AMIC) 
In allen extrahierten Studien wurden Komplikationen berichtet. Die Rate zu 
schwerwiegenden unerwünschten Ereignissen wurde in drei Studien berich-
tet und lag in den Interventionsgruppen zwischen 0 und 12,2 % und in den 
Kontrollgruppen zwischen 0 und 2,8 %. Eingriffsbezogene Komplikationen 
wurden in vier Studien berichtet und traten bei 0 bis 93,0 % der PatientIn-
nen in den Interventionsgruppen und bei 0 bis 77,0 % der PatientInnen in 
den Kontrollgruppen auf. Die Raten zu den implantatsbezogenen Kompli-
kationen lagen in drei Studien zwischen 3,0 und 22,0 %. 
Zweizeitiges Verfahren (MACI) 
Komplikationen wurden in allen drei Studien berichtet, in denen MACI mit 
MFx verglichen wurde. Die Rate zu schwerwiegenden unerwünschten Ereig-
nissen wurde in allen drei Studien berichtet und lag in den Interventions-
gruppen zwischen 4,8 und 15,3 % und in den Kontrollgruppen zwischen 11,1 
und 26,4 %. In allen drei Studien traten auch eingriffsbezogene Komplikati-
onen bei 0-34,7 % der PatientInnen in den Interventionsgruppen und bei 0-
38,9 % der PatientInnen in den Kontrollgruppen auf. In keiner der drei Stu-
dien wurde von implantatsbezogenen Komplikationen berichtet. Jedoch wur-
den in den drei RCTs von Re-operationsraten zwischen 2,5-8,3 % in den In-
terventionsgruppen und 0-9,7 % in den Kontrollgruppen berichtet. 
In beiden Studien, in denen MACI mit ACI verglichen wurde, wurden Kom-
plikationen berichtet. Die Rate zu schwerwiegenden unerwünschten Ereig-
nissen lag in den Interventionsgruppen zwischen 0 und 9,0 %, während in 
den Kontrollgruppen der Studien keine schwerwiegenden Ereignisse auftra-
ten. In beiden RCTs wurden keine eingriffsbezogenen Komplikationen be-
richtet. Die Raten zu implantatsbezogenen Komplikationen lagen in den In-
terventionsgruppen zwischen 12.5 und 36,4 % und in den Kontrollgruppen 
zwischen 9,0 und 140 %. Die angegebenen Re-operationsraten reichten von 
6,4-27,3 % der PatientInnen in den Interventionsgruppen und von 6,8-10,0 % 
der PatientInnen in den Kontrollgruppen. 
MACI vs. MFx: teilweise 
statistisch signifikante 
Verbesserungen der 
Wirksamkeit in den 
Interventionsgruppen 
1 totaler Gelenkersatz  
in einer Studie 
MACI vs. ACI: 
inkonsistente Ergebnisse 
in Bezug auf die 
Funktionalität, keine 
signifikanten Ergebnisse 
für Schmerzen 
schwere unerwünschte 
Ereignisse:  
0-12,2 % vs. 0-3,8 %,  
eingriffsbedingt:  
0-93,0 % vs. 0-77,0 %, 
implantatsbedingt:  
3,0-22,0 % in der 
Interventionsgruppe 
MACI vs. MFx:  
schwere unerwünschte 
Ereignisse:  
4,8-15,3 % vs. 11,1-26,4 %, 
eingriffsbedingt:  
0-34,7 % vs. 0-38,9 %, 
Re-operationen:  
2,5-8,3 % vs. 0-9,7 % 
MACI vs. ACI:  
schwere unerwünschte 
Ereignisse:  
0-9,0 % vs. 0 %, 
eingriffsbedingt:  
12,5-36,4 % vs. 9,0-140 %, 
Re-operationen:  
6,4-27,3 % vs. 6,8-10,0 % 
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Laufende Studien 
Derzeit sind sechs RCTs zur einzeitigen bzw. zweizeitigen Matrix-basierten 
Knorpelreparatur im Vergleich zu MFx registriert. Die Mehrheit dieser Stu-
dien sieht jedoch keine Nachbeobachtungszeiträume von länger als 24 Mo-
nate vor und wird somit die Evidenzlücke an Langzeitdaten (>24 Monate) 
nicht füllen können. 
Es konnten keine laufenden RCTs oder NRCTs identifiziert werden, die die 
klinische Wirksamkeit und Sicherheit von AMIC/MACI im Vergleich zu ACI 
untersuchen. Des Weiteren konnten keine laufenden RCTs oder NRCTs für 
die Beurteilung beider Verfahren bei Knorpelschäden im Sprunggelenk iden-
tifiziert werden. 
Kostenerstattung 
Zum Zeitpunkt des Verfassens des vorliegenden Berichts wird das einzeitige 
Matrix-basierte Reparaturverfahren (AMIC) von Knorpeldefekten, Osteo-
chondritis dissecans (OCD) oder (osteo)chondralen Läsionen im Knie- oder 
Sprunggelenk vom österreichischen Gesundheitssystem nicht erstattet. Die 
zweizeitige Matrix-basierte Knorpelreparatur (MACI) kann mit dem Code 
zur Kultivierung autologer Chondrozyten abgerechnet werden und ist dem-
nach im Leistungskatalog enthalten. 
 
Diskussion 
Insgesamt ist die Qualität der Evidenz für die Wirksamkeit und Sicherheit 
der einzeitigen Matrix-basierten Knorpelreparatur – in Kombination mit MFx 
– (AMIC) des Kniegelenks im Vergleich zur alleinigen MFx als moderat bzw. 
gering einzustufen. Die Qualität der Evidenz für die Wirksamkeit und Sicher-
heit der zweizeitigen Matrix-gestützten Knorpelreparatur (MACI) des Knie-
gelenks im Vergleich zur MFx oder zu ACI ist gering bzw. sehr gering. 
Die wesentlichen Limitationen der Evidenz bezüglich AMIC versus MFx al-
leine umfassen die geringen Stichprobengrößen und die kurzen Nachbeobach-
tungszeiträume (bis zu fünf Jahre) in der Mehrzahl der Studien. Nur zwei von 
fünf Studien hatten eine Nachbeobachtungszeit von mindestens fünf Jahre. 
Wie in den AMIC-Studien, waren die wesentlichen Limitationen der Studi-
en zu MACI versus MFx oder ACI die geringe Anzahl von PatientInnen und 
die kurzen Nachbeobachtungszeiträume. Lediglich eine Studie (im Vergleich 
zu MFx) hatte eine Nachbeobachtungszeit von mehr als 24 Monaten, wes-
halb langfristige Evidenz mangelhaft ist. 
Die Mehrzahl der Wirksamkeitsendpunkte (Mobilität/Gelenkfunktionalität, 
Lebensqualität, Schmerzen und Aktivitäten des täglichen Lebens) wurden 
von den PatientInnen selbst berichtet und könnten dadurch verzerrt sein. 
Aus diesem Grund wurde der Grad der Subjektivität bei der Beurteilung des 
Bias-Risikos berücksichtigt. 
Darüber hinaus waren aufgrund der unvollständigen oder inkonsistenten 
Berichterstattung, Erfassung bzw. Meldung unerwünschter Ereignisse in der 
Mehrzahl der eingeschlossenen Studien aggregierte Aussagen zur Sicherheit 
kaum möglich. 
Insgesamt fehlen zuverlässige Daten zur langfristigen Wirksamkeit und Si-
cherheit der beiden Verfahren (AMIC & MACI). 
 
6 laufende RCTs zu 
AMIC/MACI vs. MFx, 
jedoch Laufzeit meist 
nur bis 24 Monate 
keine laufenden RCTs 
oder NRCTs zu 
AMIC/MACI vs. ACI oder 
das Sprunggelenk 
AMIC aktuell in 
Österreich nicht 
erstattet, MACI im 
Leistungskatalog 
enthalten 
Evidenzqualität AMIC: 
moderat bis gering 
Evidenzqualität MACI: 
gering bis sehr gering 
AMIC vs. MFx: geringe 
Pat.-Anzahl und kurze 
Nachbeobachtungs-
zeiträume 
MACI vs. MFx/ACI: 
wenige PatientInnen 
und kurze Nach-
beobachtungszeiträume 
PatientInnen-berichtete 
Wirksamkeitsendpunkte 
– Subjektivität 
aggregierte Aussagen 
zur Sicherheit nur 
limitiert möglich 
langfristige 
Wirksamkeits- und 
Sicherheitsergebnisse 
fehlen 
Zusammenfassung 
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Zusammenfassung und Empfehlung  
Auf der Grundlage der verfügbaren Evidenz können keine Schlussfolgerungen 
gezogen werden, ob die ein- bzw. zweizeitige Matrix-unterstützte Knorpelre-
paratur wirksamer und sicherer ist als MFx oder zumindest genauso wirk-
sam und sicherer ist als ACI. 
Da keine kontrollierten Studien für die Knorpelreparatur des Sprunggelenks 
identifiziert werden konnten, konnte keine Empfehlung bezüglich der Auf-
nahme von AMIC und/oder MACI bei Knorpelreparaturen des Sprungge-
lenks in den österreichischen Leistungskatalog formuliert werden. 
Aufgrund der inkonsistenten Ergebnisberichterstattung der Knorpelreparatur 
im Kniegelenk zeigten die eingeschlossenen Studien eine teilweise schlechte 
Qualität der Evidenz und ein hohes Verzerrungspotenzial. Daher kann für 
beide Interventionen keine verlässliche Aussage hinsichtlich der klinischen 
Wirksamkeit und Sicherheit getroffen werden. Aus diesem Grund werden 
AMIC und MACI bei Knorpelreparaturen im Kniegelenk derzeit nicht für 
die Aufnahme in den österreichischen Leistungskatalog empfohlen. 
Neue Studienergebnisse, insbesondere aus Studien mit einer höheren Anzahl 
an PatientInnen und längeren Nachbeobachtungszeiträumen (z. B. zehn Jah-
ren), könnten die Effektschätzung der beiden Interventionen erheblich be-
einflussen. 
Eine Re-evaluierung für AMIC wird nicht vor 2022 empfohlen, da laufende 
RCTs noch ausständig sind. Für MACI könnte eine Re-evaluierung nach 
2021 sinnvoll sein, da das Verfahren im Vergleich zur MFx vielversprechend 
erscheint. 
 
Evidenz nicht 
ausreichend  
 verlässliche Aussage 
nicht möglich 
keine Evidenz  
für das Sprunggelenk  
 keine Empfehlung 
schwache Qualität  
der Evidenz zum Knie  
 AMIC & MACI derzeit 
nicht für Erstattung 
empfohlen 
Studien mit größeren 
Pat.-Populationen & 
längerem Follow-up 
erforderlich 
Re-evaluierung von 
AMIC nach 2022; 
Re-evaluierung von 
MACI nach 2021 
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Summary of the assessment 2016 
Scope 
The systematic review “Single-step scaffold-based cartilage repair in the knee” 
was performed by the Ludwig Boltzmann Institute for Health Technology 
Assessment (LBI-HTA) on behalf of the Austrian Ministry of Health in the 
year 2016 [1]. The aim was to answer the following research questions: 
1. Is the single-step scaffold-based cartilage repair in combination with 
microfracture more effective and safer in comparison to microfracture 
alone in patients with indications for cartilage knee surgery concern-
ing the outcomes listed in Table 1. 
2. Is the single-step scaffold-based cartilage repair in combination with 
microfracture as effective, but safer in comparison to two-step carti-
lage repair procedures (autologous chondrocyte implantation [ACI] or 
matrix-induced autologous chondrocyte implantation [(M)ACI]) in pa-
tients with indications for cartilage knee surgery concerning the out-
comes listed in Table 1. 
The following inclusion criteria for relevant studies summarised in Table 1 
were considered. 
Table 1: Inclusion criteria 
Population  Adult patients with indications for surgical cartilage repair in the knee 
 Grades 3-4 (Outerbridge Classification) localised cartilage damages/defects/disorders in 
the knee  
 Grades 3-4 (ICRS classification) (osteo)chondral lesions 
 Osteochondritis dissecans (OCD)  
 Contraindications: 
 Defect size <1 and >8 cm² 
 Allergies of the used material(s) 
 Inflammatory cartilage diseases 
 Malposition of the knee ≥5 degrees 
ICD-10 codes:M24.1, M94.8, M94.9, M93.2 
Intervention  Single-step cell-free scaffold-based cartilage repair in combination with microfracture 
 Alternative terms (selection): 
 Autologous matrix-induced chondrogenesis (AMIC) 
 Cell-free matrix-induced chondrogenesis 
 Cell-free (collagen) matrices/matrix 
 Product names: 
 BST-CarGel® 
 CaReS®-1S 
 Chondro-Gide® 
 Chondrotissue® 
 GelrinC® 
 Hyalofast® 
 MaioRegenTM 
 MeRG® 
Control  Microfracture surgery/microfracturing alone (main comparator) 
 Autologous chondrocyte implantation/transplantation (ACI/ACT) 
 Matrix-induced autologous chondrocyte implantation (MACI) 
 
erste systematische 
Übersichtsarbeit von 
2016 
PIKO-Fragen von 2016 
Einschlusskriterien  
von 2016 
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Outcomes  
Efficacy  Mobility/joint functionality 
 Pain 
 Return to daily activities/sports/physical activity 
 Quality of life 
 Necessity of total joint replacement 
Safety  Adverse events 
 Mortality (up to 10 days postoperatively) 
 Re-operation/additional surgery 
Study design  
Efficacy  Randomised controlled trials 
 Prospective non-randomised controlled trials 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective uncontrolled trials (n>50 pts., follow-up >24 months) 
 
Description of the technology 
In the single-step scaffold-based treatment in combination with microfracture 
of cartilage defects, a matrix is implanted in the area of the damaged carti-
lage. The used matrix acts as a temporary structure to allow the cells to be 
seeded and establish a three-dimensional structure. The matrix decomposes 
over time. 
In this report, we analysed whether the single-step scaffold-based cartilage re-
pair in combination with microfracture is more effective and safe in compar-
ison to microfracture alone or as effective but safer in comparison to two-step 
cartilage repair procedures (ACI or (M)ACI). 
 
Description of the health problem 
The systematic review of 2016 [1] focused on the treatment of chondral and 
osteochondral lesions in the knee. 
Articular (chondral) cartilage is a thin layer of connective tissue. It provides 
a smooth surface for articulation and facilitates the transmission of forces to 
the underlying subchondral bone.  
A damage of the cartilage can occur due to traumatic events or degeneration 
of the joint or due to osteochondritis dissecans (OCD). The damage can also 
affect the underlying bone (i.e., osteochondral lesion). 
 
Results 
In the report from 2016, the following outcomes were defined as crucial to 
derive a recommendation:  
Outcomes for clinical effectiveness: 
 Mobility/joint functionality measured by different scores [2]: 
 Knee Injury and Osteoarthritis Outcome Score (KOOS), 
 International Knee Documentation Committee (IKDC)  
Subjective Knee Form, 
 Western Ontario McMaster University Osteoarthritis Index 
(WOMAC), 
einzeitige 
Knorpelreparatur  
in Kombination mit 
Mikrofrakturierung 
Mikrofrakturierung + 
(M)ACI als Vergleich 
Fokus: (Knochen-) 
Knorpelschäden im Knie 
Knorpel ist Gleitschicht 
Knorpelschäden  
durch Trauma oder 
Abnutzung 
wichtige 
Wirksamkeitsendpunkte 
für Empfehlung 
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 Modified Cincinnati Knee Rating Systems, 
 Lysholm scoring scale, 
 Modified International Cartilage Repair Society (ICRS) Score. 
 Quality of life measured by different scores: 
 EQ-5D, 
 Short-Form Health Survey (SF-36, SF-12, SF-8). 
 Pain measured with several instruments: 
 Visual Analogue Scale (VAS). 
 Necessity of a total joint replacement 
A further outcome not considered crucial, but used to answer the effective-
ness-related research questions, was “return to activities”. 
Outcomes for safety: 
 Procedure-related complications associated with the surgical inter-
vention, e.g., events associated with anaesthesia, infections, damages 
to nerves or blood vessels, bleeding, or the occurrence of blood clots. 
 Device-related complications associated with the implantation of the 
scaffold, e.g., movement or release of the scaffold or allergic reactions. 
 Procedure-related mortality considering cases up to ten days  
postoperatively. 
 Re-operation rate. 
For the clinical effectiveness, no controlled trials comparing AMIC with 
(M)ACI could be identified. However, three randomised controlled trials 
(RCTs) [3-5] and one non-randomised controlled trial (NRCT) [6], with a 
total of 136 patients assessing the clinical effectiveness of AMIC (scaffold 
groups) in combination with microfracture (MFx) compared to MFx alone 
(MFx groups), could be identified. The mean age of the patients ranged from 
33 to 38 years in the scaffold groups and from 37 to 41 years in the MFx 
groups across trials. Patients had grade III-IV (Outerbridge Classification) of 
chondral defects with a mean lesion size of 2.3-3.7 cm² in the scaffold groups 
and 2.0-2.9 cm² in the MFx groups. The follow-up of the studies was 6, 24 and 
up to 60 months (five years). In one RCT [4], Chondro-Gide®, in the other 
two RCTs [3, 5] BST-CarGel®, and in the non-randomised clinical trial (CT) 
[6] a polyethylene glycol diacylate hydrogel were applied. No studies were 
available assessing the clinical effectiveness of other products like CaReS®-
1S, Chondrotissue®, MaioRegenTM or MeRG® that met the inclusion criteria. 
For the safety evaluation, RCTs, prospective non-randomised CT, and pro-
spective single-arm studies with at least 50 patients and a follow-up of at 
least 24 months were considered. No additional prospective single-arm stud-
ies met the inclusion criteria; the same four studies [3-6] as for clinical effec-
tiveness were thus considered for safety. 
The clinical effectiveness and safety of AMIC could only be evaluated com-
pared to MFx, as no studies were available for the comparison to (M)ACI. In 
the three included RCTs [3-5], the effect on mobility or joint functionality was 
measured by five different scoring systems. In one RCT [4], it was measured 
with the Modified Cincinnati Score (scale: 6-100) and with a modified ICRS 
score. For both scores, no statistically significant differences between the 
study groups could be identified. In the second RCT [3, 5], joint functionali-
ty was measured with the WOMAC subscale scores for stiffness (scale: 0-20) 
and for function (scale: 0-170). The changes of the WOMAC sub-scores be-
zusätzlicher Endpunkt 
nicht relevant für 
Empfehlung 
 
wichtige 
Sicherheitsendpunkte 
für Empfehlung 
keine RCTs:  
AMIC vs. (M)ACI, 
3 RCTs and 1 NRCT: 
AMIC vs. MFx alleine, 
Durchschnittsalter:  
33-41 Jahre, 
durchschn. Defekt-
größte: 2,3-3,7 cm², 
Leistungen:  
Chondro-Gide®,  
BST-CarGel®, etc. 
 
keine zusätzlichen 
Beobachtungsstudien 
eingeschlossen 
Mobilität/Funktionalität 
gemessen mit 5 Scores 
in 3 RCTs, 
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tween the study groups were statistically not significant at any time point. In 
the NRCT [6], joint functionality was measured with the IKDC Score; how-
ever, no statistically significant differences of the score changes between the 
study groups could be stated.  
With regard to quality of life, one RCT [3, 5] measured the generic quality of 
life using the mental components of the SF-36 (version 8); however, no dif-
ferences in changes of the scores between the study groups were statistically 
significant. In another RCT [3, 5], the disease-specific quality of life was 
measured with the physical component of the SF-36 (version 2); however, 
the differences in changes of the scores between the study groups were not 
statistically significant. Regarding the outcome “pain”, one RCT [4] measured 
pain on a VAS (scale: 0-100). In the other RCT [3, 5], pain was measured with 
the WOMAC subscale score for pain (scale: 0-50). In both RCTs, no statisti-
cally significant differences in changes of the pain scores could be identified. 
The necessity of a total joint replacement was reported in one RCT [4] and 
showed one patient who received a joint replacement after AMIC. In the MFx 
group, the joint did not need to be replaced in any of the patients. None of the 
included studies reported on the outcome “return to activities”. Two RCTs 
[3-5] and the non-randomised CT [6] reported on adverse events related to 
the surgical procedure. The reported rates ranged from 0 to 93% in the scaf-
fold groups and from 0 to 77% in the MFx groups. Adverse events related to 
the device were reported in 0 to 22% in two RCTs [3-5]. None of the included 
studies clearly stated the kind of adverse events, as well as if any re-opera-
tions were necessary. 
Overall, the strength of evidence evaluating the effectiveness and safety of 
AMIC in combination with MFx, compared to MFx alone, was “low”, indi-
cating that the confidence in the effect estimate is limited, according to the 
GRADE rating scheme. 
 
Recommendation 
The evidence included in the 2016 report was not sufficient to conclude that 
the single-step matrix-assisted cartilage repair combined with MFx (AMIC) 
is more effective and safer than MFx. No evidence was available to compare 
AMIC with the (matrix-assisted) autologous chondrocyte implantation. There-
fore, it was concluded in the report that the inclusion of the single-step ma-
trix-assisted cartilage repair combined with MFx (AMIC) was currently not 
recommended for inclusion in the Austrian hospital benefit catalogue. 
 
Lebensqualität 
gemessen mit einem 
Score in 2 RCTs, 
 
Schmerz gemessen mit  
2 Scores in 2 RCTs, 
 
Notwendigkeit eines 
totalen Knorpel-
austausches in  
1 RCT berichtet, 
 
Nebenwirkungen in 
allen inkludierten 
Studien berichtet:  
0-93 % 
Evidenzstärke für  
AMIC vs. MFx als 
„niedrig“ eingestuft 
AMIC vorerst nicht 
empfohlen für die 
Aufnahme in den 
Leistungskatalog 
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UPDATE 2019 
1 Scope 
1.1 PICO question 
According to the Austrian Ministry of Health, there have been changes of the 
original PICO from 2016, including one additional indication, as well as 
changes in the intervention and control groups. This resulted in the follow-
ing adapted research questions: 
1. Is the single-step scaffold-based cartilage repair (AMIC) in combina-
tion with MFx more effective and safer in comparison to MFx alone 
in patients with indications for cartilage surgery in the knee or ankle 
concerning the outcomes listed in Table 1-1. 
2. Is the single-step scaffold-based cartilage repair (AMIC) in combina-
tion with MFx as effective, but safer in comparison to the two-step 
cartilage repair procedure, autologous chondrocyte implantation 
without matrix (ACI), in patients with indications for cartilage sur-
gery in the knee or ankle concerning the outcomes listed in Table 1-1. 
3. Is the two-step scaffold-based cartilage repair procedure, matrix-
induced autologous chondrocyte implantation (MACI), more effec-
tive and safer in comparison to MFx in patients with indications for 
cartilage surgery in the knee or ankle concerning the outcomes listed 
in Table 1-1. 
4. Is the two-step scaffold-based cartilage repair procedure, matrix-
induced autologous chondrocyte implantation (MACI), as effective, 
but safer in comparison to the two-step cartilage repair procedure, 
autologous chondrocyte implantation without matrix (ACI), in pa-
tients with indications for cartilage surgery in the knee or ankle con-
cerning the outcomes listed in Table 1-1. 
 
  
Anpassung der 
Forschungsfragen 
PICO-Fragen für  
Update 2019 
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1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 1-1. 
 
 
Table 1-1: Inclusion criteria 
Population  Adult patients with indications for surgical cartilage repair in the knee and ankle joints 
 Grades 3-4 (Outerbridge Classification) localised cartilage damages/defects/disorders in the knee  
 Grades 3-4 (ICRS classification) (osteo)chondral lesions 
 Osteochondritis dissecans (OCD)  
 Contraindications: 
 Defect size <1 and >10 cm² 
 Allergies of the used material(s) 
 Inflammatory cartilage diseases 
 Malposition of the knee ≥5 degrees 
ICD-10 codes:M17.9, M24.1, M24.17, M94.8, M94.9, M93.2 
Intervention  Single-step cell-free scaffold-based cartilage 
repair in combination with microfracture 
 Alternative terms (selection): 
 Autologous matrix-induced chondrogenesis 
(AMIC) 
 Cell-free matrix-induced chondrogenesis 
 Cell-free (collagen) matrices/matrix 
 Product names: 
 BST-CarGel® 
 CaReS®-1S 
 Chondro-Gide® 
 Chondrotissue® 
 GelrinC® 
 Hyalofast® 
 MaioRegenTM 
 MeRG® 
 Novocart Basic®  
 Chondrofiller® 
 JointRepTM 
 Two-step scaffold-based cartilage repair  
in combination with microfracture 
 Alternative terms (selection): 
 Matrix-induced autologous chondrocyte 
implantation/ transplantation (MACI/T) 
 
 
 Product names: 
 Spherox® 
 BioSeed®-© 
 NeoCart 
Control  Microfracture surgery/microfracturing 
 Autologous chondrocyte implantation/transplantation (ACI/ACT) 
Outcomes  
Efficacy  Mobility/joint functionality 
 Pain 
 Quality of life 
 Necessity of total joint replacement 
 Complete defect filling 
 Return to daily activities/sports/physical activity 
Safety  Adverse events 
 Mortality (up to ten days postoperatively) 
 Re-operation/additional surgery 
Study design  
Efficacy  Randomised controlled trials 
 Prospective non-randomised controlled trials 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 
Einschlusskriterien  
für relevante Studien  
für Update 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is AMIC/MACI and the comparator(s)? 
A0020 For which indications has AMIC/MACI received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of AMIC/MACI in relation to the comparators? 
B0003 What is the phase of development and implementation of AMIC/MACI and the comparator(s)? 
B0004 Who administers AMIC/MACI and the comparators, and in what context and level of care  
are they provided? 
B0008 What kind of special premises are needed to use AMIC/MACI and the comparator(s)? 
B0009 What supplies are needed to use AMIC/MACI and the comparator(s)? 
A0021 What is the reimbursement status of AMIC/MACI? 
 
Health problem and current use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is AMIC/MACI used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for the disease or health condition? 
A0004 What is the natural course of the disease or health condition? 
A0005 What is the burden of disease for the patients with the disease or health condition? 
A0006 What are the consequences of the disease or health condition for the society? 
A0024 How is the disease or health condition currently diagnosed according to published guidelines 
and in practice? 
A0025 How is the disease or health condition currently managed according to published guidelines 
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is AMIC/MACI utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0005 How does AMIC/MACI affect symptoms and findings (severity, frequency) of the disease  
or health condition? 
D0006 How does the AMIC/MACI affect progression (or recurrence) of the disease or health condition? 
D0011 What is the effect of AMIC/MACI on patients’ body functions? 
D0016 How does the use of AMIC/MACI affect activities of daily living? 
D0012 What is the effect of AMIC/MACI on generic health-related quality of life? 
D0013 What is the effect of AMIC/MACI on disease-specific quality of life? 
D0017 Was the use of AMIC/MACI worthwhile? 
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Safety 
Element ID Research question 
C0008 How safe is AMIC/MACI in comparison to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying AMIC/MACI? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use  
of AMIC/MACI? 
C0007 Are AMIC/MACI and comparator(s) associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of AMIC/MACI  
and the comparator? 
D0001 What is the expected beneficial effect of AMIC/MACI on mortality? 
D0003 What is the effect of AMIC/MACI on the mortality due to causes other than the target disease? 
 
 
2.2 Sources 
Description of the technology 
 Hand search in the POP, AdHopHTA and CRD databases for Health 
Technology Assessments, and in Google 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Information provided by the submitting hospitals. 
 
Health problem and current use 
 Hand search in the UpToDate database, POP, AdHopHTA and CRD 
databases for Health Technology Assessments, and in Google 
 Background publications identified in database search: see Section 2.3 
 Documentation provided by the manufacturers 
 Information provided by the submitting hospitals 
 Hand search for management guidelines in the Trip Database1 and in 
the database of the Arbeitsgemeinschaft der Wissenschaftlichen Medi-
zinischen Fachgesellschaften e.V. (AWMF). 
For the domains of clinical effectiveness and safety, a systematic literature 
search and hand search were conducted, as described in detail in the follow-
ing chapter. 
 
 
                                                             
1 Since the National Guideline Clearinghouse (NGC) database no longer exists, the 
Trip Database is a valuable alternative, as it undertakes the existing guidelines from 
NGC. 
Quellen:  
systematische Suche, 
Handsuche sowie 
Informationen der 
Hersteller und 
Einreicher 
Quellen:  
systematische Suche, 
Handsuche, sowie 
Informationen der 
Hersteller und 
Einreicher 
systematische 
Literatursuche für 
Wirksamkeit und 
Sicherheit 
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2.3 Systematic literature search 
The systematic literature search was conducted from the 7th until the 14th of 
December 2018 in the following databases: 
 Medline via Ovid (including PubMed) 
 Embase 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was not limited to years, but it was limited to articles 
published in English or German and to only (non-) randomised controlled 
trials or prospective observational studies. After deduplication, a total of 323 
citations were included. The specific search strategy employed can be found 
in the Appendix (Chapter “Literature search strategies”). 
Manufacturers from the most common products (CaReS®-1S, Chondro-Gide®, 
Chondrotissue®, Hyalofast®, JointRepTM, Spherox®) submitted 28 publica-
tions, from which two new citations were identified. 
From the hand search of the original report [1], one additional relevant study 
could have been identified. 
A total of eleven systematic reviews and health technology assessments (HTAs) 
on the surgical management (AMIC, [M]ACI) of (osteo)chondral defects in 
the knee and ankle joint could be identified through the systematic literature 
search. However, due to methodological differences (e.g., other study pur-
poses, inclusion of retrospective studies) of the reviews, we decided to ex-
clude the systematic reviews and HTAs from our analysis. Nonetheless, we 
searched through the reviews to see if they identified studies that we did not 
find via our systematic literature search. Most of the reviews provided rele-
vant background information for this report and 22 additional studies were 
identified, resulting in 374 hits (after deduplication) overall. 
The submitting hospital sent seven publications, from which no new cita-
tions were identified. 
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trial registries (ClinicalTrials.gov, WHO-ICTRP, EU Clinical Tri-
als [EudraCT]) was conducted from the 14th until 16th of January 2019, re-
sulting in 85 hits. Of those 85 hits, six were identified as potentially relevant 
trials (RCTs) and included in the Appendix (see Chapter “List of ongoing 
randomised controlled trials”). The other 79 ongoing trials were excluded be-
cause of other study designs (e.g., single-arm), other interventions or other 
populations. 
 
  
systematische 
Literatursuche in  
4 Datenbanken 
Suche eingegrenzt  
nach Sprache und 
Studiendesign: 
323 Treffer 
28 Publikationen  
von Herstellern 
1 zusätzliche Publikation 
vom Report 2016 
11 systematische 
Übersichtsarbeiten, 
jedoch ausgeschlossen, 
 
22 zusätzliche Studien 
identifiziert 
 
insgesamt 374 Treffer 
identifziert 
keine neue Publikation 
Suche nach laufenden 
Studien: 6 Treffer 
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2.4 Flow chart of study selection 
Overall, 374 hits (after deduplication) were identified. The references were 
screened by two independent researchers and in case of disagreement, a third 
researcher was involved to solve the differences. The selection process is dis-
played in Figure 2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
* Two of the six RCTs were interim analyses of the included two extension studies (Volz 2017 [7] & Anders 2013 [4]; Shive 2015 [3] 
& Stanish 2013 [5]). For Volz/Anders only the data of Volz 2017 were considered for the analysis due to longer follow-up and larger 
patient population. For Shive/Stanish, the data from both studies are presented: from Stanish after 12 months and from Shive after 
60 months, since Shive had a longer follow-up but included fewer patients. 
** This study, Sharma 2013 [6], was initiated as a RCT. 
*** One of the six RCTs was an interim analysis of the included extension study (Saris 2014 [8] & Brittberg 2018 [9]). Efficacy data 
were extracted from Brittberg 2018 and safety data from Saris 2014. 
Literaturauswahl: 
13 Studien 
eingeschlossen, davon  
3 „Erweiterungsstudien“ 
Records identified through 
database searching  
(n=403) 
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 Additional records identified 
through other sources  
(n=50) 
Records after duplicates  
removed 
(n=374) 
Records screened 
(n=374) 
Records excluded 
(n=326) 
Full-text articles  
assessed for eligibility 
(n=48) Full-text articles excluded,  
with reasons 
(n=35) 
 Other study design (n=17) 
 Full text not available 
(abstract only) (n=11) 
 Other outcome (n=4) 
 Other intervention (n=2) 
 Other population (n=1) 
 Not English/German (n=0) 
 Background literature (n=0) 
Studies included in qualitative synthesis 
(n=13, with original and extension studies) 
(n=10, without original studies of the 
recent extension studies) 
AMIC: 
 RCT (n=6*) 
 NRCT (n=1**) 
MACI: 
 RCT (n=6***) 
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2.5 Analysis 
The data retrieved from the selected studies (see Chapter 2.4) were systemat-
ically extracted into data extraction tables (see Appendix Table A-1, Table 
A-2, Table A-3 and Table A-4). No further data processing (e.g., indirect com-
parison) was applied. The studies were systematically assessed for quality and 
risk of bias (RoB) by two independent researchers (SW, KR) using the Coch-
rane Collaboration’s tool for assessing risk of bias for randomised controlled 
studies [10] and the Risk Of Bias In Non-randomised Studies of Interven-
tions assessment tool (ROBINS-I) [11] presented in the Appendix (see Table 
A-5, Table A-6, and Table A-7). 
 
 
2.6 Synthesis 
Based on the data extraction tables (see Appendix Table A-1, Table A-2, Ta-
ble A-3 and Table A-4), data on each selected outcome category were synthe-
sised across studies according to GRADE (Grading of Recommendations As-
sessment, Development and Evaluation) [12]. The research questions were 
answered in plain text format with reference to GRADE evidence tables that 
are included in the Appendix; results were summarised in Table A-8 and Ta-
ble A-9. 
 
Datenextraktion  
und Bewertung des 
Bias-Risikos laut 
Cochrane RoB-Tool  
und ROBINS-I 
Evidenzsynthese  
mittels GRADE 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What is the technology and the comparator(s)? 
The standard single-step cartilage repair technique is the microfracture tech-
nique (MFx) [13, 14]. It consists of the perforation of the subchondral bone 
of the articular cartilage defect, leading to the formation of a blood clot and 
egress of marrow components, including stem cells and growth factors that 
stimulate chondrogenesis and cartilage repair [15, 16]. It is used for small 
defects (≤ 2 cm²). 
This systematic review focuses on approaches where the MFx technique is 
combined with the implantation of a scaffold, like the single-step scaffold-based 
treatment of cartilage defects. This technique uses a matrix which is implanted 
in the area of the damaged cartilage to cover the blood clot after MFx. Thus, 
it is also called the autologous matrix-induced chondrogenesis (AMIC) [13, 15-
17]. The scaffolds are implanted arthroscopically or by a mini-arthrotomy for 
“in situ” repair, permitting the ingrowing of mesenchymal stem cells (MSCs) 
to differentiate into the chondrogenic lineage. The used matrix acts as a tem-
porary structure to allow the cells to be seeded and establish a three-dimen-
sional structure. The used matrices are cell-free scaffolds; however, the ma-
terial and configuration of the scaffolds vary between the individual prod-
ucts, and decompose over time [1, 18]. 
For larger defects (≤ 10 cm²), the autologous chondrocyte implantation (ACI) 
is indicated, which can also be used in combination with a matrix (so-called 
matrix-induced autologous chondrocyte implantation [MACI]). These tech-
niques include two steps. In a first step, intact cartilage is sampled arthroscop-
ically from a non-weight-bearing area of the affected cartilage. The generated 
cells are then cultured in vitro until there are enough cells to be re-implant-
ed into the cartilage lesion. Chondrocytes are applied onto the damaged area 
in combination with a membrane (tibial periosteum or biomembrane) or pre-
seeded in a scaffold matrix (e.g., collagen matrix, hyaluronan matrix) [1]. 
In the present review, MFx and ACI, both treatments without a matrix, were 
considered as the comparators. 
  
MFx stimuliert 
Knochenmark 
Fokus: einzeitiges 
(AMIC) und zweizeitiges 
(MACI) Verfahren für 
Knorpelreparatur in 
Kombination mit 
Mikrofrakturierung 
(MFx) 
MACI speziell für 
größere Defekte  
(≤ 10 cm2) 
 
zellfreie Matrix als 
Unterstützung für 
Zellansiedlung 
MFx und ACI als 
Vergleichsinterventionen 
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A0020 – For which indications has the technology  
received marketing authorisation or CE marking? 
In the original systematic review from 2016, eight products from eight man-
ufacturers were listed for the single-step intervention, AMIC (Table 3-1): 
Table 3-1: Manufacturers and products of the single-step procedure of the original assessment in 2016 
Manufacturer Product Characteristics CE marking 
Pirimal Enterprises Limited, 
Canada 
BST-CarGel® Gel that consists of a chitosan solution  
(a natural polymer) and a buffer. 
Yes (2014) 
Arthro Kinetics AG,  
Germany 
CaReS®-1S A collagen type I matrix for the treatment  
of chondral lesions. 
Yes  
(year unknown) 
Geistlich Pharma,  
Switzerland 
Chondro-Gide® A bilayer matrix made from porcine collagen type 
I/III for the treatment of traumatic chondral and 
osteochondral lesions. Besides AMIC, the product 
can also be used for MACI (matrix-assisted 
autologous chondrocyte implantation). 
Yes (2010) 
BioTissue Technologies GmbH, 
Switzerland 
Chondrotissue® The matrix is made from polyglycolic acid fleece 
and freeze-dried sodium hyaluronate for the 
treatment of chondral lesions. 
Yes  
(year unknown) 
Regentis Biomaterials Ltd., 
Israel 
GelrinC® A hydrogel of polyethylene glycol di-acrylate  
(PEG-DA) and denatured fibrinogen, crosslinked 
with UVA light in-situ, for the treatment of 
chondral defects. 
Yes (2013) 
Anika Therapeutics, Inc.,  
USA 
Hyalofast® A biodegradable, hyaluronan-based (HYAFF) 
scaffold; it is intended for the repair of chondral  
or osteochondral lesions. 
Yes (2013) 
Fin-Ceramica Faenza S.p.A., 
Italy 
MaioRegenTM A multi-layer scaffold: the superficial layer  
consists of deantigenated type I equine collagen 
and resembles the cartilaginous tissue, while the 
lower layer consists mostly of magnesium-enriched 
hydroxyapatite (Mg-HA) and stimulates the 
subchondral bone structure. 
Yes  
(year unknown) 
Bioteck S.p.A.,  
Italy 
MeRG® A microfibrilla collagen membrane that is inserted 
in the chondral lesion after microfracture. 
Yes (2012) 
 
For the present systematic review, three additional products from three manu-
facturers could be identified for the single-step intervention (AMIC) (Table 
3-2): 
Table 3-2: Additional manufacturers and products of the single-step procedure 
Manufacturer Product Characteristics CE marking 
B. Braun Novocart 
Basic® 
Biphasic, three-dimensional collagen-based matrix 
inserted after microfracture technique. 
Yes  
(year unknown) 
Amedrix GmbH Chondrofiller® Biological cartilage implant made of high-purity, 
native collagen, available as a cell-free matrix in  
the form of a gel or a liquid. 
Gel: Yes (2012) 
Liquid: Yes 
(2013) 
Oligo Medic JointRepTM Injectable hydrogel from chitosan/glucosamine  
to fill in cartilage defects. 
Yes (2013) 
 
Furthermore, three additional products from three manufacturers for the two-
step intervention (MACI) were added to this report (in the original assess-
ment of 2016 MACI was only included as a comparator) (Table 3-3): 
8 AMIC Hersteller  
in Bericht aus 2016 
3 zusätzliche Produkte 
im aktuellen Bericht 
3 Produkte für MACI 
Verfahren identifziert 
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Table 3-3: Additional manufacturers and products of the two-step procedure 
Manufacturer Product Characteristics CE marking 
BioTissue Technologie GmbH, 
Germany 
BioSeed®-C Autologous three-dimensional chondrocyte 
transplantation. 
Yes  
(year unknown) 
CO.DON AG Spherox® Matrix-associated endogenous three-dimensional 
cartilage cell transplantation. 
Authorised  
as ATMP 
(07/2017) 
Histogenics® NeoCart® Cells seeded on a unique three-dimensional 
collagen scaffold and cultured under exacting 
conditions of high pressure, oxygen concentration 
and perfusion in their proprietary Tissue 
Engineering Processor (TEP). 
NR 
Abbreviations: ATMP – Advanced therapy medicinal product, NR – not reported 
 
B0002 – What is the claimed benefit of the technology  
in relation to the comparators? 
The single-step scaffold-based treatment of cartilage damages (AMIC) ena-
bles the treatment of larger cartilage defects than MFx alone. Furthermore, 
it provides a better microenvironment and structure for cell proliferation 
[19, 20]. In comparison to ACI, AMIC claims the advantage of the single-step 
procedure, sparing the need for a second intervention (one for the biopsy and 
one for the implant), resulting in fewer complications and lower costs, but at 
comparable effectiveness with regards to clinical outcomes [1, 20, 21]. 
The two-step matrix-induced procedure (MACI), in contrast to ACI, claims 
an easier intraoperative handling (e.g., no need for the extraction of perios-
teal flap), resulting in shorter duration of the surgery and the development 
of a stable hyaline cartilage. In addition, MACI might lead to fewer hyper-
trophies of the transplant compared to ACI. Furthermore, in comparison to 
matrix-free techniques (e.g., MFx), the use of an autologous matrix seems to 
enhance the cell proliferation. However, compared to the single-step inter-
ventions (e.g., MFx), during (M)ACI, healthy cartilage needs to be damaged 
and it is more cost-intensive [1, 20, 21]. 
B0003 – What is the phase of development and implementation  
of the technology and the comparator(s)? 
No evidence was available to answer this research question for both inter-
ventions (AMIC & MACI). 
There are three generations of the ACI procedure. According to the original 
ACI technique, the cartilage defect is covered by a periosteal flap removed 
from the tibia, the so-called ACI-P technique. To avoid removal of perioste-
um from the tibia, a more advanced ACI technique was developed. A mem-
brane of porcine type I/III collagen is used to cover the lesion filled with cul-
tured chondrocytes (ACI-C). In the third ACI generation, chondrocyte cells 
are implanted on a membrane by using a membrane consisting of a porcine 
type I/III collagen bilayer seeded with chondrocytes. However, problems in 
the cultivation of chondrocytes are the slow growth and the dedifferentiation 
of cells, including a switch of collagen synthesis from type II to type I [22, 
23]. 
 
AMIC: Behandlung 
größerer Defekte vs. 
MFx; einzeitiger Eingriff 
 weniger 
Komplikationen & 
geringere Kosten vs. ACI 
MACI einfachere 
Operation als ACI & 
verbesserte Zell-
ansiedlung als MFx,  
aber kostenintensiver 
vs. MFx 
3 Generationen des  
ACI Verfahrens: 
- ACI-P (Periost) 
- ACI-C (Collagen) 
- ACI 3. Generation 
(MACI) 
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Administration, investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers the technology and the comparators,  
and in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use the technology 
and the comparator(s)? 
B0009 – What supplies are needed to use the technology  
and the comparator(s)? 
Both techniques of the present review (AMIC & MACI) should be performed 
by an orthopaedic surgeon with the support of two persons from the nursing 
staff. The procedures can be performed under general or spinal anaesthesia. 
For the surgery, a sterile operation theatre and several instruments are re-
quired. For both techniques, matrices are needed, while for MACI a labora-
tory for cell culturing and expansion is additionally required [1, 21, 24-26]. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of the technology? 
At the time of the first report in 2016, the single-step scaffold-based repair 
(AMIC) of cartilage defects or osteochondritis dissecans (OCD) or (osteo)-
chondral lesions in the knee joint was not included in the Austrian hospital 
benefit catalogue and, therefore, was not reimbursed by the Austrian health 
care system [1]. 
Currently, the single-step scaffold-based repair (AMIC) of cartilage defects 
or osteochondritis dissecans (OCD) or (osteo)chondral lesions in the knee or 
ankle joint, are not included in the Austrian DRG system (Leistungsorien-
tierte Krankenanstaltenfinanzierung/LKF). Therefore, the intervention itself 
is still not reimbursed by the Austrian health care system. However, the in-
tervention could be billed with other codes, e.g., for arthroscopic operations of 
the knee or ankle joint (Code NF020 – Arthroskopische Operation des Knie-
gelenks; Code NG020 – Arthroskopische Operation des Sprunggelenks) [27]. 
The two-step matrix-induced procedure (MACI) can be billed with the code 
for the cultivation of autologous chondrocytes (Code NF130 – Kultivierung 
autologer Chondrozyten) and therefore, it is included in the Austrian DRG 
system [27]. 
 
Operationen an 
Gelenksknorpel von 
OrthopädInnen 
auszuführen, steriler OP 
erforderlich, für MACI 
zusätzlich Labor 
zum Zeitpunkt des 
Berichts 2016 wurde 
AMIC nicht erstattet 
aktuell keine Erstattung 
von AMIC in Österreich 
Erstattung von MACI 
mit Code NF130 
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4 Health problem and current use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is the technology used? 
A0002 – What is the disease or health condition in the scope  
of this assessment? 
The described AMIC and MACI techniques are intended for the treatment 
of articular chondral or osteochondral lesions, a debilitating condition, Outer-
bridge grade III-IV [1, 14, 16, 24] (additional information from the submit-
ting hospitals). The scope of the present assessment comprises matrix-assist-
ed treatments (AMIC and MACI) of cartilage defects in the knee and talus 
(ankle joint). 
A0003 – What are the known risk factors for the disease  
or health condition? 
Articular (chondral) cartilage is a thin layer of connective tissue. It provides 
a smooth surface for articulation and facilitates the transmission of forces to 
the underlying subchondral bone. Damage of the cartilage can occur due to 
traumatic events, such as sport injuries or incorrect weight-bearing, degen-
eration of the joint that mostly occurs in elderly people or due to osteochon-
dritis dissecans (OCD). OCD is an acquired idiopathic lesion of subchondral 
bone characterised by osseous resorption, collapse, and sequestrum formation, 
thus, it can also cause an osteochondral lesion [1, 14, 26, 28]. 
A0004 What is the natural course of the disease or health condition? 
(Osteo)chondral lesions can occur in nearly every phase of life. Besides older 
persons with degenerative cartilage damage, especially young and active per-
sons are likely to acquire such damages. Due to the low intrinsic healing ca-
pacity of human articular cartilage, spontaneous healing of the damaged tis-
sue cannot be expected. Besides pain and functional impairment, cartilage 
lesions can lead to the development of osteoarthritis [1, 24, 29]. 
(Osteo)chondral defects and OCD (of both, knees and ankles) can be graded 
via different systems, which are mainly determined by the type of diagnostic 
examination (e.g., MRI or arthroscopy), such as [1]: 
 The classification of chondral effects by ICRS [1, 30]: 
Grade/stage Characteristics 
0 Normal 
1 Nearly normal (soft indentation and/or superficial fissures  
and cracks) 
2 Abnormal (lesions extending down to <50% of cartilage depth) 
3 Severely abnormal (cartilage defects >50% of cartilage depth) 
4 Severely abnormal (through the subchondral bone) 
Abbreviation: ICRS – International Cartilage Regeneration &  
Joint Preservation Society 
 
Behandlung 
(osteo)chondraler 
Defekte 
 
Fokus auf Knie- und 
Sprunggelenk 
Knorpel ist dünne 
Gewebsschicht 
 
Risikofaktoren: Trauma 
(z. B. Sportverletzung), 
Abnutzung, 
Osteochondritis 
dissecans 
Defekte v. a. bei älteren 
und jungen, sportlich 
aktiven Personen 
 
geringes intrinsisches 
Heilungsvermögen 
verschiedene 
Klassifikationssysteme 
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 The classification of chondral defects by Outerbridge [1, 30]: 
Grade/stage Characteristics 
0 Normal 
1 Softening and swelling of cartilage 
2 Fragmentation and fissuring, less than 1.5 cm in diameter 
3 Fragmentation and fissuring, greater than 1.5 cm in diameter 
4 Erosion of cartilage down to exposed subchondral bone 
 
 The classification of OCD and osteochondral defects by Kramer [1, 31]: 
Grade/stage Characteristics 
0 Bone marrow oedema 
1 Demarked bone, possibly altered cartilage 
2 Partial osteochondral fissure, partial discontinued cartilage 
3 Entire osteochondral fissure, completely discontinued cartilage 
4 Dislocated OCD 
Abbreviation: OCD – Osteochondritis dissecans 
 
 The classification of OCD and osteochondral defects by Guhl [1, 32]:  
Grade/stage Characteristics 
1 Normal articular cartilage 
2 Fragmentation in situ 
3 Partial detachment 
4 Complete detachment, loose body present 
Abbreviation: OCD – Osteochondritis dissecans 
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with the disease  
or health condition? 
Patients with (osteo)chondral defects are suffering from pain and impaired 
mobility, leading to a lower quality of life [17]. In severe cases, it can lead to 
degenerative osteoarthritis and further progression accompanied with the 
requirement of a joint replacement [1, 24, 25]. 
A0006 – What are the consequences of the disease or health condition 
for the society? 
In Austria, 78,277 surgeries of the knee joint and 2,855 surgeries of the talus 
were performed in 2016 [33]. Out of the surgeries of the knee joint, a total of 
37,364 interventions were arthroscopic surgeries [34]. 
However, neither information on the number of AMIC or MACI interven-
tions of the knee joint or talus performed, nor information regarding the 
prevalence or incidence of cartilage disorders or OCD have been identified. 
Furthermore, a vast majority of the patients suffering from defect cartilage 
of the knee or ankle are in their productive age. As a result, some of the pa-
tients are incapacitated for work, which can be assumed to result in addi-
tional societal costs. 
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Current clinical management of the disease or health condition 
A0024 – How is the disease or health condition currently  
diagnosed according to published guidelines and in practice? 
There is a German guideline for the diagnosis (and treatment) of OCD avail-
able that was conducted in cooperation of the German and the Austrian As-
sociation for trauma surgery. In addition, one international guideline for the 
diagnosis and treatment of OCD and one for articular cartilage lesions were 
identified for the report of 2016 [1, 35-38]2: According to the guidelines, the 
first step is a physical examination of the affected joint, including an inspec-
tion (swelling of the joint, gait, etc.), a palpation (pressure pain, extrusion in 
the joint, etc.) and specific tests for functioning and pain (motion, Wilson’s 
test2, etc.). Secondly, the affected joint should be examined by diagnostic im-
aging, i.e., X-rays and/or magnetic resonance imaging (MRI). Alternative di-
agnostic imaging techniques, like ultrasound, computed tomography, or ar-
throscopy, can also be used. 
A0025 – How is the disease or health condition currently  
managed according to published guidelines and in practice? 
The guidelines listed above [35-37] also cited several treatment alternatives 
for (osteo)chondral lesions or OCD after diagnosis, starting with conservative 
treatment followed by surgical interventions. 
Generally, the treatments aim for pain reduction, regaining joint mobility, 
reactivating the affected area, preventing/slowing the progression and pre-
vention of osteoarthritis, and avoiding total joint replacement. Conservative 
therapies include physical therapy, partial weight-bearing or activity restric-
tions, dietary supplements or pain management (e.g., non-steroidal anti-in-
flammatory drugs). A variety of surgical techniques exist, for example, arthro-
scopic lavage (or debridement), bone marrow stimulating techniques like 
MFx, (M)ACI, autologous osteochondral transplantation or osteochondral 
allografts or total knee/joint replacement in later stages of (osteo)chondral 
lesions. For example, during an osteochondral transplantation (OCT), a car-
tilage-bone cylinder is removed from a less burdensome area of the joint and 
planted in the appropriate, drilled defect area. However, none of the interna-
tional guidelines recommends one specific surgical intervention, as it depends 
on factors such as the defect size and localisation, the age of the patient, and/ 
or the grade of discomfort [1, 35-38]. 
 
Target population 
A0007 – What is the target population in this assessment? 
In the systematic review from 2016, patients older than 18 years of age with 
chondral or osteochondral lesions or OCD of the knee joint, with an ICRS or 
Outerbridge 3-4, a defect size of 1-8 cm² were considered for the evaluation. 
Patients with two or more corresponding cartilage defects or an allergy to 
one of the scaffold components were excluded. 
  
                                                             
2 For the current assessment, these guidelines were found to be still valid or received 
a revision. No additional guidelines could be identified. 
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In the present update of the systematic review from 2016, next to chondral or 
osteochondral lesions or OCD of the knee joint, the ankle joint was also con-
sidered. Furthermore, due to the inclusion of a second intervention (MACI), 
a defect size of 1-10 cm² instead of 1-8 cm² was determined. The other inclu-
sion criteria stayed constant. 
A0023 – How many people belong to the target population? 
No information on the Austrian, European or international data for the pre-
valence or incidence of (osteo)chondral defects or OCD was identified to in-
form this research question. Similarly, the frequency of AMIC and MACI in-
terventions conducted in Austria is currently unknown. 
A0011 – How much are the technologies utilised? 
According to the submitting hospitals, the estimated annual utilisation of the 
AMIC intervention in their institutions ranged from 5-15 and is estimated 
for MACI to be about five interventions. 
The estimated annual utilisation of the AMIC intervention in Austria ranged 
from 30-50 and more than 20 for the MACI intervention (information from 
the submitting hospitals in 2018). 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Mobility/joint functionality 
 Quality of life 
 Pain 
 Necessity of total joint replacement 
The outcomes chosen represent the aims of a treatment of chondral and os-
teochondral defects: regaining joint mobility, reactivation of the affected ar-
ea, pain reduction, prevention/delay of disease progression, and prevention 
of osteoarthritis and/or avoiding total joint replacement. 
Mobility and joint functionality can be measured by different scores: 
 Knee Injury and Osteoarthritis Outcome Score (KOOS):  
42 items in five separately scored subscales: 
(1) Pain (nine items) 
(2) Other symptoms (seven items) 
(3) Function in daily living (ADL) (17 items) 
(4) Function in sport and recreation (sport/rec) (five items) 
(5) Knee-related quality of life (QoL) (four items). 
A Likert scale is used and all items have five possible answer options 
scored from 0 (no problems) to 4 (extreme problems), and each of the 
five scores is calculated as the sum of the items included. Scores are 
transformed to a 0-100 scale, 0 representing extreme problems and 
100 representing no problems [39]. 
 International Knee Documentation Committee (IKDC) Subjective   
Knee Form designed to assess patients with a variety of knee disor-
ders, including ligamentous and meniscal injuries, as well as patello-
femoral pain and osteoarthritis. A patient-completed tool, which con-
tains sections on knee symptoms (seven items), function (two items), 
and sports activities (two items). Scores range from 0 points (lowest 
level of function or highest level of symptoms) to 100 points (highest 
level of function and lowest level of symptoms) [40]. 
 Western Ontario McMaster Universities Osteoarthritis Index   
(WOMAC): a self-administered questionnaire consisting of 24 items 
divided into three subscales: 
(1) Pain (five items): during walking, using stairs, in bed, sitting  
or lying, and standing upright 
(2) Stiffness (two items): after first waking and later in the day 
(3) Physical Function (17 items): using stairs, rising from sitting, stand-
ing, bending, walking, getting in/out of a car, shopping, putting 
on/taking off socks, rising from bed, lying in bed, getting in/out 
of bath, sitting, getting on/off toilet, heavy domestic duties, light 
domestic duties. 
 The test questions are scored on a scale of 0-4, which correspond to: 
none (0), mild (1), moderate (2), severe (3), and extreme (4). The scores 
for each subscale are summed up, with a possible score range of 0-20 
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for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores 
indicate worse pain, stiffness, and functional limitations [41]. 
 Modified Cincinnati Knee Rating System   
consists of 12 questions, eight of which are included in the summary 
score. These scored questions cover the domains of pain, swelling, 
function and activity level. The total score is calculated as the sum of 
all questions responses, with 100 representing the best/excellent knee 
function, and 0 representing the worst/poor knee function [42]. 
 Lysholm scoring scale:   
a patient-reported outcome measure (PROM) consisting of eight items 
that measure: pain (25 points), instability (25 points), locking (15 points), 
swelling (10 points), limp (5 points), stair climbing (10 points), squat-
ting (5 points), and need for support (5 points). Every question re-
sponse has been assigned an arbitrary score on an increasing scale. 
The total score is the sum of each response to the eight questions and 
may range from 0-100. Higher scores indicate a better outcome with 
fewer symptoms or disability [43]. 
 Short Form Health Survey (SF-8, SF-12, SF-36):   
a patient-reported survey of patient health consisting of eight scaled 
scores, which are the weighted sums of the questions in their section. 
Each scale is directly transformed into a 0-100 scale. A score of zero is 
equivalent to maximum disability and a score of 100 is equivalent to 
no disability. A shorter version is the SF-12; for the case, only adequate 
physical and mental health summary scores are of interest [44]. 
 The (modified) International Cartilage Repair Society (ICRS)   
macroscopic score (consisting of ratings by patient and surgeon): due 
to the lacking scoring instructions, the interpretation of reported scores 
was not possible. 
Quality of life can be measured by different scores: 
 Knee Injury and Osteoarthritis Outcome Score (KOOS):  
see more information above. 
 EQ-5D consists of a descriptive system and the EQ Visual Analogue 
Scale (VAS), and comprises five dimensions: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. The five dimen-
sions are rated via the VAS scale, numbered from 0 to 100: 100 mean-
ing the best health imaginable and 0 meaning the worst health [45]. 
 Short Form Health Survey (SF-8, SF-12, SF-36):  
see more information above. 
Pain can be measured by different scores: 
 Knee Injury and Osteoarthritis Outcome Score (KOOS):  
see more information above. 
 Visual Analogue Scale (VAS): The VAS [0-100 mm scale] for pain in-
tensity is most commonly anchored by “no pain” (score of 0) and “pain 
as bad as it could be” or “worst imaginable pain” (score of 100). 
 Western Ontario McMaster Universities Osteoarthritis Index 
(WOMAC): see more information above. 
Necessity of total joint replacement: 
Since one major aim of the treatment of chondral and osteochondral defects 
is to avoid progression of the disease and joint replacement, the necessity of 
a joint re-placement was considered as a crucial long-term outcome. 
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The following outcomes were not considered as crucial to derive a recommen-
dation, but were used to answer the effectiveness-related questions: 
 Activities of daily living, which can be measured with the KOOS score 
(see more information above) or the Tegner Activity Score (a one-item 
score that graded activity based on work and sports activities on a 
scale of 0-10. Zero represents disability because of knee problems and 
10 represents national or international level soccer). 
 Complete defect filling can be measured with the magnetic resonance 
observation of cartilage repair tissue (MOCART) score (lower MOCART 
scores indicate more positive/normal MRI diagnostic findings of the 
cartilage repair). 
In the following sections of this report, the results of the included studies are 
presented separately for the AMIC (Chapters 5.2 and 5.3) and the MACI in-
tervention (Chapters 5.4 and 5.5). 
 
 
5.2 Included studies: AMIC 
For evaluating efficacy-related outcomes, we exclusively considered RCTs and 
prospective NRCTs (see Chapter 1.2). 
No controlled trials comparing the single-step scaffold-based treatment 
(AMIC) of (osteo)chondral defects in the ankle joint with MFx or ACI could 
be identified. 
Further, no controlled trials comparing the single-step scaffold-assisted tech-
nique (AMIC) of (osteo)chondral defects in the knee with ACI could be iden-
tified. 
The only studies that met our inclusion criteria were five RCTs3 [3, 5, 7, 46, 
47] and one NRCT [6], with a total of 314 patients, assessing the clinical ef-
fectiveness of the single-step scaffold-assisted chondral repair (AMIC) in the 
knee joint, compared to MFx alone. Out of these patients, 43 were lost to fol-
low-up across the studies. 
 
Study characteristics 
In all five RCTs3, the intervention (AMIC) was performed with products of 
different manufacturers. In one study, it was performed with Chondro-Gide® 
[7], in one study with MaioRegenTM [47], in one study with JointRepTM [46], 
in another with BST-CarGel® [3, 5], and in the NRCT, a polyethylene glycol 
diacylate hydrogel (comparable to GelrinC®) was applied [6]. 
 
                                                             
3 In total, six RCTs were included; two of the six RCTs were interim analyses of the 
included two extension studies (Volz 2017 [7] & Anders 2013 [4]; Shive 2015 [3] & 
Stanish 2013 [5]). For Volz/Anders, only the data of Volz 2017 were considered for 
the analysis due to longer follow-up and larger patient population. For Shive/Stan-
ish, the data from both studies are presented: from Stanish after 12 months and 
from Shive after 60 months, since Shive had a longer follow-up, but included fewer 
patients. 
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There were no studies assessing the clinical effectiveness of other products, 
like CaReS®-1S, Chondrotissue®, or MeRG® (see Chapter 3) that met our in-
clusion criteria. 
One RCT was assessed in nine countries (Italy, Sweden, Belgium, Switzer-
land, Austria, Germany, Poland, South Africa) [47], one RCT in Italy [46], one 
RCT in Canada, Spain and South Korea respectively [3, 5], and the other RCT 
in Germany [7]. The NRCT was assessed in Germany, Italy and the Nether-
lands [6]. One of the five included studies [46] did not report any funding of 
the study. 
 
Patient characteristics 
The mean age of patients ranged from 34.0-54.5 years in the intervention groups 
and from 35.2-56.6 years in the control groups across the RCTs [3, 5, 7, 46, 47]; 
in the NRCT, the age of patients ranged from 20.0-59.0 years in the treatment 
group versus 40.0-49.0 in the control group [6]. Between 20.6 and 43.9% of the 
patients in the intervention groups and 23.1-52.2% of the patients in the con-
trol groups were females across trials. Patients had grades 3-4 (Outerbridge 
Classification) of chondral defects with a mean lesion size of 2.3-3.9 cm² in the 
intervention groups and 1.9-3.5 cm² in the control groups. The follow-up of the 
studies was six months [6], 24 [46, 47] and up to 60 months (five years) [3, 
5, 7]. 
Three of the included studies considered only patients aged 18 to 55 years 
[3, 5-7], whereas one study included patients between 26 and 72 years of age 
[46]. One study did not report on inclusion or exclusion criteria [47]. In three 
studies, osteoarthritis or any form of inflammatory arthritis, as well as mul-
tiple lesions or kissing lesions, were defined as exclusion criteria [3, 5-7]. All 
of the studies reported on postoperative rehabilitation programs [3, 5-7, 46] 
or isometric and isotonic exercises and electrical neuromuscular stimulation 
[47]. 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2, and in the evidence profile in Table A-8. 
 
 
5.3 Efficacy results: AMIC 
Since we could not identify any controlled studies regarding AMIC for carti-
lage repair for the ankle joint, the results presented are exclusively for AMIC 
for the knee joint. 
 
Morbidity 
D0005 – How does AMIC affect symptoms and  
findings (severity, frequency) of the disease or health condition? 
Answering this research question was based on the outcome “pain” and “com-
plete defect filling”. 
The effect on pain was measured in five studies by two different scoring sys-
tems comparing the single-step scaffold-assisted cartilage repair (AMIC) plus 
MFx with MFx alone [3, 5, 6, 46, 47]. 
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Single-step scaffold-based treatment + MFx vs. MFx alone 
(1) VAS scale (0-100, lower scores indicate lower pain) 
One study [47] stated a mean reduction of -26.3 points in the intervention 
group versus -23.9 for the control group after 12 months (p=n/a), and -23.6 
vs. -29.9 points after 24 months (p=n/a). 
The NRCT [6] reported changes after three and six months on severity and 
frequency of pain. The changes for severity for the intervention versus the con-
trol group were: -29.0 vs. -34.7 points, and -32.1 vs. -15.3 points at three and 
six months, respectively. The changes for frequency assessed for the interven-
tion versus the control group were: -41.0 vs. -62.6 points, and -52.9 vs. -41.0 
points at three and six months, respectively. The study did not mention 
whether the changes were statistically significant between the groups (p=n/a). 
(2) WOMAC scale (subscale: pain, 0-20, lower scores indicate lower pain) 
The first study [46] reported changes after six, 12 and 24 months. After six 
months, a change of -11.3 vs. -5.2 was reported for the intervention versus the 
control group, both statistically significant compared to baseline (p<0.0001; 
p<0.0001). After 12 months, the change from baseline was only statistically 
significant for the intervention group with -11.6 (p<0.0001) vs. the control 
group with -1.5 (p=0.3154). After 24 months, there was a mean reduction in 
pain for the intervention group of -12.1 (p<0.0001) vs. the control group of 
-0.1 (p=0.9446) compared to baseline. The interim and extension studies [3, 
5]4 reported slightly poorer changes for the intervention versus the control 
group: -16.2 vs. -16.9, and -15.4 vs. -16.6 at 12 and 60 months compared to 
baseline, respectively. However, the study did not state whether the changes 
were statistically significant between the groups (p=n/a). 
Across the scoring systems, the improvements for pain were higher in the in-
tervention groups (after >6 months). However, the differences between the 
study groups were not statistically significant [3, 5]. 
Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “pain”, compared to ACI. 
The effect on complete defect filling was measured in two studies by two 
scoring systems comparing the single-step scaffold-assisted cartilage repair 
(AMIC) plus MFx with MFx alone [7, 47]. 
Single-step scaffold-based treatment + MFx vs. MFx alone 
(1) Unknown scoring system 
One RCT [7] only describes that 35.0-50.0% of the patients had a defect fill-
ing of ≥2/3 after 12 months. After 24 months, the defect filling was more 
complete in the AMIC groups, where at least 60.0% of the patients had a de-
fect filling of >2/3 compared to only 25.0% of the patients in the MFx group. 
At 60 months follow-up, defect filling was the lowest in the MFx group ver-
sus both AMIC groups (sutured & glued). 
                                                             
4 In this study, the WOMAC subscales were reported in the VAS format of 0 to 10 cm 
length. Scores had a maximum value of 50 points for pain, 20 points for stiffness, 
and 170 points for function. 
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(2) MOCART scale  
(subscale: defect filling, 0-20, higher scores indicate more complete filling) 
The other RCT [47] describes a complete filling of the defect after 12 and 24 
months. After six months, 53.3% of patients had a complete defect filling in 
the intervention group versus 39.5% in the control group. After 12 and 24 
months, a complete defect filling was assessed more frequently in the control 
group with 55.6 and 65.9% of patients, in comparison to the intervention 
group with 40.8 and 49.0%. No statistically significant differences were ob-
tained in the MRI scores between the groups. 
Across the two studies, contradictory results appeared: a complete defect fill-
ing was described more often for the intervention group in [7], as opposed to 
[47], where a complete defect filling was reported more frequently for the 
control group (after 12 and 24 months). 
Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “complete defect filling”, 
compared to ACI. 
D0006 – How does AMIC affect progression (or recurrence)  
of the disease or health condition? 
To answer this research question, the outcome “necessity of a total joint re-
placement” was used. Thus, the higher the rate of the total joint replacement, 
the less the effect of the intervention on the disease progression is. 
Single-step scaffold-based treatment + MFx vs. MFx alone 
Only one RCT addressed this outcome [46]. In this study, there was one to-
tal knee arthroplasty reported after 12 months, without mentioning in which 
study group this event occurred. 
Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “necessity of a total joint 
replacement”, compared to ACI. 
 
Function 
D0011 – What is the effect of AMIC on patients’ body functions? 
Answering this research question was based on the outcome “mobility/joint 
functionality”. 
The effect on mobility or joint functionality was measured in six studies by 
five different scoring systems comparing the single-step scaffold-assisted carti-
lage repair (AMIC) plus MFx with MFx alone [3, 5-7, 46, 47]. 
Single-step scaffold-based treatment + MFx vs. MFx alone 
(1) IKDC scale (0-100, higher scores indicate better function) 
The IKDC score was reported in one RCT [47] and the NRCT [6]. In the RCT, 
the score improved in all study groups over time. After 12 months, the score 
improved by 17.5 and 20.7 points in the intervention and control group com-
pared to baseline, respectively. After 24 months, the score increased slightly 
more to 23.5 in the intervention group and to 22.5 in the control group com-
pared to baseline. There were no p-values given in the study. Overall, the im-
provement in the RCT was slightly higher in the intervention group for all 
follow-ups. 
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The NRCT [6] only mentions that there were no statistically significant 
changes from baseline after three and six months. 
(2) WOMAC scale (lower scores indicate better function) 
WOMAC stiffness subscale (0-8): 
Three studies assessed the WOMAC stiffness subscale [3, 5, 46]. In the studies, 
the score improved in all study groups over time. In one RCT [46], the score 
improved after 12 and 24 months by -5.3 and -5.4 in the intervention group 
and by -1.9 and -1.9 in the control group, respectively. These mean reductions 
were statistically significant in both groups compared to baseline (p<0.0001, 
p<0.0001 vs. p=0.0024, p=0.0004). The interim and extension studies [3, 5]4 
reported similar improvements after 12 and 60 months compared to base-
line: -5.9 and -5.6 for the intervention group and -6.6 and -6.7 for the control 
group, respectively. As the baseline scores were very high in this study, the 
changes were not statistically significant in either group (p=n/a). 
WOMAC physical function subscale (0-68): 
Three studies reported the WOMAC physical function subscale [3, 5, 46]. In 
the studies, the score improved in all study groups over time. In the first RCT 
[46], the score improved after 12 and 24 months compared to baseline by -35.1 
and -36.0 in the intervention group and by -10.6 and -6.3 in the control group, 
respectively. These mean reductions were statistically significant in both groups 
compared to baseline (p<0.0001, p<0.0001 vs. p=0.0001, p=0.044). The inter-
im and extension studies [3, 5]4 also reported improvements after 12 and 60 
months compared to baseline: -55.9 and -56.5 for the intervention group and 
-60.6 and -62.1 for the control group. As the baseline scores were very high in 
these studies, the changes were not statistically significant in either group; no 
statistically significant differences were reported between the groups (p=n/a). 
Overall, contradictory results across the studies were found for both WOM-
AC subscales: one RCT had higher improvements for the intervention group 
[46], whereas the interim and extension studies had higher improvements 
for the control group [3, 5]. However, the higher improvements in the con-
trol group were not statistically significant. 
(3) Modified Cincinnati Knee score (0-100, higher scores indicate better function) 
Only one study reported on this scoring system [7]. The mean scores improved 
similarly after 12 and 24 months compared to baseline by 37.0 | 19.0 and n/a | 
37.0 for the intervention groups (AMIC sutured | AMIC glued) versus 34.0 
and 36.0 for the control group. After 60 months, the study only stated that 
the score was stable or improving in both AMIC groups, whereas a signifi-
cant decrease was observed for the MFx group (p=n/a). 
(4) Short Form Health Survey  
(subscale: physical components, 0-100, higher scores indicate better function) 
In two studies [3, 5] there were improvements for the SF-36 subscale in all 
study groups. The changes were not statistically significant, but with slightly 
better improvements for the control group: 13.0 and 13.1 in the intervention 
group and 14.8 and 14.5 in the control group after 12 and 60 months com-
pared to baseline, respectively. 
(5) (Modified) ICRS macroscopic score 
Due to lacking scoring instructions, it was not possible to interpret the re-
ported scores in one study [7]. 
Across all scoring types, for the comparison of AMIC + MFx versus MFx 
alone, improvements in functionality were reported for the intervention 
groups, as well as the control groups after six, 12, 24 and 60 months. 
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Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on functionality, compared to 
ACI. 
D0016 – How does the use of AMIC affect activities of daily living? 
Answering this research question was based on the outcome “activities of daily 
living”. 
Single-step scaffold-based treatment + MFx vs. MFx alone 
This outcome was addressed only in one RCT [47] and was measured with the 
Tegner Activity Score (TAS). All study groups showed improvements after 12 
and 24 months compared to baseline. In both groups, the mean improve-
ments were +1.0 after 12 months and +1.0 after 24 months (p=n/a). Over-
all, no differences occurred between the intervention and the control group. 
Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “activities of daily living”, 
compared to ACI. 
 
Health-related quality of life 
D0012 – What is the effect of AMIC on generic  
health-related quality of life? 
D0013 – What is the effect of AMIC on disease-specific quality of life? 
Answering these research questions was based on the outcome “quality of life”. 
The effect on quality of life (QoL) was measured only in the interim and ex-
tension studies [3, 5] by one scoring system comparing the single-step scaf-
fold-assisted cartilage repair (AMIC) plus MFx with MFx alone. 
(1) Short Form Health Survey  
(subscale: mental components, 0-100, higher scales indicate better function) 
Single-step scaffold-based treatment + MFx vs. MFx alone 
The two studies [3, 5] assessed improvements on the SF-36: +3.5 and +2.7 
in the intervention group and +0.8 and -0.2 in the control group after 12 and 
60 months compared to baseline, respectively. The changes were not statisti-
cally significant (p=n/a). 
Overall, for the comparison of AMIC + MFx versus MFx alone, better im-
provements in QoL were reported for the intervention group after 12 and 60 
months. 
Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the effect of a single-step scaffold-
assisted cartilage repair (combined with MFx) on “quality of life”, compared 
to ACI. 
 
Patient satisfaction 
D0017 – Was the use of AMIC worthwhile? 
There was no evidence to answer this research question. 
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5.4 Included studies: MACI 
No controlled trials comparing the two-step scaffold-based treatment (MACI) 
of (osteo)chondral defects in the ankle with MFx or ACI could be identified. 
The only studies that met the inclusion criteria (see Chapter 1.2) were five 
RCTs [9, 22, 23, 48, 49]5 with a total of 330 (184 vs. 146) patients assessing 
the clinical efficacy of the two-step scaffold-assisted chondral repair of the 
knee joint (MACI) compared to MFx [9, 48, 49] or ACI [22, 23]. 
 
Study characteristics 
In all five RCTs, the intervention (MACI) was from another manufacturer. 
In three studies, collagen type I/III matrices [9, 22, 48], in another study a 
bovine type I collagen matrix [49], and in the fifth study, a rectangular re-
sorbable scaffold of polyglactin 910 and poly-p-dioxanone [23] were applied. 
There were only studies assessing the clinical effectiveness of products like 
Spherox®, BioSeed®-C and NeoCart® that met the inclusion criteria (see Chap-
ter 1.2). 
One study was assessed in seven European countries (n/a) [9], two studies in 
Germany [23, 48], one study in England [22] and one study in the USA [49]. 
One of the five studies [48] did not report on the funding of the study. 
 
Patient characteristics 
The mean age of patients ranged from 29.1-41.0 years in the intervention 
groups and from 29.5-39.0 in the control groups across the studies. Between 
10.0 and 45.5% of the patients in the intervention groups and between 0 and 
33.0% of the control groups were female across the studies. Patients had 
grades 3-4 (Outerbridge or ICRS Classification) of chondral defects with a 
mean lesion size of 2.9-6.1 cm² in the intervention groups and 2.5-6.0 cm² in 
the control groups. The follow-up of the studies was 24 and 60 months (five 
years). 
Three of the included studies only considered patients aged 18 to 55 years 
[9, 48, 49], whereas two studies included patients between 15 and 50 years of 
age [22, 23]. All five studies considered osteoarthritis or any form of inflam-
matory arthritis as an exclusion criterion and reported a postoperative reha-
bilitation program. 
Detailed study characteristics and results of included studies are displayed 
in Table A-3 and Table A-4, and in the evidence profile in Table A-9. 
 
 
                                                             
5 In total, six RCTs were included. One of the six RCTs was an interim analysis of 
the included extension study (Saris 2014 [8] & Brittberg 2018 [9]). Efficacy data were 
extracted only from Brittberg 2018. 
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5.5 Efficacy results: MACI 
Since we could not identify any controlled studies regarding MACI for carti-
lage repair for the ankle joint, the results presented are exclusively for MACI 
for the knee joint. 
 
Morbidity 
D0005 – How does MACI affect symptoms and findings  
(severity, frequency) of the disease or health condition? 
Answering this research question was based on the outcomes “pain” and 
“complete defect filling”. 
The effect on pain was measured in four studies by three different scoring 
systems comparing the scaffold-based two-step cartilage repair (MACI) with 
MFx [9, 49] or with ACI [22, 23]. 
(1) KOOS score (subscale: pain, 0-100, higher scales indicate lower pain) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], the KOOS score (pain) increased in all study groups over 
time. After 24 months, the score improved by 45.1 and 36.6 points in the in-
tervention and control group compared to baseline, respectively. After 60 
months, the score improved by 45.1 points in the intervention group and by 
38.8 points in the control group. However, the higher increase in the control 
groups for both follow-ups was not statistically significant (p=n/a). Another 
study [49] reported a significant score improvement in the intervention group 
(+12.06, 95% CI 2.388-21.74, p<0.05) after 24 months. 
Overall, the two RCTs reported a score improvement for the intervention 
group; however, the improvement was statistically significant only in one 
study. 
Two-step scaffold-based treatment vs. ACI: 
There was no evidence available assessing the KOOS score (pain) of a two-step 
scaffold-assisted cartilage repair, compared to ACI. 
(2) Visual analogue scale (0-100, lower scales indicate lower pain) 
Two-step scaffold-based treatment vs. MFx: 
One RCT [49] reported significant pain improvements in the intervention 
group after 24 months (p<0.05). 
Two-step scaffold-based treatment vs. ACI: 
In one study [22], a deterioration of the scale from baseline to follow-up 
(n/a) was reported for the intervention group (-1.9), as well as for the control 
group (-1.7). However, the difference was not statistically significant. 
Overall, in both RCTs, the VAS showed an improvement of pain in the in-
tervention group. However, this improvement was only statistically signifi-
cant in one study [49].  
(3) Short Form Health Survey  
(subscale: pain, 0-100, higher scores indicate lower pain) 
Two-step scaffold-based treatment vs. MFx: 
There was no evidence available assessing the Short Form Health Survey 
(pain) of a two-step scaffold-assisted cartilage repair, compared to MFx. 
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Two-step scaffold-based treatment vs. ACI: 
One RCT [23] reported that there was no significant difference between the 
intervention and the control group after 12 and 24 months. 
Overall, no conclusions can be made for the pain outcome with the Short 
Form Health Survey. 
Across all scores, some statistically significant pain improvements were re-
ported in the intervention groups. 
The effect on complete effect filling was measured in two studies by three 
different scoring systems comparing the scaffold-based two-step cartilage re-
pair (MACI) with MFx [48] or with ACI [23]. 
(1) Unknown scoring system 
Two-step scaffold-based treatment vs. MFx: 
There was no evidence available assessing the complete defect filling of a two-
step scaffold-assisted cartilage repair on an unknown score, compared to MFx. 
Two-step scaffold-based treatment vs. ACI: 
In one study [23], a complete defect filling could be diagnosed after six months 
via MRI imaging technique in 50.0% of the intervention group versus 11.1% 
of the control group. 
(2) MOCART score  
(subscale: defect filling, 0-20, higher points indicate more complete filling) 
Two-step scaffold-based treatment vs. MFx:  
There was no evidence available assessing the MOCART score of a two-step 
scaffold-assisted cartilage repair, compared to MFx. 
Two-step scaffold-based treatment vs. ACI: 
In one study [23], 6.3 points and 8.4 points were reported for the interven-
tion and control group, respectively, at 12 months. After 24 months, the fill-
ing did not change in the intervention group (a stable 6.3 points), while the 
filling deteriorated in the control group to 6.8 points. However, the differ-
ences in points between the study groups were not statistically significant at 
both follow-up. 
Overall, the reported points indicate a defect fill of >50% of the defect (5-10 
points) in both study groups for both 12 and 24 months [50]. 
D0006 – How does MACI affect progression (or recurrence)  
of the disease or health condition? 
Answering this research question was based on the outcome “necessity of to-
tal joint replacement”. Thus, the higher the rate of the total joint replacement, 
the less the effect of the intervention on the disease progression is. 
Two-step scaffold-based treatment vs. MFx: 
The effect on necessity of total joint replacement was measured in one study 
comparing the scaffold-based two-step cartilage repair (MACI) with MFx [49]. 
In the study, one case of total knee arthroplasty was reported in the interven-
tion group (4.8%) versus zero cases in the control group. 
Two-step scaffold-based treatment vs. ACI: 
There was no evidence available assessing the necessity of total joint replace-
ment of a two-step scaffold-assisted cartilage repair, compared to ACI. 
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Function 
D0011 – What is the effect of MACI on patients’ body functions? 
Answering this research question was based on the outcome “mobility/joint 
functionality”. 
The effect on mobility or joint functionality was measured in all five studies 
by six different scoring systems comparing the scaffold-based two-step carti-
lage repair (MACI) with MFx [9, 48, 49] or with ACI [22, 23]. 
(1) KOOS score (subscale: sport/rec, 0-100, higher scores indicate better function) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], the KOOS score (sport/rec) increased in all study groups over 
time. After 24 months, the score improved by 45.1 and 37.0 points in the in-
tervention and control group, respectively. After 60 months, the score im-
proved by 46.5 points in the intervention group and by 38.8 points in the con-
trol group. The higher increase in the intervention group after 60 months was 
statistically significant (p=0.0122). In another RCT [49], the difference in the 
KOOS scores (sport/rec) from baseline to 24 months was statistically signifi-
cantly higher in the intervention group compared to the control group. 
Two-step scaffold-based treatment vs. ACI:  
There was no evidence available assessing the KOOS score (sport/rec) of a 
two-step scaffold-assisted cartilage repair, compared to ACI. 
(2) IKDC score (0-100, higher scores indicate better function) 
Two-step scaffold-based treatment vs. MFx:  
In one RCT [9], the IKDC score increased in all study groups over time. Af-
ter 24 months, the score improved by 32.2 and 30.8 points in the intervention 
and control group, respectively. After 60 months, the score increased slightly 
more to 35.4 points in the intervention group and to 32.5 points in the con-
trol group. However, the differences between the study groups were not sta-
tistically significant (p=0.113) at 60 months. In another RCT [49], the dif-
ference in the adjusted means (IKDC score) at 24 months was statistically 
significantly higher in the intervention group (+11.59 points, 95% CI 1.353-
21.82, p=0.028). 
Two-step scaffold-based treatment vs. ACI: 
In one RCT [23], the IKDC score increased in all study groups over time. At 
24 months, the score improved by 19.0 points and 25.2 points in the inter-
vention and control group, respectively. However, the difference in improve-
ment was not statistically significant (p=0.4994). 
Overall, the three RCTs reported similar improvements from baseline to fol-
low-up in the score. However, in two of the three RCTs, the improvement 
was higher in the intervention group, whereas in one RCT the improvement 
was higher in the control group (not significant). 
(3) Modified Cincinnati Knee score (0-100, higher scores indicate better function) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], the Modified Cincinnati Knee score improved in all study 
groups over time. After 24 and 60 months, the score improved by 3.3 and 3.6 
points in the intervention group and by 2.5 and 2.8 points in the control group, 
respectively. The higher increase in the intervention group after 60 months 
was statistically significant (p=0.035). 
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Two-step scaffold-based treatment vs. ACI: 
In another RCT [22], the score increased in all study groups over time. After 
12 months, the score improved by 19.6 points in the intervention group and 
by 17.5 points in the control group. However, the difference between the study 
groups was not statistically significant (p=0.32). 
Overall, the two RCTs reported different improvements in the score from 
baseline to follow-up. However, in both studies, the improvement was higher 
in the intervention group for all follow-up. Across the studies, the score was 
1.5 points higher in the intervention group compared to the control group. 
(4) Lysholm score (0-100, higher scores indicate better function) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [48], the Lysholm score increased in all study groups over time. 
After 24 months, the score improved by 40.0 points in the intervention group 
and by 14.0 points in the control group. There was a statistically significant 
improvement in the intervention group after 24 months (p=0.005). 
Two-step scaffold-based treatment vs. ACI: 
In another RCT [23], the score increased in all study groups over time. At 24 
months, the score improved by 1.2 points in the intervention group and by 
22.7 points in the control group. There was a significantly higher increase for 
the control group after 24 months (p=0.0487). 
Overall, the RCTs reported very inconsistent results regarding the improv-
ement in the score between intervention and control groups and between the 
two studies. In one study, the improvement was higher in the intervention 
group, whereas in the other study the improvement was higher in the control 
group (statistically significant). 
(5) Short Form Health Survey  
(subscale: physical components, 0-100, higher scores indicate better function) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], negative scores of the SF-12, which were not translated on a 
0-100 score, were reported. Thus, these negative values could not be inter-
preted. 
Two-step scaffold-based treatment vs. ACI: 
In another RCT [23], it was only reported that the differences in the changes 
of scores from baseline to 12 and 24 months between the study groups were 
not statistically significant. 
(6) ICRS macroscopic score (subjective and objective scales) 
Two-step scaffold-based treatment vs. MFx: 
Due to lacking scoring instructions, it was not possible to interpret the re-
ported scores in one study [48]. 
Two-step scaffold-based treatment vs. ACI: 
Due to lacking scoring instructions, it was not possible to interpret the re-
ported scores in one study [22]. 
Across all scoring types, for the comparison MACI versus MFx, (partly sta-
tistically significant) improvements in joint functionality were reported for 
the intervention groups after 24 and 60 months [9, 48, 49]. For the compari-
son MACI versus ACI, inconsistent results about improvements in joint func-
tionality were reported [22, 23]. 
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D0016 – How does the use of MACI affect activities of daily living? 
Answering this research question was based on the outcome “activities of 
daily living”. 
The effect on activities of daily living (ADL) was measured in three studies 
by two different scoring systems comparing the scaffold-based two-step car-
tilage repair (MACI) with MFx [9, 48] or with ACI [23]. 
(1) KOOS score (subscale: ADL, 0-100, higher scores indicate improved ADL) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], the score improved by 43.7 points in the intervention group 
and by 34.4 points in the control group after 24 months. After 60 months, 
the improvement in the intervention group decreased to 42.8 points and in-
creased to 37.4 points in the control group.  
Overall, the improvements were higher in the intervention group for both 24 
and 60 months, but statistically significant only after 60 months (p=0.007). 
Two-step scaffold-based treatment vs. ACI: 
There was no evidence available assessing the KOOS score (ADL) of a two-
step scaffold-assisted cartilage repair, compared to ACI. 
(2) TAS (0-10, higher scores indicate better daily activities): 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [48], a significantly better improvement in the daily activity was 
reported for the intervention group at 24 months (p=0.04). 
Two-step scaffold-based treatment vs. ACI: 
In one RCT [23], the score increased by 0.1 points in the intervention group 
and by 0.9 points in the control group after 12 months. After 24 months, the 
improvement was slightly higher in the intervention group (+0.6 points from 
baseline) and in the control group (+1.7 points from baseline). However, the 
differences in improvements between the study groups were not statistically 
significant for both follow-ups (p=0.4063 vs. p=0.1043). 
Overall, the two RCTs reported inconsistent results about the effect on daily 
activity. On the one hand, the daily activity improved in the intervention 
group [48]; on the other hand, the daily activity score was higher in the con-
trol group (not significant) – indicating better daily activity [23]. 
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(1) KOOS scale (subscale: QoL, 0-100, higher scores indicate better QoL) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], the KOOS score (QoL) increased for all study groups over 
time. After 24 months, the score improved by 35.5 points in the intervention 
group and by 30.7 points in the control group. After 60 months, the score im-
proved slightly more by 39.9 points and 35.3 points in the intervention and 
the control group, respectively (p=n/a). In another RCT [49], a marginal im-
provement in the score for the intervention group after 24 months was report-
ed (p=0.05). 
Overall, in both studies, the improvement was higher in the intervention group 
for all follow-up. 
Two-step scaffold-based treatment vs. ACI: 
There was no evidence available assessing the KOOS score (QoL) of a two-step 
scaffold-assisted cartilage repair, compared to ACI. 
(2) EQ-5D score (0-100, higher scores indicate higher QoL) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], the EQ-5D scores increased in both study groups over time. 
After 24 and 60 months, the score improved by 16.2 and 20.1 points in the 
intervention group and by 1.4 and 19.1 in the control group, respectively. 
There was a statistically significant improvement (+1 point) in the interven-
tion group after 60 months (p=0.043). 
Two-step scaffold-based treatment vs. ACI: 
There was no evidence available assessing the EQ-5D score of a two-step 
scaffold-assisted cartilage repair, compared to ACI. 
(3) Short Form Health Survey  
(subscale: mental components, 0-100, higher scores indicate better QoL) 
Two-step scaffold-based treatment vs. MFx: 
In one RCT [9], negative scores of the SF-12, which were not translated on a 
0-100 score, were reported. Thus, these negative values could not be inter-
preted and this study could not be graded for this outcome. 
Two-step scaffold-based treatment vs. ACI: 
One study [23] reported that there was no statistically significant difference 
in the scores between the study groups after 12 and 24 months. Score values 
were not described. 
Across all scoring types, for the comparison MACI versus MFx, (partly sta-
tistically significant) improvements of QoL were reported for the interven-
tion groups after 24 and 60 months. For the comparison MACI versus ACI, 
no conclusions can be made regarding the effect on QoL. 
 
Patient satisfaction 
D0017 – Was the use of MACI worthwhile? 
There was no evidence to answer this research question. 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Severe adverse events, which were rated as such in the study. 
 Procedure-related adverse events: Complications that were associated 
with the surgical intervention. Possible procedure-related complications 
are events associated with anaesthesia, infections, damages to nerves 
or blood vessels, bleeding, or the occurrence of blood clots (e.g., throm-
bosis). 
 Device-related adverse events: Complications that were associated with 
the implantation of the scaffold. Possible complications are movement 
or release of the scaffold or allergic reactions. 
 Re-operation rate, which shows how often patients had  
to undergo additional surgeries. 
The following outcome was not considered as crucial to derive  
a recommendation, but was used to answer the safety-related questions: 
 Procedure-related mortality 
 
 
6.2 Included studies: AMIC 
For evaluating safety-related outcomes, we considered RCTs and prospective 
NRCTs (see Chapter 1.2). 
In order to assess safety-related outcomes of AMIC, we identified the same 
five RCTs [3, 5, 7, 46, 47] and the same NRCT [6] as for efficacy, with a total 
of 187 patients treated with AMIC and 127 patients with MFx. Patient and 
study characteristics are described in Chapter 5.2. 
No controlled trials comparing the single-step scaffold-based treatment of 
(osteo)chondral defects in the ankle joint with MFx or ACI could be identi-
fied. 
Further, we could not identify any clinical trials comparing the single-step 
scaffold-assisted treatment of (osteo)chondral defects in the knee with ACI. 
Study characteristics and results of included studies are displayed in Table 
A-1, Table A-2, and in the evidence profile in Table A-8. 
 
  
entscheidende 
Endpunkte für Sicherheit:  
schwerwiegende 
Komplikationen 
 
 
eingriffsbezogene 
Komplikationen 
implantatsbezogene 
Komplikationen 
Re-Operationsrate 
weiterer Endpunkt  
zur Beantwortung  
der Fragen: eingriffs-
bezogene Mortalität 
(un)kontrollierte 
Studien für Sicherheit 
gleiche Studien  
wie für Wirksamkeit 
eingeschlossen 
keine kontrollierten 
Studien für das 
Sprunggelenk 
keine Studien  
im Vergleich zu ACI 
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6.3 Safety results: AMIC 
Since we could not identify any controlled studies regarding AMIC for the 
ankle joint, the results presented are exclusively for AMIC for the knee joint. 
 
Patient safety 
C0008 – How safe is AMIC in comparison to the comparator(s)? 
Answering this research question was based on the outcome “severe adverse 
events”, “procedure-related adverse events”, “device-related adverse events” 
and “re-operation rate”. 
Single-step scaffold-based treatment + MFx vs. MFx alone 
Severe adverse events 
Severe adverse events were reported in four studies [3, 5, 7, 47]. The reported 
rates ranged from 0-12.2% in the intervention groups and from 0-3.8% in the 
control groups (slightly favouring the control groups). 
Procedure-related adverse events 
Adverse events related to the procedure, in comparison to MFx, were reported 
in four studies [3, 5, 7, 47] and the NRCT [6]. The rates ranged from 0-93.0% 
in the intervention groups and from 0-77.0% in the control groups. 
Only in one RCT was it clearly stated that the most reported procedure-
related adverse events were inflammation, joint adhesion or persistent pain 
in the intervention group and joint instability in the control group [47]. None 
of the other identified studies clearly described which kind of adverse events 
occurred. 
Device-related adverse events 
Adverse events related to the device were reported in three studies [3, 5, 47] 
and the NRCT [6], and occurred in 3.0-22.0% of the patients. Only one study 
[47] stated that the event occurred due to failures of the scaffold. Since the 
control groups did not receive a scaffold, no device-related complications oc-
curred. 
Re-operation rate 
Re-operations were stated in two RCTs [3, 7]. One study reported no re-oper-
ations in the AMIC sutured group, one in the AMIC glued versus one in the 
MFx group after 12 months [7]. The other study [3] reported no re-operations 
in the intervention group versus one in the control group after 60 months. 
Overall, one re-operation was stated for the intervention groups and two re-
operations for the control groups across the studies. 
Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the safety of a single-step scaffold-
assisted cartilage repair (combined with MFx), compared to ACI. 
C0002 – Are the harms related to dosage or frequency of applying AMIC? 
No direct evidence was found to answer this research question. 
Sicherheit  
nur zum Kniegelenk 
4 Studien: 
schwerwiegende 
Komplikationen: 
0-12.2 % vs. 0-3.8 % 
4 Studien: 
eingriffsbezogene 
Komplikationen: 
0-93 % vs. 0-77 %  
keine umfangreichen 
Details zu 
Komplikationen 
3 Studien, 1 NRCT: 
implantatsbezogene 
Komplikationen: 0-22 % 
1 RCT nach 12 Monaten: 
1 vs. 1 Re-Operation 
 
1 RCT nach 60 Monaten: 
0 vs. 1 Re-Operation 
keine Evidenz 
keine Evidenz 
Safety 
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C0004 – How does the frequency or severity of harms change over time 
or in different settings? 
Based on the identified evidence, this research question cannot be answered 
in an appropriate way. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of AMIC? 
No direct evidence was found to answer this research question. 
C0007 – Are AMIC and the comparator(s) associated with  
user-dependent harms? 
No direct evidence was found to answer this research question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of AMIC and the comparator? 
No direct evidence was found to answer this research question. 
 
Mortality 
D0001 – What is the expected beneficial effect of AMIC on mortality? 
Answering this research question was based on the outcome “procedure-
related mortality”. 
Single-step scaffold-based treatment + MFx vs. MFx alone 
Data on procedure-related mortality was only reported in three studies: the 
interim and extension studies [3, 5] and the NRCT [6]. No patient deaths 
were reported either in the intervention or in the control groups (0 vs. 0). 
Single-step scaffold-based treatment + MFx vs. ACI 
There was no evidence available assessing the procedure-related mortality of 
a single-step scaffold-assisted cartilage repair (combined with MFx), com-
pared to ACI. 
D0003 – What is the effect of AMIC on the mortality  
due to causes other than the target disease? 
No direct evidence was found to answer this research question. 
 
 
  
keine verlässliche 
Evidenz 
keine Evidenz 
keine Evidenz 
keine Evidenz 
Beantwortung  
anhand Endpunkt 
„eingriffsbezogene 
Mortalität” 
 
3 Studien: keine 
eingriffsbezogenen 
Todesfälle aufgetreten 
keine Evidenz 
keine Evidenz 
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6.4 Included studies: MACI 
For evaluating safety outcomes, we also exclusively considered RCTs and 
prospective NRCTs. 
Again, no controlled trials comparing the two-step scaffold-based treatment 
of (osteo)chondral defects in the ankle with MFx or ACI could be identified 
for safety. Thus, the following questions are only answered for cartilage de-
fects of the knees. 
Nearly the same five RCTs [8, 22, 23, 48, 49]6, with a total of 346 (191 vs. 
155) patients assessing the clinical efficacy of the two-step scaffold-assisted 
chondral repair of the knee joint (MACI) compared to MFx [8, 48, 49] or ACI 
[22, 23] were also included for safety.  
Detailed study characteristics are described before (see Chapter 5.4) and dis-
played in Table A-3, Table A-4, and in the evidence profile in Table A-9. 
 
 
6.5 Safety results: MACI 
Patient safety 
C0008 – How safe is MACI in comparison to the comparators? 
Answering this research question was based on the outcome “severe adverse 
events”, “procedure-related adverse events”, “device-related adverse events” 
and “re-operation rate”. 
Adverse events were reported in all five RCTs comparing the scaffold-based 
two-step cartilage repair (MACI) with MFx [8, 48, 49] or with ACI [22, 23]. 
Two-step scaffold-based treatment vs. MFx: 
Severe adverse events 
Severe adverse events were reported in all three RCTs comparing MACI with 
MFx [8, 48, 49]. In one RCT [48], there were no severe adverse events in any 
study group. In the other two RCTs [8, 49], the reported rates ranged from 
4.8% to 15.3% in the intervention groups and from 11.1% to 26.4% in the 
control groups. The two RCTs reported on severe adverse events, like treat-
ment failure, cartilage injury and arthralgia [8], and total knee arthroplasty 
and one case of cancer of gynaecologic origin; however, the relation to the 
procedure was unknown [49]. 
Procedure-related adverse events 
Adverse events related to the surgical procedure were reported in two RCTs [8, 
49]. In one of the two studies [49], no procedure-related adverse events oc-
curred in any study group. The other RCT [8] reported on rates of 34.7% and 
38.9% in the intervention and control group, respectively. Thereof, the most 
common adverse events were treatment failure, arthralgia and joint swelling. 
                                                             
6 In total, six RCTs were included. One of the six RCTs was an interim analysis of the 
included extension study (Saris 2014 [8] & Brittberg 2018 [9]). Safety data were ex-
tracted only from Saris 2014, because only this study reported on safety outcomes. 
RCTs und NRCTs 
keine Evidenz für 
Knöchel – Sicherheit 
zum Knie 
5 Studien für 
Wirksamkeit inkludiert: 
3 Studien vs. MFx &  
2 Studien vs. ACI 
Beantwortung anhand 
von mehreren 
Endpunkten berichtet  
in allen 5 Studien 
3 RCTs: schwerwiegende 
Nebenwirkungen: 
0 %-15.3 % vs.  
0 %-26.4 % 
2 RCTs: 
eingriffsbezogene 
Nebenwirkungen: 
0 %-34.7 % vs. 
0 %-38.9 % 
Safety 
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Device-related adverse events 
Adverse events related to the scaffold were not reported in any of the three 
RCTs [8, 48, 49]. 
Re-operation rates 
Re-operation rates were reported in all three studies [8, 48, 49], ranging from 
2.5% to 8.3% in the intervention groups and from 0% to 9.7% in the control 
groups. 
Overall, across the three RCTs, the rates for the different adverse event cate-
gories (severe, procedure-related, re-operation) were higher in the control 
groups. However, the differences in rates between the intervention and con-
trol groups were not statistically significant. 
Two-step scaffold-based treatment vs. ACI: 
Severe adverse events 
Severe adverse events were reported in both RCTs comparing MACI with ACI 
[22, 23]. In one RCT [22], there were no severe adverse events in any study 
group. In the other RCT [23], one severe case of inability to work was re-
ported in the intervention group (9.0%). 
Procedure-related adverse events 
None of the two RCTs [22, 23] reported procedure-related adverse events. 
Device-related adverse events 
Adverse events related to the scaffold were reported in both RCTs [22, 23]. 
The rates ranged from 12.5% to 36.4% in the intervention groups and from 
9.0% to 140% (as one patient could suffer from several adverse events) in the 
control groups. The most reported device-related adverse events in the RCTs 
were symptomatic hypertrophy, painful catching, wound infection and graft 
failure. 
Re-operation rates 
Re-operation rates were also reported in both RCTs [22, 23], ranging from 
6.4% to 27.3% in the intervention groups and from 6.8% to 10.0% in the con-
trol groups. 
Overall, across the two RCTs, the rates for the different adverse event cate-
gories (severe, procedure-related, device-related, re-operation) were incon-
sistent. While the maximum rates for severe adverse events and re-opera-
tions were higher in the intervention groups, the maximum rate of proce-
dure-related adverse events was higher in the control groups. However, the 
difference between the study groups within a study showed different conclu-
sions: e.g., for device-related adverse events, in one study [22] the rate was 
higher in the intervention group, whereas in the other RCT [23], the rate was 
higher in the control group. The opposite held true for the re-operation rates. 
C0002 – Are the harms related to dosage or frequency of applying MACI? 
No direct evidence was found to answer this research question. 
C0004 – How does the frequency or severity of harms change over time 
or in different settings? 
Based on the identified evidence, this research question cannot be answered 
in an appropriate way. 
keine Evidenz 
3 RCTs:  
Re-Operationsraten: 
2.5 %-8.3 % vs. 
0 %-9.7 %  
insgesamt höhere 
Nebenwirkungsraten  
in den Kontrollgruppen 
(jedoch nicht statistisch 
signifikant) 
2 RCTs: schwerwiegende 
Nebenwirkungen: 
0 %-9 % vs. 0 % 
keine Evidenz 
2 RCTs: 
implantatsbezogene 
Nebenwirkungen: 
12.5 %-36.4 % vs.  
9.0 %-140 % 
2 RCTs:  
Re-Operationsraten: 
6.4 %-27.3 % vs. 
6.8 %-10.0 %  
insgesamt inkonsistente 
Resultate zwischen den 
Studiengruppen vs. ACI 
keine Evidenz 
keine verlässliche 
Evidenz 
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C0005 – What are the susceptible patient groups  
that are more likely to be harmed through the use of MACI? 
No direct evidence was found to answer this research question. 
C0007 – Are MACI and comparators associated  
with user-dependent harms? 
No direct evidence was found to answer this research question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of MACI and the comparators? 
No direct evidence was found to answer this research question. 
 
Mortality 
D0001 – What is the expected beneficial effect of MACI on mortality? 
D0003 – What is the effect of MACI on the mortality due to causes  
other than the target disease? 
One of the five studies [8] reported on procedure-related mortality. According 
to the study, no patients died due to the two-step scaffold-assisted surgery 
(MACI). 
 
keine Evidenz 
keine Evidenz 
keine Evidenz 
1 RCT: keine eingriffs-
bezogenen Todesfälle  
in MACI-Gruppe 
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7 Quality of evidence 
The risk of bias (RoB) for individual studies was assessed with the Cochrane 
Collaboration tool for assessing risk of bias for randomised controlled stud-
ies [51] and the Risk Of Bias In Non-randomized Studies of Interventions 
assessment tool (ROBINS-I) [11], and is presented in Table A-5, Table A-6, 
and Table A-7 in the Appendix. 
The four RCTs (and two interim studies) for AMIC were graded with a high 
and the NRCT was graded with a serious RoB. The five RCTs (and one inter-
im study) for MACI were also graded with a high RoB. 
The main reasons for downgrading were no blinding of patients and outcome 
assessors, incomplete outcome data (e.g., no statistical analyses of outcomes 
between groups, missing confidence intervals and p-values), unclear report-
ing of confounding variables (e.g., no adherence of possible effect of physio-
therapy/rehabilitation or pain killers), and possible conflicts of interests of 
the authors. 
The strength of evidence was rated according to the GRADE (Grading of Re-
commendations Assessment, Development and Evaluation) scheme [12] for 
each endpoint individually. Each study was rated by two independent re-
searchers. In case of disagreement, a third researcher was involved to resolve 
the difference. A more detailed list of the criteria applied can be found in the 
recommendations of the GRADE Working Group [12]. 
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect. 
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different. 
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect. 
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings tables below (Table 7-1 and Table 7-2) 
and in the evidence profile in the Appendix (Table A-9). 
As the outcomes were measured with different scores, each score for the spe-
cific outcome was graded individually. Due to lacking data, the following 
scores could not be graded for AMIC (KOOS sport/rec & QoL & pain, Lys-
holm score, EQ-5D) and for MACI (WOMAC stiffness & physical function & 
pain). With regard to the AMIC and MACI studies, the ICRS score was not 
interpretable, due to missing scoring instructions. Additionally, three AMIC 
studies [3, 5, 46] reported on the WOMAC score; however, different scales 
were used. Thus, the WOMAC scores were graded separately for the two stud-
ies. With regard to the MACI studies, negative scores of the SF-12, which 
were not translated on a 0-100 score, were reported in one study [9]. Conse-
quently, the reported negative values could not be interpreted and this study 
could not be graded. 
RoB bewertet mit 
Cochrane Collaborations 
Tool (RCTs) sowie 
ROBINS-I (NRCT) 
hoher RoB in den 
eingeschlossen Studien 
Hauptgründe:  
fehlende Verblindung, 
unvollständige Daten, 
Interessenskonflikte etc. 
Qualität der Evidenz 
nach GRADE 
GRADE Tabelle  
nächste Seite 
nicht alle Endpunkte/ 
Scores mittels GRADE 
evaluiert, aufgrund 
fehlender Daten  
bzw. unmöglicher 
Interpretation der 
berichteten Daten 
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Overall, the strength of evidence for the efficacy and safety of the single-step 
scaffold-based cartilage repair of the knee in combination with MFx in com-
parison to MFx alone is “moderate” and “low”, respectively. For the compar-
ison to ACI, no evidence was available (Table 7-1). 
Overall, the strength of evidence for the efficacy and safety of the two-step 
scaffold-assisted cartilage repair of the knee in comparison to MFx or ACI is 
“low” and “very low”, respectively (Table 7-2). 
 
AMIC vs. MFx: 
moderate Evidenzstärke 
für Wirksamkeit und 
niedrige für Sicherheit 
MACI vs. MFx/ACI: 
niedrige Evidenzstärke 
für Wirksamkeit und sehr 
niedrige für Sicherheit 
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Table 7-1: Summary of findings table of AMIC compared to MFx for cartilage repair in the knee 
Outcomes 
Anticipated absolute effects 
Relative  
effect 
№ of 
participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments Risk with 
MFx or ACI 
Risk with 
AMIC 
Difference 
Efficacy 
Mobility/joint functionality: improvement from baseline 
assessed with: IKDC 
Scale from: 0 to 100 
follow-up: mean 24 months 
NR NR MD 1 point higher in 
AMIC group a 
Not estimable 100 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b,c 
Higher score 
indicates better 
function 
Mobility/joint functionality: improvement from baseline 
assessed with: WOMAC stiffness 
Scale from: 0 to 8 
follow-up: mean 24 months 
NR NR MD 3.5 points lower 
in AMIC group a 
Not estimable 69 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b 
Lower score 
indicates less 
stiffness 
Mobility/joint functionality: reduction from baseline 
assessed with: WOMAC stiffness 
Scale from: 0 to 20 
follow-up: mean 60 months 
NR NR MD 1.1 points higher 
in AMIC group a 
Not estimable 80 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b Lower score indicates less 
stiffness 
Mobility/joint functionality: improvement from baseline 
assessed with: WOMAC physical function 
Scale from: 0 to 68 
follow-up: mean 24 months 
NR NR MD 29.7 points lower 
in AMIC group a 
Not estimable 69 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b 
Lower score 
indicates better 
function 
Mobility/joint functionality: reduction from baseline 
assessed with: WOMAC physical function 
Scale from: 0 to 170 
follow-up: mean 60 months 
NR NR MD 5.6 points higher 
in AMIC group a 
Not estimable 80 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b Lower score indicates better 
function 
Mobility/joint functionality: reduction from baseline 
assessed with: Modified Cincinnati Knee Rating System 
Scale from: 0 to 100 
follow-up: mean 12 months 
NR NR MD 6.0 points lower 
in AMIC group a 
Not estimable 47 
(1 RCT) 
⨁⨁◯◯ 
LOW b,c,,f 
Higher score 
indicates better 
function 
Mobility/joint functionality: reduction from baseline 
assessed with: SF-12, SF-36 
Scale from: 0 to 100 
follow-up: mean 60 months 
NR NR MD 1.4 points lower 
in AMIC group a 
Not estimable 80 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b,c 
Higher score 
indicates better 
function 
Quality of life: improvement from baseline 
assessed with: SF-36 
Scale from: 0 to 100 
follow-up: mean 60 months 
NR NR MD 2.9 points higher 
in AMIC group a 
Not estimable 80 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b,c 
Higher score 
indicates better 
QoL 
Pain: improvement from baseline 
assessed with: VAS 
Scale from: 0 to 100 
follow-up: mean 24 months 
NR NR MD 6.3 points lower 
in AMIC group a 
Not estimable 100 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b,c 
Higher score 
indicates worse 
pain 
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Outcomes 
Anticipated absolute effects 
Relative  
effect 
№ of 
participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments Risk with 
MFx or ACI 
Risk with 
AMIC 
Difference 
Pain: improvements from baseline 
assessed with: WOMAC pain 
Scale from: 0 to 20 
follow-up: mean 24 months 
NR NR MD 12.0 points fewer 
in AMIC group a 
Not estimable 69 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b 
Lower score 
indicates less 
pain 
Pain: reduction from baseline 
assessed with: WOMAC pain 
Scale from: 0 to 50 
follow-up: mean 60 months 
NR NR MD 1.2 points higher 
in AMIC group a 
Not estimable 80 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b Lower score indicates less 
pain 
Necessity of total joint replacement 
assessed with: in % of pts. 
At 12 months: 1 total knee arthroplasty  
(study group N/A). 
N/A 69 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE b,c 
- 
Safety 
Safety: Severe adverse events (SAE) 
assessed with: in % of pts. 
follow-up: range 24 months to 60 months 
30 per 1,000 62 per 1,000 N/A RR 2.1 a 227 
(3 RCTs) 
⨁◯◯◯ 
VERY LOW b, g,h 
- 
Safety: Procedure-related adverse events 
assessed with: in % of pts. 
follow-up: range 24 months to 60 months 
347 per 1,000 381 per 1,000 N/A RR 1.1 a 227 
(3 RCTs) 
⨁◯◯◯ 
VERY LOW b,g,h 
- 
Safety: Device-related adverse events 
assessed with: in % of pts. 
follow-up: range 24 months to 60 months 
0 per 1,000 0 per 1,000 N/A Not estimable 180 
(2 RCTs) 
⨁⨁⨁◯ 
MODERATE b, 
- 
Safety: Re-operation rate 
assessed with: in % of pts. 
follow-up: range 12 months to 60 months 
38 per 1,000 13 per 1,000 N/A RR 0.34 a 127 
(2 RCTs) 
⨁⨁◯◯ 
LOW b,h 
- 
Abbreviations: CI: Confidence interval; MD: Mean difference; N/A: not available; RR: Risk ratio. 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. 
Comments 
a. Based on self-calculated mean difference between study groups/relative risk. 
b. There was a serious risk of bias due to possible confounding, missing data,  
and the use of un-blinded patient-reported outcome measures.  
c. N/A (only one trial).  
e. Different age of pts. between studies.  
f. Low incidence/pts. numbers.  
g. Heterogeneity in reported cases across studies.  
h. Low incidence/pt. numbers in one study.  
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Table 7-2: Summary of findings table of MACI compared to MFx or ACI for cartilage repair in the knee 
Outcomes 
Anticipated absolute effects 
Relative  
effect 
№ of 
participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments Risk with 
MFx or ACI 
Risk with 
MACI 
Difference 
Efficacy 
Mobility/joint functionality: improvement from baseline 
assessed with: KOOS sport/rec 
Scale from: 0 to 100 
follow-up: mean 60 months 
NR NR MD 8.1 points higher 
in MACI group a 
Not estimable 158 
(2 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,f 
Higher score 
indicates better 
function 
Mobility/joint functionality: reduction from baseline 
assessed with: IKDC 
Scale from: 0 to 100 
follow-up: mean 24 months 
NR NR MD 2.4 points fewer 
in MACI group a 
Not estimable 179 
(3 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,h 
Higher score 
indicates better 
function 
Mobility/joint functionality: improvement from baseline 
assessed with: Modified Cincinnati Knee Scoring System 
Scale from: 0 to 100 
follow-up: range 12 months to 60 months 
NR NR MD 1.5 points higher 
in MACI group a 
Not estimable 219 
(2 RCTs) 
⨁⨁◯◯ 
LOW c,d 
Higher score 
indicates better 
function 
Mobility/joint functionality: improvement from baseline 
assessed with: Lysholm scoring scale 
Scale from: 0 to 100 
follow-up: mean 24 months 
NR NR MD 2.3 points higher 
in MACI group a 
Not estimable 81 
(2 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,f 
Higher score 
indicates better 
function 
Mobility/joint functionality: change from baseline 
assessed with: SF-36 
Scale from: 0 to 100 
follow-up: mean 24 months 
At 12/24 months  
n.s. difference between study groups. 
Not estimable 21 
(1 RCT) 
⨁⨁◯◯ 
LOW c,d,f,m 
Higher score 
indicates better 
function 
Quality of life: improvement from baseline 
assessed with: KOOS QoL  
Scale from: 0 to 100 
follow-up: mean 60 months 
NR NR MD 4.6 points higher 
in MACI group a 
Not estimable 158 
(2 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,f 
Higher score 
indicates better 
QoL 
Quality of life: improvement from baseline 
assessed with: EQ-5D 
Scale from: 0 to 100 
follow-up: mean 60 months 
NR NR MD 1.0 point higher 
in MACI group a 
Not estimable 128 
(1 RCT) 
⨁⨁⨁◯ 
MODERATE c,i 
Higher score 
indicates better 
QoL 
Mobility/joint functionality: change from baseline 
assessed with: SF-36 
Scale from: 0 to 100 
follow-up: mean 24 months 
At 12/24 months  
n.s. difference between study groups. 
Not estimable 21 
(1 RCT) 
⨁⨁◯◯ 
LOW c,d,f,m 
Higher score 
indicates better 
QoL 
Pain: improvement from baseline 
assessed with: KOOS pain 
Scale from: 0 to 100 
follow-up: mean 60 months 
NR NR MD 5.5 points higher 
in MACI group a 
Not estimable 158 
(2 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,f 
Higher score 
indicates less 
pain 
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Outcomes 
Anticipated absolute effects 
Relative  
effect 
№ of 
participants  
(studies) 
Certainty of  
the evidence 
(GRADE) 
Comments Risk with 
MFx or ACI 
Risk with 
MACI 
Difference 
Pain: improvement from baseline 
assessed with: VAS 
Scale from: 0 to 100 
follow-up: N/A 
NR NR MD 0.2 points lower 
in MACI group a 
Not estimable 121 
(2 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,f 
Higher score 
indicates worse 
pain 
Pain: assessed with: SF-12, SF-36 
follow-up: mean 24 months 
N.s. difference between IG vs. CG  
for 12 and 24 months. 
Not estimable (1 RCT) ⨁⨁◯◯ 
LOW c,i,k 
Higher score 
indicates less 
pain 
Necessity of total joint replacement  
assessed with: in % of pts. 
0 per 1,000 0 per 1,000 N/A Not estimable 30 
(1 RCT) 
⨁⨁◯◯ 
LOW c,i,k 
- 
Safety 
Safety: Severe adverse events (SAE) 
follow-up: range 24 months to 60 months 
7 per 1,000 11 per 1,000 N/A RR 1.57 a 330 
(5 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,h 
- 
Safety: Procedure-related adverse events 0 per 1,000 0 per 1,000 N/A Not estimable 30 
(1 RCTs) 
⨁⨁◯◯ 
LOW c,f, l 
- 
Safety: Device-related adverse events 
follow-up: range 6 months to 24 months 
333 per 1,000 173 per 1,000 N/A RR 0.52 a 112 
(2 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,f, g 
- 
Safety: Re-operation rate 
follow-up: mean 24 months 
27 per 1,000 44 per 1,000 N/A RR 1.59 a 330 
(5 RCTs) 
⨁◯◯◯ 
VERY LOW c,d,e,h 
- 
Abbreviations: MD: Mean difference; N/A: not available; RR: Risk ratio 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. 
Comments 
a. Based on self-calculated mean difference between study groups/relative risk. 
b. Absolute effect based on one study (Brittberg 2018).  
c. There was a serious risk of bias due to possible confounding, missing data,  
and the use of un-blinded patient-reported outcome measures.  
d. Heterogeneity in reported cases across studies.  
e. Different defect size in pts. between studies.  
f. Low incidence/pt. numbers in one study. 
g. For device-related adverse events, only the studies with ACI as the comparator were considered. 
h. Low incidence/pt. numbers in two studies.  
i. N/A (only one trial)  
j. Absolute effect based on one study (Bartlett 2005).  
k. Low incidence/pt. numbers.  
l. Absolute numbers for adverse events given only in one study. 
m. In one RCT [9], negative scores of the SF-12, which were not translated  
on a 0-100 score, were reported. Thus, the reported negative values could  
not be interpreted and this study could not be graded for this outcome. 
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8 Discussion 
Chondral or osteochondral lesions are difficult-to-treat entities that often af-
fect young and active persons. Moreover, cartilage has limited intrinsic heal-
ing potential due to the isolation from the systemic regulation and lacking 
vessels plus nerve supply. This contributes to the fact that cartilage healing 
remains challenging. 
Chondral and osteochondral defects severely reduce the quality of life of the 
affected persons, especially due to the associated pain. Untreated or progress-
ing defects can lead to osteoarthrosis and to the necessity to replace the affect-
ed joint in the long run. 
The aims of this report were, on the one hand, to assess the clinical efficacy 
and safety of the single-step matrix-assisted cartilage repair combined with 
MFx (AMIC) in the knee or ankle joint, compared to MFx alone or ACI. On 
the other hand, the clinical efficacy and safety of the two-step matrix-assisted 
cartilage repair (MACI) in the knee or ankle joint was investigated compared 
to MFx or ACI. 
 
Results of the single-step matrix-assisted cartilage repair (AMIC) 
No studies investigating the clinical efficacy of AMIC in the ankle joint or in 
comparison to ACI met the inclusion criteria. Thus, only results for the effi-
cacy and safety of AMIC in the knee joint compared to MFx alone were re-
ported. 
For assessing the clinical efficacy and safety of AMIC combined with MFx 
in the knee joint compared to MFx alone, six studies (five RCTs3 and one 
NRCT) that met our inclusion criteria could be identified, involving 314 pa-
tients overall. 
All trials used different products of scaffolds: Chondro-Gide®, MaioRegenTM, 
JointRepTM, BST-CarGel® and another device comparable to GelrinC®. 
All of the identified studies included patients with (osteo)chondral defects in 
the knee. The mean defect sizes were slightly larger in the intervention groups 
compared to the control groups (2.3-3.9 vs. 1.9-3.5 cm²). As AMIC is indi-
cated for a defect size of up to 8 cm², the patients included in the studies had 
relatively small defect sizes. 
Different scores measuring the mobility/joint functionality (six scores), quality 
of life (three scores) and pain (three scores) were reported in the included stud-
ies. With regard to mobility/joint functionality, inconsistent results were re-
ported across the scores. For quality of life, an improvement was reported for 
the intervention group; however, this improvement was not statistically sig-
nificant. For pain, similar improvements were reported between the study 
groups across the studies. In only one study, the necessity of a total joint re-
placement was addressed. In this study, one total knee arthroplasty was re-
ported after 12 months. 
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Complications were reported in all extracted studies. However, the compli-
cation rates between the studies differed considerably, keeping in mind that 
different follow-up periods might have contributed to this observation. Se-
vere adverse event rates ranged from 0-12.2% in the intervention groups and 
from 0-3.8% in the control groups of three studies. Procedure-related adverse 
events occurred in 0-93.0% of the patients in the intervention groups (0-77.0% 
in the control groups) across four studies [3, 5-7, 47]. The rates for device-re-
lated complications differed from 3.0 to 22.0% across three studies [3, 5, 6, 47]. 
Overall, the strength of evidence for the clinical effectiveness and safety of 
AMIC compared to MFx alone was determined as “moderate” and “low”, re-
spectively, by considering only the highest available level of evidence (RCTs). 
The strength of evidence of identified RCTs was mainly downgraded due to 
the fact that the outcomes were subjective and the patients, as well as the as-
sessing personnel, were aware of the intervention. 
 
Interpretation of findings of the single-step matrix-assisted 
cartilage repair (AMIC) 
There is no robust evidence that AMIC leads to better efficacy and safety 
outcomes than MFx alone. In the following, different aspects that might have 
influenced these results are presented: 
 A major issue of the identified trials is the low number of patients of 
each study. One RCT [47] consisted of 100 patients, whereas the small-
est controlled trial included only 18 patients (NRCT [6]). Initially, 
this study was conducted as a RCT. However, the randomisation was 
stopped after only three patients were assigned to the control group. 
This study was thus treated as a NRCT in the present report. Espe-
cially for identifying rare (unanticipated) complications, these patient 
numbers might be insufficient. Furthermore, small patient numbers 
are likely to have an impact on the trials’ ability to detect between-
group differences in efficacy outcomes. 
 Two of the studies had a relatively short follow-up of one year or less 
(six months for the NRCT [6]). Only two of the studies had a follow-
up of at least five years. Therefore, reliable data on long-term efficacy 
and safety-related outcomes are missing, which might have especially 
impacted the safety results. 
 The applied interventions (different products) differed slightly be-
tween the individual studies. First of all, in two studies the scaffold 
was a hydrogel and in the other studies it was a kind of “fleece”. An-
other potential effect on the outcomes could be the fixation technique 
of the scaffold (e.g., if it was glued or sutured). Moreover, the MFx-
procedure in the control groups was either performed arthroscopical-
ly or by mini-arthrotomy. 
In addition, some outcomes were reported incomplete or inconsistent and 
lacked sufficient data: 
 One outcome defined as crucial – necessity of a total joint replace-
ment – was exclusively reported in one trial (one patient required a 
new joint – study group unknown). However, this outcome is important 
to assess the long-term efficacy of the treatment of chondral or oste-
ochondral defects. For meaningful prospective data on joint replace-
ment rates, a very long follow-up and/or large samples might be nec-
essary. 
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 Due to the incomprehensive or inconsistent screening, recording and/ 
or reporting of adverse events across the majority of included studies, 
aggregated statements on the safety are barely possible. This was 
deemed an important shortcoming for the majority of included stud-
ies. In one RCT, it seems that adverse events were recorded systemat-
ically, resulting in a procedure-related complications rate of about 
93.0% in the treatment group. In another RCT, the rates of proce-
dure-related complications were reported as 0%. This discrepancy 
hints at different approaches to safety. It has to be stated that due to 
the invasive nature of the interventions compared, an adverse event 
rate close to 0% could be questioned. Furthermore, in only one out of 
five studies was it clearly stated which adverse events occurred. 
 
Results of the two-step matrix-assisted cartilage repair (MACI) 
No studies investigating the clinical efficacy and safety of MACI in the an-
kle joint met the inclusion criteria. Thus, only results about the efficacy and 
safety of MACI in the knee joint compared to MFx or ACI could be reported. 
For assessing the clinical efficacy and safety of MACI in the knee joint com-
pared to MFx or ACI, three and two RCTs were identified, respectively, in-
volving a total of 330 patients. 
In three trials, different products of scaffolds were used: Spherox®, BioSeed®-C 
and NeoCart®. 
All of the identified studies included patients with chondral defects in the 
knee. The mean defect sizes were slightly larger in the intervention groups 
compared to the control groups (2.9-6.1 vs. 2.5-6.0 cm²). As MACI is indicat-
ed for a defect size of up to 10 cm², the patients included in the studies had 
relatively small defect sizes. 
Different scores measuring the mobility/joint functionality (six scores), qual-
ity of life (three scores) and pain (three scores) were reported in the included 
studies. 
For the comparison to MFx, partly statistically significant improvements in 
joint functionality and quality of life were reported for the intervention group. 
For pain, partly statistically significant improvements were also reported in 
the intervention groups across scores and studies. In only one study, the ne-
cessity of a total joint replacement was addressed. In this study, one total 
knee arthroplasty was reported after 12 months. 
For the comparison MACI versus ACI, inconsistent results regarding im-
provements in joint functionality were reported across scores and studies. 
Moreover, no evidence was available for quality of life. For pain, no statisti-
cally significant differences between the study groups could be identified. 
There was no evidence for the necessity of a total joint replacement. 
Complications were reported in all three studies comparing MACI to MFx. 
The complication rates between the studies differed considerably, which 
might be related to the different follow-up periods. Severe adverse event rates 
ranged from 4.8-15.3% in the intervention groups and from 11.1-26.4% in 
the control groups across the three studies. Procedure-related adverse events 
occurred in 0-34.7% of the patients in the scaffold groups (0-38.9% in the 
control groups) across all three studies. No evidence was available for de-
vice-related complications. In addition, re-operation rates were reported in 
all three RCTs ranging from 2.5-8.3% versus 0-9.7%. 
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Furthermore, complications were reported in both studies comparing MACI 
to ACI. Again the complication rates differed considerably between the stud-
ies. Severe adverse event rates ranged from 0-9.0% in the intervention groups, 
while zero events occurred in the control groups of the studies. No procedure-
related adverse events were reported in the two RCTs. The rates for device-
related complications differed from 12.5-36.4% in the intervention groups 
and from 9.0-140% in the control groups across the studies. The reported re-
operation rates ranged from 6.4-27.3% versus 6.8-10.0% between the study 
groups of both RCTs. 
Overall, the strength of evidence for the clinical efficacy and safety of MACI 
compared to MFx or ACI was determined as “low” and “very low”, respec-
tively. The strength of evidence of identified RCTs was mainly downgraded 
due to the fact that the outcomes were subjective and the patients, as well as 
the assessing personnel, were aware of the intervention. 
 
Interpretation of findings of the two-step matrix-assisted 
cartilage repair (MACI) 
There is no robust evidence that MACI leads to better efficacy and safety out-
comes than ACI. However, from the extracted evidence, slightly better im-
provements (partly statistically significant) in joint functionality, quality of 
life and pain, as well as slightly lower complications rates, could be identi-
fied in the intervention groups compared to MFx. In the following, different 
aspects that might have influenced these results are presented: 
 Similar to the AMIC studies, a major issue of the identified studies 
for MACI is the low number of patients in some studies. Only one 
RCT (in comparison to MFx) [9] consisted of more than 100 patients 
(n=128), whereas one study (in comparison to ACI) included only 21 
patients [23]. Thus, in total, the comparison to MFx involved 218 pa-
tients (3 RCTs), whereas the comparison to ACI only included 112 pa-
tients (2 RCTs). Especially for identifying rare (unanticipated) com-
plications, these patient numbers, in particular for the comparison to 
ACI, might be insufficient. The small patient numbers in the studies 
“MACI vs. ACI” are also likely to have an impact on the trials’ ability 
to detect between-group differences in efficacy outcomes. 
 Furthermore, only one study (in comparison to MFx) [9] had a follow-
up longer than 24 months. Therefore, reliable data of long-term effi-
cacy and safety-related outcomes are missing, which might have es-
pecially impacted the safety results. 
 The applied interventions (different products) differed slightly be-
tween the individual studies. First of all, the material of the used scaf-
fold differed between studies (e.g., bovine vs. porcine collagen matrix). 
Secondly, in three of the five studies, MACI was compared to MFx, 
and to ACI, in the remaining two studies. Of these two studies, the first 
ACI generation, including a periosteal flag matrix, was investigated 
in one study [23], whereas the third ACI generation [22], involving a 
porcine derived matrix, was assessed in the second study. 
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In addition, some outcomes were reported incomplete or inconsistent and 
lacked sufficient data: 
 One outcome defined as crucial – necessity of a total joint replacement 
– was exclusively reported in only one trial (one patient in the scaf-
fold-group required a new joint) in comparison to MFx. In compari-
son to ACI, no evidence about the necessity of a total joint replace-
ment was available. However, this outcome is important to assess the 
long-term efficacy of the treatment of (osteo)chondral defects. Thus, 
for meaningful prospective data on joint replacement rates, a very long 
follow-up and/or larger samples might be necessary. 
 Due to the incomprehensive or inconsistent screening, recording and/ 
or reporting of adverse events across the majority of included studies, 
aggregated statements on the safety are barely possible. This was 
deemed an important shortcoming for the majority of included stud-
ies. In all five studies, the ranges of adverse events were wide within 
and between study groups. This discrepancy hints at different ap-
proaches to safety. It has to be stated that due to the invasive nature 
of the interventions compared (involving one to two operations), an 
adverse event rate close to zero could be questioned. 
 Moreover, different adverse event rate results between intervention 
and control groups might also be related to the control group (MFx 
or ACI). Interestingly, the adverse event rates of MACI compared to 
MFx were lower in the intervention groups, even though MACI in-
volves two operations, while MFx only one. In comparison to ACI (al-
so a two-step approach), the adverse event rates were partly higher in 
the control groups. However, this could also be an effect of the smaller 
patient numbers and shorter follow-up in the studies comparing MACI 
vs. ACI. 
In 2009, the Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA) 
in Germany concluded that MACI is a promising intervention. However, the 
evidence was not sufficient to demonstrate a clinical benefit and, therefore, 
the intervention should be re-evaluated (the re-evaluation was planned for 
2014, but no results have been published yet) [52]. 
 
General discussion points 
To date, no RCTs and NRCTs could be identified to assess the clinical effec-
tiveness and safety of AMIC and MACI versus MFx and/or ACI for the ankle 
joint. 
Not all studies conclusively reported additional interventions (e.g., menisc-
ectomies) before the initial surgery. However, it is possible that additional 
surgeries had an impact on the outcomes. 
Moreover, all included studies reported on post-operative rehabilitation pro-
grammes. However, the effects of these post-operative therapies on the over-
all efficacy and safety outcomes were not considered. Thus, there is a possi-
ble confounding effect on the reported findings. 
In addition, it was barely reported whether patients received additional med-
ication after the surgical procedure or even in the long run, e.g., for symptom 
control. It is evident that, e.g., the intake of painkillers at the time of follow-
up could have impacted outcome assessment, such as pain and quality of life. 
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Moreover, limited long-term evidence of both interventions (AMIC & MACI) 
is currently available, as only a few studies had a follow-up longer than 24 
months. Thus, it remains questionable whether the interventions have a sus-
tainable effect. Especially in terms of safety and the necessity of a total joint 
replacement, longer follow-up periods are substantial in order to identify rare 
adverse events and to investigate the sustainable preservation of the rebuilt 
cartilage. Besides longer follow-up, larger clinical trials are also necessary to 
identify serious rare complications and to be able to detect more reliable be-
tween-group differences in efficacy and safety outcomes. 
All studies included relatively young patients of working age. The mean ages 
in the AMIC studies were slightly higher (34.0-54.5 vs. 35.2-56.6 years) com-
pared to the mean ages in the MACI studies (29.5-41.0 vs. 29.5-39.0 years). 
Nevertheless, assuming that mean ages in the studies display the mean ages 
of the general patient population with cartilage defects, these patients might 
be incapacitated for work, require more sick leave, have to quit their current 
jobs, including a subsequent need for retraining, or even require early retire-
ment, which might significantly impact their quality of life. Consequently, 
cartilage defects – or more precisely the challenge of healing cartilage defects 
– can result in additional societal costs. 
In all included studies (for AMIC and MACI), efficacy outcomes were meas-
ured with various different scores within and across the studies. As a result, 
the interpretation of the effect of the intervention on one specific outcome 
was difficult for one study and across all studies and, in some cases, not even 
possible. For example, the ICRS scores were not interpretable due to lacking 
scoring instructions. Moreover, one study reported negative SF-12 scores, 
which were not translated on a 0-100 score. Consequently, the reported nega-
tive scores could not be interpreted (see Applicability table). 
Moreover, the majority of the efficacy outcomes (mobility/joint functionali-
ty, quality of life, pain and activities of daily living) were patient-reported 
outcomes and thus may be confounded. Therefore, the level of subjective-
ness was taken into account within the risk of bias assessment. 
 
Upcoming evidence 
Six ongoing RCTs ( Table A-11) will provide further data on the efficacy and 
safety of AMIC or MACI (for different products) in comparison to MFx. How-
ever, the majority of these studies will not provide long-term follow-up of 
more than 24 months, and thus will not fill the gap of long-term evidence 
exceeding 24 months. Only one RCT (NCT01656902) will investigate the safe-
ty and effectiveness of the NOVOCART® 3D plus (MACI) compared to MFx 
for 36 months (estimated completion date May 2019). 
No ongoing RCTs or NRCTs investigating the clinical efficacy and safety of 
AMIC/MACI compared to ACI could be identified. Further, no ongoing 
RCTs or NRCTs for the assessment of both interventions for the ankle joint 
could have been identified. 
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Limitations to the present report 
First of all, we decided to exclusively include studies with a high level of evi-
dence, RCTs and NRCTs, due to the richness of these detected studies. Con-
sequently, we excluded the only study (case series) for the ankle joint that 
had been identified via the systematic literature and additional hand search. 
Secondly, we excluded retrospective studies – even controlled studies with a 
retrospective control group – because the sources of error due to confound-
ing and bias are more common in retrospective studies than in prospective 
ones. 
Thirdly, possibly not all appropriate studies could have been identified, alt-
hough different terms in the systematic literature search were used, the man-
ufacturers contacted for additional studies and a supplemented hand search 
was conducted. This is mainly due to the inconsistent wording for the as-
sessed technology of cartilage repair. In addition, it is possible that not all 
manufacturers could have been identified. 
Further, we did not distinguish between chondral and osteochondral defects. 
Therefore, studies investigating other comparative interventions for osteochon-
dral defects, for example osteochondral autograft transplantation (OATS) were 
not considered in this report. 
In all included studies (for AMIC and MACI), efficacy outcomes were meas-
ured with various different scores within and across the studies. Therefore, for 
most of the scores, only one study was available for performing the GRADE 
analysis. This could have had an impact on the explanatory power of the 
strength of evidence resulting from the analysis. 
Finally, although the present report includes various different comparisons 
between interventions/control interventions (AMIC vs. MFx; MACI vs. MFx 
or ACI), the two interventions (AMIC and MACI) as well as the two compara-
tive interventions (MFx and ACI) have not been compared with each other, 
as this would have been beyond the scope of this assessment. Therefore, ad-
ditional studies might have been excluded. 
 
Conclusion 
Overall, no conclusions can be made that the single-step scaffold-assisted car-
tilage repair combined with MFx (AMIC) leads to better outcomes than MFx 
alone. No evidence (RCTs and NRCTs) is available for investigating the effect 
on AMIC compared to ACI. 
For the comparison of the two-step scaffold-assisted cartilage repair (MACI) 
to MFx, slightly better efficacy outcomes (joint functionality, quality of life, 
pain) were identified in the intervention groups. Moreover, MACI seems to 
be slightly safer compared to MFx. However, there was no robust evidence 
that MACI leads to better outcomes compared to ACI. 
Because the included studies showed partly poor quality of evidence and high 
risk of bias, it is not possible to draw a reliable conclusion on the clinical ef-
fectiveness and safety for both interventions. 
lediglich RCTs und 
NRCTs eingeschlossen 
 keine kontrollierten 
Studie zum 
Sprunggelenk  
Ausschluss 
retrospektiver Studien 
Möglichkeit der  
Nicht-Identifikation von 
relevanten Studien 
keine Unterscheidung 
chondraler/ 
osteochondraler Defekte 
Aussagekraft der 
GRADE Analyse evtl. 
limitiert 
kein Vergleich von  
AMIC vs. MACI, sowie 
MFx vs. ACI 
keine klare Aussage  
zu AMIC vs. MFx 
MACI scheinbar  
etwas wirksamer und 
sicherer als MFx,  
keine Aussage vs. ACI 
jedoch generell Qualität 
der Evidenz niedrig 
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Future RCTs and/or NRCTs investigating, on the one hand, the effect of 
AMIC and/or MACI for the ankle joint and, on the other hand, the effect of 
AMIC compared to ACI for the knee joint, need to be reported. Moreover, 
longer follow-up periods (with a minimum of five years) and larger clinical 
trials are necessary in order to be able to investigate the sustainable preserva-
tion of the rebuilt cartilage, as well as to identify serious rare adverse events. 
Further evidence is likewise needed to confirm the possible positive effect of 
MACI over MFx and to clarify the inconsistent evidence of AMIC compared 
to MFx and of MACI versus ACI. 
 
weitere Studien zu 
Sprunggelenk, zu AMIC 
vs. ACI, längere Nach-
beobachtungszeiträume 
& größere Studien 
notwendig 
Effekt von MACI über 
MFx bestätigen 
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9 Recommendation 
Table 9-1 shows the scheme for recommendations and highlights  
the respective choice. 
Table 9-1: Evidence-based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning single-step scaffold-assisted cartilage repair (AMIC) 
The current evidence is not sufficient to conclude that the single-step scaf-
fold-assisted cartilage repair (AMIC) combined with microfracture is more ef-
fective and safer than microfracture alone for the treatment of cartilage de-
fects in the knee joint. 
In comparison to the autologous chondrocyte implantation (ACI), no evi-
dence was available to conclude that AMIC is as effective, but safer than 
ACI for the treatment of cartilage defects in the knee joint. 
Reasoning two-step scaffold-assisted cartilage repair (MACI) 
To date, the evidence shows that the two-step scaffold-assisted cartilage re-
pair (MACI) seems to be slightly more effective and safer than microfracture 
for the treatment of cartilage defects in the knee joint. 
In comparison to ACI, the current evidence is not sufficient to prove that 
MACI is as effective, but safer than ACI for the treatment of cartilage de-
fects in the knee joint. 
Recommendation 
As no controlled studies could be identified for the cartilage repair of the an-
kle joint, it was not possible to give a recommendation about whether AMIC 
and/or MACI should be considered for the inclusion into the hospital bene-
fit catalogue for the ankle joint. 
Due to inconsistent outcome reporting, the included studies showed partly 
poor quality of evidence and high risk of bias. Hence, it is not possible to 
draw a reliable conclusion on the clinical effectiveness and safety for both 
interventions. As a result, AMIC and MACI are currently not recommended 
for the inclusion in the hospital benefit catalogue. 
New study results, especially from studies with larger patient numbers and 
longer follow-up periods (e.g., ten years), will potentially influence the effect 
estimate in a considerable manner. 
A re-evaluation for AMIC is recommended not before 2022, since there are 
still ongoing RCTs (see Table A-11). For MACI a re-evaluation might be rea-
sonable not before 2021, as the technique seems to be promising compared 
to MFx. 
AMIC vs. MFx: 
unzureichende Evidenz 
zum Kniegelenk 
AMIC vs. ACI: 
keine Evidenz zum 
Kniegelenk 
MACI scheint  
wirksamer und sicherer 
als MFx zu sein 
MACI vs. ACI: 
unzureichende Evidenz 
für das Kniegelenk 
keine Evidenz zum 
Sprunggelenk, daher 
keine Empfehlung dazu 
niedrige Evidenzqualität 
 verlässliche Aussage 
nicht möglich 
Studien mit mehr 
PatientInnen + längerer 
Nachbeobachtung 
Re-Evaluierung AMIC 
2022 empfohlen; 
Re-Evaluierung MACI 
nach 2021 empfohlen 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Autologous matrix-induced chondrogenesis in combination with MFx (AMIC) for cartilage repair of knee joints: Results from randomised controlled trials 
Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
Country Italy, Sweden, Belgium, 
Switzerland, Austria, Germany, 
Norway, Poland, South Africa 
Italy Canada, Spain, South Korea Germany 
Sponsor Fin-Ceramica Faenza S.p.A., Italy None BioSyntech Canada Inc.,  
Piramal Life Sciences 
Geistlich Pharma AG, Switzerland 
Intervention/Product AMIC (MaioRegenTM, Fin-Ceramica 
Faenza S.p.A., Italy): 
Arthrotomy, nanostructured 
collagen-hydroxyapatite (coll-HA) 
multilayer scaffold (osteochondral 
biomimetic scaffold) 
AMIC (JointRepTM, Oligo Medic Inc., 
Laval, Quebec Canada): 
Microfracture surgery + injectable 
thermogelling system 
AMIC (BST-CarGel®, Piramal Life 
Sciences, Bio-Orthopaedic Division): 
Arthroscopy + miniarthrotomy, 
single-step cartilage repair + 
microfracture/BST-CarGel® 
AMIC (Chondro-Gide®, Geistlich Pharma 
AG, Wolhusen, Switzerland): 
Miniarthrotomy + microfracture  
+ collagen type I/III membrane 
(AMIC® sutured | AMIC® glued) 
Comparator MFx alone MFx alone Arthroscopic MFx alone Arthroscopic MFx alone 
Study design Multicentre randomised 
controlled trial (RCT) 
Matched pair study (RCT) Multi-centre randomised  
controlled trial (RCT) 
Two-centred, prospective,  
randomised controlled trial (RCT) 
Number of pts., n 100 (51 vs. 49)10 69 (46 vs. 23) 80 (41 vs. 39)12 
60 (34 vs. 26) 
47 (17 | 1711 vs. 13) 
Location of lesion,  
n (%) 
Chondral and osteochondral lesions: 
Condyle: 37 (72.6) vs. 23 (47.0) 
Trochlea: 2 (3.9) vs. 6 (12.2) 
Patella: 12 (23.5) vs. 20 (40.8) 
Osteochondral defect lesions (NR) Femoral condyle cartilage lesion12: 
Medial femoral condyle:  
40 (97.6) vs. 38 (97.4) 
Lateral femoral condyle: 1 (2.4) vs. 1 (2.6) 
Cartilage defect (NR) 
                                                             
  7 Study already included in initial report DSD98 2016. 
  8 Study results after one year were published in Stanish 2013 (assessing 41 vs. 39 pts.) and results after five years follow-up were presented in Shive 2014 (assessing 34 vs. 26 pts.). 
Therefore, data from both publications are presented together. However, the initial study protocol was planned for 12 months follow-up only. 67 of the 80 initial pts. were enrolled 
in the extension study. 
  9 Study results after two years were published in Anders 2013 (assessing 28 vs. 10 pts.) and results after two and five years follow-up were presented in Volz 2017 (assessing 34 vs. 13 pts.). 
Therefore, only the data from the latest publication are presented. 
10 Per protocol population. Safety population (n=124), 14 drop-outs and protocol violators and ten loss to follow-up. 
11 In 17 patients the scaffold was sutured and in 17 patients the scaffold was glued. 
12 Extracted from Stanish 2013. 
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Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
Inclusion criteria NR  moderate to severe (Outerbridge III–
IV) osteochondral lesions in the knee 
secondary to primary osteoarthritis 
or trauma and refractory to 
conservative measures, 
 pts. with associated conditions such 
as previous partial meniscectomy, 
cruciate ligament lesions, or failed 
microfracture surgery (only in one 
case) were also included in the study 
and the associated procedures 
were performed simultaneously 
and in addition to the surgical 
treatment of the chondropathy. 
 aged 18-55 yrs, 
 single, focal cartilage lesion  
on the femoral condyle, 
 moderate knee pain  
(>4 on a 10 point VAS). 
 aged 18-50 yrs, 
 one or two isolated cartilage defects of 
the knee grade III or IV according to the 
Outerbridge classification, 
 located either on the medial or lateral 
femoral condyle, trochlea or patella, 
 defect size between 2 and 10 cm2. 
Exclusion criteria NR NR  pts. with multiple lesions or  
kissing lesions, 
 clinically relevant compartment 
malalignment (>5 degrees), 
 pts. who underwent ligament 
treatments in the affected knee 
within two years prior to trial, 
 inflammatory arthropathy, such as 
rheumatoid arthritis, systemic 
lupus, or active gout, 
 previous surgical cartilage 
treatments in the affected knee  
in the last 12 months. 
 pts. with >2 defects, 2 corresponding 
defects or bilateral defects, 
 osteoarthritis, 
 bone lesions deeper than 0.7 cm, 
 axis deviation of more than ±5° in the 
frontal plane, 
 unresolved knee instability, 
 rheumatoid arthritis, 
 infectious diseases, 
 endocrine, metabolic or  
autoimmune diseases, 
 previous subtotal or total meniscus 
resection or mosaicplasty, 
 treatment with cartilage specific 
medication (e.g., hyaluronic acid), 
 chondropathia patellae, patella dysplasia 
or patella instability, 
 concomitant lesions of anterior cruciate 
ligament, meniscus or axial malalignement. 
Prior surgery, n (%) 27 (52.9) vs. 23 (46.9) 1 (2.2*) vs. 0 (0) NR13 10 (58.8*) | 8 (47.1*) vs. 6 (46.2*) 
Postoperative 
treatment(s) 
Early isometric and isotonic 
exercises and electrical 
neuromuscular stimulation  
(n/a) 
Postoperative rehabilitation protocol 
(all pts.): weightbear as tolerated 
(WBAT), after 15 days formal 
standard physical therapy 
Physiotherapy/rehabilitation  
(all pts.) 
Staged rehabilitation program  
(all pts.) 
                                                             
13 There was no prior surgery in the last 12 months before the start of the study. 
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1 
Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
Age of patients, 
mean, yrs (SD/range)  
34.0 (± 10.9) vs.  
35.2 (± 10.2) 
54.5 (±9.5/26–72) vs.  
56.6 (±7.6/44–70) 
35.1 (±9.6) vs.  
37.2 (±10.6)12 
34 (±11.0) | 39 (±9.0) vs.  
40 (±6.0) 
Female sex, n (%) 15 (29.4) vs. 18 (36.7) 17 (37.0) vs. 12 (52.2) 18 (43.9*) vs. 14 (35.9*)12 5 (29.4*) | 2 (11.8*) vs. 3 (23.1*) 
Follow-up (months) 24 24 60 60 
Loss to follow-up,  
n (%) 
10 (n/a) 2 (4.3*) vs. 0 (0) 12 months: 0 (0) vs. 2 (5) 
60 months: 8 (20.0) vs. 13 (33.3)14 
1 (5.9*) | 3 (17.6*) vs. 4 (30.8*) 
BMI, mean, kg/m² 
(SD/range) 
25.6 (± 3.3) vs. 25.2 (± 3.2) NR 27.0 (±3.3) vs. 25.2 (±3.0)12 27.4 (±4.4) | 27.6 (±4.0) vs. 25.0 (±2.9) 
Defect size, mean, 
cm2 (SD) 
3.4 (± 1.5) vs. 3.5 (± 1.6) 2.7* (n/a) vs. 2.6* (n/a) 2.3 (±1.4) vs. 1.9 (±1.4)12 3.8 (±2.1) | 3.9 (±1.1) vs. 2.9 (±0.8) 
Clinical classification,  
n (%) 
NR Outerbridge III: 10 (23) vs. 6 (39) 
Outerbridge IV: 36 (78) vs. 17 (61) 
NR Grade III (Outerbridge): NR 
Grade IV (Outerbridge): NR 
Primary endpoint(s) IKDC subjective knee evaluation 
form 2000 score after 24 months 
NR Degree of lesion fill & repair cartilage 
T2 relaxation time (both via MRI) 
Clinical evaluation as well as MRI evaluation 
at one, two and five years follow-up 
Outcomes 
Efficacy 
Mobility/joint functionality, scales: 
KOOS15 (sport/rec), 
mean (SD) 
NR NR NR NR 
IKDC 16, mean (SD) 
Higher scores indicate 
better function. 
Subjective IKDC: 
Baseline: 43.2 (±16.6) vs. 41.1 (±15.9) 
12 months: 60.7 (±17.3) vs.  
61.8 (±18.0) 
Change after 12 months:  
+17.5* vs. +20.7* 
24 months: 66.7 (±21.0) vs.  
63.6 (±18.2), n.s., p=n/a 
Change after 24 months:  
+23.5* vs. +22.5* 
NR NR NR 
                                                             
14 Loss to follow-up for assessing joint functionality by WOMAC score. 
15 The KOOS holds 42 items in five separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec),  
and knee-related Quality of Life (QOL). Scores are transformed to a 0–100 scale, 0 representing extreme problems and 100 representing no problems. 
16 The IKDC (International Knee Documentation Committee) scoring system includes ten items investigating symptoms, function and return to sporting activities.  
It combines objective clinician and subjective patient measures. Scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points  
(highest level of function and lowest level of symptoms). 
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Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
WOMAC17 stiffness 
subscale,  
mean (%/SD) 
Lower scores indicate 
better function. 
NR Baseline: 5.6 (3.1) vs. 5.1 (2.1), 
p=1.000, n.s. 
Change after 6 months: 
-4.9* (87.6) (p<0.0001) vs. -2.8* (55.6) 
p<0.0001, s.s. 
Change after 12 months: 
-5.3* (94.2) (p<0.0001) vs. -1.9* (37.6) 
(p=0.002418), s.s. 
Change after 24 months: 
-5.4* (97.2) (p<0.0001) vs. -1.9* (37.6) 
(p= 0.0004), s.s. 
Baseline19: 10.5 (±4.4) vs. 9.4 (±4.9), 
n.s. 
Change after 12 months12: 
-5.9 (±0.7) vs. -6.6 (±0.71), n.s. 
Change after 60 months: 
-5.6 (±0.7) vs. -6.7 (±0.6), n.s. 
NR 
WOMAC17 physical 
function subscale, 
mean (%/SD) 
Lower scores indicate 
better function.  
NR Baseline: 38.1 (8.1) vs. 41.7 (5.7), 
p=0.3394, n.s. 
Change after 6 months: 
-33.2* (87.1) (p<0.0001) vs. -19.4* 
(46.6) (p<0.0001), s.s. 
Change after 12 months: 
-35.1* (92.1) (p<0.0001) vs. -10.6* 
(25.5) (p<0.0001), s.s. 
Change after 24 months: 
-36.0* (94.4) (p<0.0001) vs. -6.3* 
(15.2) (p=0.044), s.s. 
Baseline19: 80.3 (±38.5) vs.  
75.9 (±38), n.s. 
Change after 12 months12: 
-55.9 (±4.24) vs. -60.6 (±4.4), n.s. 
Change after 60 months: 
-56.5 (±4.6) vs. -62.1 (±3.4), n.s. 
NR 
Modified Cincinnati 
Knee total core20, 
mean (SD) 
Higher scores indicate 
better function. 
NR NR NR Baseline21: 45 (±19) | 48 (±15) vs. 38 (±19) 
12 months: 82 (±15) (p< 0.001) | 67 (±26) 
(p=0.028) vs. 72 (±18) (p<0.001), s.s. 
Change after 12 months: +37* | +19* vs. +34* 
24 months: n/a | 85 (±18) vs. 74 (±26) 
Change after 24 months: n/a | +37* vs. +36* 
60 months: n/a | n/a vs. n/a 
stable or improving in both AMIC groups, 
whereas a significant decrease was 
observed in the MFx group (p = 0.002 
AMIC glued, p =0.01 AMIC sutured). 
                                                             
17 The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scoring system includes pain, stiffness and physical function, measured on a visual  
analogue scale (VAS). The scores for each subscale are summed up, with a possible score range of 0-8 for stiffness, 0-68 for physical function and 0-20 for pain.  
Higher scores indicate worse stiffness, functional limitations and pain. 
18 According to the study, no statistical difference. 
19 Scores had a maximum value of 50 for Pain, 20 for Stiffness, and 170 for Function. 
20 The Modified Cincinnati Score is divided into three parts: knee function (6-30 points), clinical pathology (0-20 points), highest activity level without pain (0-50 points).  
The total score is calculated as the sum of all questions responses, with 100 representing the best/excellent knee function, and 0 representing the worst/poor knee function. 
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3 
Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
Lysholm score22, 
mean (SD) 
NR NR NR NR 
Short Form Health 
Survey (SF-36, SF-12, 
SF-8)23, mean (SD) 
Subscale: physical 
functioning (PF), 
physical role (PR), 
vitality (VI) 
Higher scores indicate 
better function. 
NR NR SF-36 v2 physical component: 
Baseline: n/a 
Change after 12 months12: 
+13.0 (±1.5) vs. +14.8 (±1.5), n.s. 
Change after 60 months: 
+13.1 (±1.6) vs. +14.5 (±1.4), n.s. 
NR 
(Modified) ICRS 
macroscopic score24, 
mean (SD) 
NR NR NR Baseline: 54 (±19) | 46 (±20) vs. 57 (±22) 
12 months: 16 (±15) (p<0.001) | 15 (±13) 
(p<0.001) vs. 15 (±17) (p<0.001), s.s. 
Change after 12 months:  
-38.0* | -31.0* vs. -42.0* 
60 months: n/a | n/a vs. n/a 
both AMIC groups still reported  
very low pain, whereas pain increased  
non-significantly in the MFx group. 
Quality of life (QoL), scales: 
KOOS15 (QoL),  
mean (SD) 
NR NR NR NR 
EQ-5D NR NR NR NR 
                                                                                                                                                                                                                                                                                   
21 Baseline values are based on whole study sample, whereas changes from baseline are calculated based on the sample that remained at follow-up, only. 
22 The Lysholm score consists of eight items that measure: pain (25 points), instability (25 points), locking (15 points), swelling (10 points), limp (5 points), stair climbing  
(10 points), squatting (5 points), and need for support (5 points). The total score is the sum of each response to the eight questions, and may range from 0-100. Higher scores  
indicate a better outcome with fewer symptoms or disability. 
23 The Short-Form Health Survey (SF-36) version 2 is an eight-scale profile of functional health and well-being scores plus summary components of physical and mental health. 
Each scale is directly transformed into a 0-100 scale. A score of 0 is equivalent to maximum disability and a score of 100 is equivalent to no disability. Only the subscale scores  
for the physical and mental component were presented. 
24 The (modified) ICRS (International Cartilage Repair Society) macroscopic score consists of ratings by patient (pain, functional status of knee) and surgeon  
(functional status knee, classification crepitation). However, due to lacking scoring instruction, the interpretation of reported scores was not possible. 
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Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
Short Form Health 
Survey (SF-36, SF-12, 
SF-8)23, mean (SD) 
Subscale: emotional 
role (ER), psychological 
well-being (PS) 
Higher scores indicate 
better QoL. 
NR NR Baseline: n/a 
Change after 12 months12: 
+3.5 (±1.7) vs. +0.8 (±1.6), n.s. 
Change after 60 months: 
+2.7 (±1.3) vs. -0.17 (±1.8), n.s. 
NR 
Pain, scales: 
KOOS15 (pain),  
mean (SD) 
NR NR NR NR 
VAS25, mean (SD) 
Lower scores indicate 
less pain. 
Baseline: 50.1 (±26.7) vs.  
53.1 (±22.7), p=n/a 
12 months: 23.8 (±20.8) vs.  
29.2 (±23.2), p=n/a 
Change after 12 months:  
-26.3* vs. -23.9* 
24 months: 26.5 (±27.5) vs.  
23.2 (±20.9), p=n/a 
Change after 24 months:  
-23.6* vs. -29.9* 
NR NR NR 
WOMAC17 pain 
subscale, mean 
(%/SD) 
Lower scores indicate 
less pain. 
NR Baseline: 12.6 (6.1) vs. 7.9 (4.7), 
p=0.0153, s.s. 
Change after 6 months: 
-11.3* (90.0) (p<0.0001) vs. -5.2* (65.4) 
(p<0.0001), s.s. 
Change after 12 months: 
-11.6* (92.4) (p<0.0001) vs. -1.5* (19.2) 
(p=0.3154) 
Change after 24 months: 
-12.1* (96.4) (p<0.0001) vs. -0.1* (1.6), 
(p=0.9446) 
Baseline19:  
22.4 (±10.3) vs. 22.9 (±9.1), n.s. 
Change after 12 months12: 
-16.2 (±1.2) vs. -16.9 (±1.2), n.s. 
Change after 60 months: 
-15.4 (±1.5) vs. -16.6 (±1.2), n.s. 
NR 
Short Form Health 
Survey (SF-36, SF-12, 
SF-8)23, mean (SD) 
Subscale: physical 
pain (PA) 
NR NR NR NR 
                                                             
25 The visual analogue scale (VAS) for pain intensity is most commonly anchored by “no pain” (score of 0) and “pain as bad as it could be” or “worst imaginable pain”  
(score of 100 [100‐mm scale]). 
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5 
Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
Necessity of total joint 
replacement, n (%) 
NR At 12 months:  
total knee arthroplasty: 1 (n/a) 
NR NR 
Activities of daily living, scales: 
KOOS15 (ADL) score/ 
Return to activities, 
mean (SD) 
NR NR NR NR 
Tegner Activity Score 
(TAS)26,  
mean (range) 
Higher scores indicate 
improved ADL. 
Baseline: 3.0 (0.0-7.0) vs.  
3.0 (0.0-9.0) 
12 months: 4.0 (2.0-7.0) vs.  
4.0 (1.0-9.0) 
Change after 12 months:  
+1.0* vs. +1.0* 
24 months: 4.0 (1.0-9.0) vs.  
4.0 (2.0-8.0) 
Change after 24 months:  
+1.0* vs. +1.0* 
NR NR NR 
Complete defect 
filling (MRI/MRT 
imaging), n (%) 
   At 12 months: 35-50% of the pts. had a 
defect filling of two-thirds or more. 
At 24 months: defect filling was more 
complete in the AMIC groups, where at 
least 60% of the pts. had a defect filling of 
more than two-thirds compared to only 
25% of the pts. in the MFx group. 
At 60 months: defect filling was the lowest 
in the MFx group, versus both AMIC groups. 
MOCART score27 
Higher scores indicate 
more complete defect 
filling. 
Complete filling of the defect (%)28: 
6 months: 53.3 vs. 39.5 
12 months: 40.8 vs. 55.6 
24 months: 49.0 vs. 65.9 
n.s. difference in the MRI scores 
between groups 
NR NR NR 
                                                             
26 The Tegner Activity Score is a one-item score that graded activity based on work and sports activities on a scale of 0 to 10.  
Zero represents disability because of knee problems and 10 represents national or international level soccer. 
27 Lower MOCART scores indicate more positive/normal MRI diagnostic findings of the cartilage repair. 
28 Scores were calculated on the sample that remained at follow-up only. 
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Author, year 
[Reference] Kon, 2018 [47] Pipino, 2018 [46] 
Shive, 2015 [3]  
(Stanish, 20137 [5])8 
Volz, 2017 [7]  
(Anders, 20137 [4])9 
Safety 
Complications/ 
adverse events, n (%) 
13 (21.0*) vs. 4 (6.5*)29 NR 12 months (41 vs. 37 pts.)12: 
40 (98.0)30 vs. 36 (92.0)31, n.s. 
60 months (34 vs. 26 pts.): 
13 (19.0) vs. 18 (27.0)32; p=n/a 
13 adverse events in 9 pts. 
Severe adverse 
events, n(%) 
3 (4.8*) vs. 1 (1.6*)33 
Joint adhesions: 2 vs. 0 
Persistent pain: 1 vs. 0 
Loose body: 0 vs. 1 
NR 12 months (41 vs. 37 pts)12: 
5 (12.2*)30 vs. 1 (2.7*)31 
60 months (34 vs. 26 pts.): 
0 (0) vs. 1 (3.8*)34 
0 (0.0) vs. 0 (0.0) 
Procedure-related 
adverse event, n (%) 
8 (12.9*) vs. 3 (4.8*)35 
Inflammation: 3 vs. 0 
Joint adhesions: 1 vs. 0 
Persistent pain: 1 vs. 0 
Loose body: 0 vs. 0 
Joint instability: 0 vs. 1 
NR 12 months (41 vs. 37 pts.)12: 
38 (93.0) vs. 30 (77.0)36; p=n/a 
60 months (34 vs. 26 pts.): 
2 (6.0*) vs. 2 (8.0*)36; p=n/a 
0 (0.0) vs. 0 (0.0) 
Device-related 
adverse events, n (%) 
Failures: 
2 (3.2*) vs. 0 (0.0) 
NR 12 months (41 vs. 37 pts.)12: 
9 (22.0)37 vs. 0 (0.0) 
60 months (34 vs. 26 pts.): 
1 (3.0*)36 vs. 0 (0.0) 
NR 
Re-operation rate,  
n (%) 
NR NR 60 months (34 vs. 26 pts.): 
0 (0) vs. 1 (3.8*)34 
12 months: 
0 (0.0) | 1 (5.9*) vs. 1 (7.7*) 
Procedure-related 
mortality, n (%) 
NR NR 0 vs. 0 NR 
Abbreviations: AMIC autologous matrix-induced chondrogenesis; ADL Activities of daily living; EQ-5D EuroQual-5D; ICRS International Cartilage Repair Society;  
IKDC International Knee Documentation Committee; KOOS Knee Injury and Osteoarthritis Outcome Score; n number; n/a data not available; NR not reported; n.s. not significant;  
MFx microfracture; MOCART Magnetic Resonance Observation of Cartilage Repair Tissue; MRI magnetic resonance imaging; pts. patients; RCT randomised controlled trial;  
s.s. statistically significant; TAS Tegner Activity Score; VAS Visual Analogue Pain Scale; WOMAC Western Ontario and McMaster Universities Osteoarthrisits Index; yrs years; 
* Own calculations. 
                                                             
29 Safety was evaluated focusing on number and type of adverse events after surgery in all patients randomised and treated (124 patients); safety population: 62 vs. 62 pts. 
30 Five patients experienced severe adverse events. Most frequent (mild to moderate) events: arthralgia, pain and nausea. 
31 One patient experienced a severe adverse event. Most frequent (mild to moderate) events: arthralgia and pain. 
32 Most frequent event in both groups: pain (11% vs. 17%). 
33 Reported severe adverse events were related to the treatment. 
34 Severe adverse event was not related to the study treatment or index knee but required surgery and radiotherapy. 
35 Reported adverse events were minor early post-operation symptoms. 
36 Kind of complications not stated. 
37 Kind of complications not clearly stated. 
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7 
Table A-2: Autologous matrix-induced chondrogenesis in combination with MFx (AMIC) for cartilage repair of knee joints: Results from non-randomised controlled studies 
Author, year [Reference] Sharma, 201338 [6] 
Country Germany, Italy, Netherlands 
Sponsor Arthritis Foundation, NIH 
Intervention/Product AMIC (/n/a39): Miniarthrotomy, single-step cartilage repair + MFx 
Comparator Miniarthrotomic MFx alone 
Study design Multi-centre controlled trial (CT)40 
Number of pts, n 18 (15 vs. 3) 
Location of lesion, n (%) Medial femoral condyle defect (NR) 
Inclusion criteria  aged 18-50 yrs, 
 standing radiograph showing a Kellgren score of 0–2, 
 diagnostic arthroscopy/MRI identification of a medial femoral condyle defect, 
 stable and asymptomatic contralateral knee. 
Exclusion criteria  alcohol or drug abuse, 
 passive motion deficit of the knee (>5° of extension, >15° of flexion), 
 osteoarthritis, rheumatoid arthritis or gout, 
 pregnant or nursing mothers, 
 active inflammatory disease, such as lupus, 
 history of severe allergy (as defined by a reaction which required treatment such as injection with epinephrine),  
atopic disease, or known allergy to bovine proteins, 
 evidence of significant haematological disorder (severe preexisting coagulation disorder requiring active coagulation 
therapy), cardiovascular, liver, or neoplastic disease, bone malignancy, autoimmune disorders, or kidney disease, 
 recent history (less than 4 weeks) of myocardial infarction or concurrent acute injury that might compromise  
the subject’s welfare, 
 diabetes mellitus, 
 life expectancy of less than 5 years, 
 untreated depression, 
 chronic steroid intake, 
 patellofemoral instability, 
 malalignment with >5° valgus or varus compared to normal, 
 prior cartilage surgery of the affected knee (e.g., subchondral drilling, microfracture, abrasion arthroplasty, 
mosaicplasty, autologous chondrocyte implantation). 
Prior surgery, n (%) None (exclusion criterion) 
                                                             
38 Study already included in initial report DSD98 2016. 
39 A polyethylene glycol diacrylate hydrogel was used as scaffold (like GelrinC). 
40 Study was initiated as a RCT; however, randomisation was stopped during the study to increase the size of the hydrogel cohort. 
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Author, year [Reference] Sharma, 201338 [6] 
Postoperative treatment(s) Physiotherapy/rehabilitation (all pts.) 
Age of patients, mean, yrs (SD/range)  (20-59) vs. (40-49)41 
Female sex, n (%) NR 
Follow-up (months) 6 
Loss to follow-up, n (%) 0 vs. 0 
BMI, mean, kg/m² (SD/range) (20-30) vs. (20-30)41 
Defect size, mean, cm2 (range) (1-3) vs. (2-3)41 
Clinical classification, n (%) NR 
Primary endpoint(s) NR 
Outcomes 
Efficacy 
Mobility/joint functionality, scales: 
KOOS15 (sports/rec), mean (SD) NR 
IKDC score16, mean (SD) 
Higher scores indicate better function. 
Baseline: n/a, n.n.;  
Change after 3 months: n/a, n.s.;  
Change after 6 months: n/a, n.s. 
WOMAC17 stiffness subscale, mean (%/SD) NR 
WOMAC17 physical function subscale, mean (%/SD) NR 
Modified Cincinnati Knee Score20, mean (SD) NR 
Lysholm score22, mean (SD) NR 
Short Form Health Survey (SF-36, SF-12, SF-8)23, mean (SD)  
Subscales: physical functioning (PF), physical role (PR), 
vitality (VI) 
NR 
(Modified) ICRS macrosopic score24, mean (SD) NR 
Quality of life (QoL), scales: 
KOOS15 (QoL), mean (SD) NR 
EQ-5D NR 
Short Form Health Survey (SF-36, SF-12, SF-8)23, mean (SD)  
Subscales: emotional role (ER), psychological well-being (PS) 
NR 
                                                             
41 Values were only given as ranges and not as means or medians (or exact numbers). 
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Author, year [Reference] Sharma, 201338 [6] 
Pain, scales: 
KOOS15 (pain), mean (SD) NR 
VAS25, mean (SD) 
Lower scores indicate less pain. 
Severity: 
Baseline: 54.3 (±16.4) vs. 54.0 (±21.0), p=n/a. 
Change after 3 months: -29.0 (±n/a) vs. -34.7 (±n/a), p=n/a 
Change after 6 months: -32.1 (±n/a) vs. -15.3 (±n/a), p=n/a 
Frequency: 
Baseline: 77.0 (±20.3) vs. 84.3 (±24.5), p=n/a. 
Change after 3 months: -41.0 (±n/a) vs. -62.6 (±n/a), p=n/a 
Change after 6 months: -52.9 (±n/a) vs. -41.0 (±n/a), p=n/a 
WOMAC17 pain subscale, mean (%/SD) NR 
Short Form Health Survey (SF-36, SF-12, SF-8)23, mean (SD) 
Subscale: physical pain (PA) 
NR 
Necessity of total joint replacement, n (%) NR 
Activities of daily living, scales: 
KOOS15 (ADL) score/Return to activities, mean (SD) NR 
Tegner Activity Score (TAS)26 NR 
Complete defect filling (MRI/MRT imaging), n (%)  
MOCART score27 NR 
Safety 
Complications/adverse events, n (%) NR 
Severe adverse events, n (%) NR 
Procedure-related adverse events, n (%) 1 (7.0)42 vs. 0 (0.0), p=n/a 
Device-related adverse events, n (%) n/a vs. 0 (0.0) 
Re-operation rate, n (%) NR 
Procedure-related mortality, n (%) 0 (0.0) vs. 0 (0.0) 
Abbreviations: AMIC autologous matrix-induced chondrogenesis; ADL Activities of daily living; EQ-5D EuroQual-5D; ICRS International Cartilage Repair Society;  
IKDC International Knee Documentation Committee; KOOS Knee Injury and Osteoarthritis Outcome Score; n number; n/a data not available; NR not reported; n.s. not significant;  
MFx microfracture; MOCART Magnetic Resonance Observation of Cartilage Repair Tissue; MRI magnetic resonance imaging; pts. patients; RCT randomised controlled trial;  
s.s. statistically significant; TAS Tegner Activity Score; VAS Visual Analogue Pain Scale; WOMAC Western Ontario and McMaster Universities Osteoarthrisits Index; yrs years; 
* Own calculations. 
 
                                                             
42 Mild haemarthrosis in one patient. 
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Table A-3: Matrix-induced autologous chondrocyte implantation (MACI) for cartilage repair of knee joints: Results from randomised controlled trials 
Author, year [Reference] Bartlett, 2005 [22] Basad, 2010 [48] Brittberg43, 2018 [9] (Saris, 2014 [8]) 
Country England Germany 7 European countries (n/a) 
Sponsor n/a44 NR Vericel Cooperation, 
Genzyme (Sanofi company), previous sponsor  
of the SUMMIT Extension study 
Intervention/Product MACI (Verigen, Leverkusen, Germany): 
Membrane of a porcine type I/type III collagen 
bilayer seeded with chondrocytes 
MACITM (Genzyme Biosurgery, Cambridge, MA): 
Third generation ACI product – chondrocytes 
seeded onto a type I/III collagen scaffold (secured 
into the lesion with fibrin glue) + miniarthrotomy 
MACI (ACI-Matix, Matricel GmbH): 
Autologous chondrocytes isolated, cultured and 
seeded onto a purified, resorbable,  
porcine-derived collagen type I/III membrane 
Comparator ACI-C45 MFx MFx 
Study design Single-centre, prospective, randomised 
controlled trial (RCT) 
Prospective, randomised controlled trial (RCT) Prospective, randomised, open-label,  
parallel-group, multi-centre study (RCT) 
Number of pts., n 91 (47 vs. 44) 60 (40 vs. 20) Original SUMMIT trial: 144 
Extension study: 128 (65 vs. 63) 
Location of lesion, n (%) Chondral lesions: 
Medial femoral condyle: 25 (47.2) vs. 25 (42.4) 
Lateral femoral condyle: 6 (11.3) vs. 5 (8.5) 
Patella: 16 (30.2) vs. 20 (33.9) 
Trochlea: 6 (11.3) vs. 9 (15.2) 
Chondral lesions: 
Condylar: 29 (73.0) vs. 16 (80.0) 
Patellar-trochlear: 11 (28.0) vs. 4 (20.0) 
Cartilage defects: 
Medial femoral condyle: 48 (74.0) vs. 44 (70.0) 
Lateral femoral condyle: 13 (20.0) vs. 15 (24.0) 
Trochlea: 4 (6.0) vs. 4 (6.0) 
Inclusion criteria  aged 15-50 years, 
 isolated osteochondral defect >1 cm², 
 ability to follow the rehabilitation 
programme. 
 aged 18-50 years, 
 post-traumatic, single, isolated, symptomatic 
chondral defects (4-10 cm²) of the femoral 
condyle or patella. 
 aged 18-55 years, 
 ≥1 symptomatic cartilage defects, 
 moderate to severe KOOS pain value (<55)  
at baseline, 
 Outerbridge grade III/IV focal cartilage defects 
on the medial femoral condyle (MFC), lateral 
femoral condyle (LFC), and/or trochlea ≥ 3 cm². 
Exclusion criteria  osteoarthritis, 
 inflammatory joint disease. 
 resence of chronic inflammatory arthritis, 
 instability of the knee joint, 
 prior or planned meniscectomy  
(>30% of the meniscus), 
 BMI > 30, 
 any knee joint surgery within 6 months before 
screening, 
 modified Outerbridge III/IV on the patella or tibia, 
 symptomatic musculoskeletal condition in the 
lower limbs that could impede efficacy 
measures in the target knee, 
                                                             
43 Brittberg 2018, the SUMMIT extension study (NCT01251588), is a three year follow-up of the original SUMMIT clinical trial (NCT00719576; Saris 2014), entailing up to five years 
of observation after surgery. Study results after two years were published in Saris 2014 (assessing 70 vs. 67 pts.) and results after two and five years follow-up were presented in 
Brittberg 2018 (assessing 65 vs. 63 pts.). Therefore, only the data from the latest publication are presented. 
44 One or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article. 
45 ACI-C includes the use of a cover manufactured from porcine-derived type I/type III collagen (Matricel, Herzogenrath, Germany). Compared to MACI,  
the implantation of the chondrocytes takes place via a suspension. 
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1 
Author, year [Reference] Bartlett, 2005 [22] Basad, 2010 [48] Brittberg43, 2018 [9] (Saris, 2014 [8]) 
Exclusion criteria 
(continuation) 
   varus or valgus abnormality, 
 osteonecrosis, 
 osteoarthritis, 
 chondrocalcinosis, 
 pts. with osteochondral defects. 
 total meniscectomy, meniscal allograft, bucket-
handle tear or displaced tear requiring >50% 
removal of the meniscus in the target knee, 
 malalignment requiring osteotomy to correct 
tibial-femoral or patella-femoral alignment, 
 Kellgren-Lawrence grade 3 or 4 osteoarthritis, 
 inflammatory disease or other condition 
affecting the joints, or septic arthritis within  
1 year before screening46. 
Prior surgery, n (%) 2.1 (NR) vs. 2.3 (NR) NR n/a47 
Postoperative treatment(s) First postoperative days: weight-bearing days 
with aid of crutches, 
after 2-3 days: discharge from hospital with 
light-weight cylinder cast, 
after 10 days: cast is removed and beginning  
of supervised regime of physiotherapy. 
IG: dorsal plaster cast (10° flexion) for 2 days  
post-operatively, continuous passive motion and 
physiotherapy, followed by 8 weeks of partial 
weight-bearing (10 kg) on crutches. 
CG: 6 weeks of partial weight-bearing (10 kg) on 
crutches, CPM and physiotherapy. From 6 weeks 
post-operatively, gradual progression to  
full weight-bearing. 
IG & CG: anti-thrombotic prophylaxis with  
low-molecular heparin certoparin-natrium 
(Monoembolex s.c. 1/day) for entire weight-
bearing period. 
4-phase standardised rehabilitation program: 
physical therapy48 
Age of patients, mean, yrs 
(SD/range)  
33.4 (17-47) vs. 33.7 (15-49) 33.0 (NR) vs. 37.5 (NR) 35 (18-54) vs. 34 (18-54) 
Female sex, n (%) 37 (40.7*) 15 (38.0) vs. 3 (15.0) 60 (38.0) 
Follow-up (months) 24 24 60 
Loss to follow-up, n (%) 0 (0.0) vs. 0 (0.0) 12 months: 1 (2.5) vs. 3 (15.0) 
24 months: 6 (15.0) vs. 2 (10.0) 
0 (0.0) vs. 4 (6.3*) 
BMI, mean, kg/m² (SD/range) NR 25.3 (20-34) vs. 27.3 (24-35) 26.2 (±4.3) vs. 26.4 (±4.0)49 
Defect size, mean, cm2 
(SD/range) 
6.1 (1.0-22) vs. 6.0 (1.5-16) NR 5.1 (±3.0) vs. 4.9 (±2.0) 
Clinical classification, n (%) NR NR Outerbridge grade III: 19 (29.0) vs. 12 (19.0) 
Outerbridge grade IV: 46 (71.0) vs. 51 (81.0) 
                                                             
46 Exclusion criteria were extracted from the original SUMMIT study (Saris 2014), as the extension study did not report any criteria. 
47 Major exclusion criteria included any knee joint surgery within six months before screening. 
48 Postoperative treatment was extracted from the original SUMMIT study (Saris 2014), as the extension study did not report it. 
49 Extracted from Saris 2014. 
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Author, year [Reference] Bartlett, 2005 [22] Basad, 2010 [48] Brittberg43, 2018 [9] (Saris, 2014 [8]) 
Primary endpoint(s) NR NR Change from baseline to week 156 (year 3)  
in KOOS pain and function  
(sports and recreational activities) scores50 
Outcomes 
Efficacy 
Mobility/joint functionality, scales: 
KOOS15, 51 (sports, rec), 
mean (SD) 
Higher scores indicate  
better function. 
NR NR Baseline vs. 24 months: 
IG: 15.4 (±14.8) vs. 60.5 (±26.5) 
CG: 11.9 (±16.2) vs. 48.9 (±30.6) 
Change after 24 months: +45.1* vs. + 37.0* 
Baseline vs. 60 months: 
IG: 15.4 (±14.8) vs. 61.9 (±30.9) 
CG: 11.9 (±16.2) vs. 50.3 (±32.3) 
Change after 60 months: +46.5* vs. +38.4* 
s.s. improvement IG vs. CG, p=0.0122 
IKDC score16, mean (SD) 
Higher scores indicate  
better function. 
NR NR Baseline vs. 24 months: 
IG: 33.1 (±13.5) vs. 65.3 (±18.1) 
CG: 29.3 (±12.0) vs. 60.1 (±22.7) 
Change after 24 months: +32.2* vs. +30.8* 
Baseline vs. 60 months: 
IG: 33.1 (±13.5) vs. 68.5 (±21.2) 
CG: 29.3 (±12.0) vs. 61.8 (±21.5) 
Change after 60 months: +35.4* vs. +32.5* 
n.s. differences between IG and CG, p=0.113 
WOMAC17 stiffness sub-scale, 
mean (%/SD) 
NR NR NR 
WOMAC17 physical function 
subscale, mean (%/SD) 
NR NR NR 
Modified Cincinnati Knee 
total score20, mean (SD) 
Higher scores indicate  
better function. 
Baseline vs. 12 months: 
IG: 44.5 (NR) vs. 64.1 (NR) 
[s.s. improvement +19.6* (p=0.002)] 
CG: 41.4 (NR) vs. 59.0 (NR) 
[s.s. improvement +17.5* (p=0.01)] 
Change after 12 months: +19.6* vs. +17.5*, n.s., 
p=0.32 
NR Baseline vs. 24 months: 
IG: 3.0 (±1.2) vs. 6.3 (±1.9) 
CG: 3.0 (±1.2) vs. 5.5 (±2.3) 
Change after 24 months: +3.3* vs. +2.5* 
Baseline vs. 60 months: 
IG: 3.0 (±1.2) vs. 6.6 (±2.1) 
CG: 3.0 (±1.2) vs. 5.8 (±2.2) 
Change after 60 months: +3.6* vs. +2.8* 
s.s. better improvement for IG, p=0.035 
                                                             
50 Primary endpoint of the extension study Brittberg 2018. 
51 A responder was defined as having at least a ten-point improvement in both the KOOS pain and function subscales. 
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3 
Author, year [Reference] Bartlett, 2005 [22] Basad, 2010 [48] Brittberg43, 2018 [9] (Saris, 2014 [8]) 
Lysholm score22, mean (SD) 
Higher scores indicate  
better function. 
NR Baseline vs. 12 months: 
IG: 52.0 (±26.0) vs. 92.0 (±11.0) 
CG: 55.0 (±25.0) vs. 82.0 (±22.0) 
Change after 12 months: +40.0* vs. +27.0* 
Baseline vs. 24 months: 
IG: 52.0 (±26.0) vs. 92.0 (±9.0), s.s., p<0.0001 
CG: 55.0 (±25.0) vs. 69.0 (±26.o), s.s., p<0.0001 
Changer after 24 months: +40.0* vs. +14.0* 
s.s. better improvements for IG vs. CG, p=0.005 
NR 
Short Form Health Survey 
(SF-36, SF-12, SF-8)23,  
mean (SD) 
Subscales: physical 
functioning (PF), physical 
role (PR), vitality (VI) 
Higher scores indicate  
better function. 
NR NR Baseline vs. 24 months: 
IG: -1.7 (±0.8) vs. -0.35 (±0.09) 
CG: -2.0 (±0.8) vs. -0.79 (±1.1) 
Change after 24 months: +1.4* vs. +1.2*, p=n/a 
Baseline vs. 60 months: 
IG: -1.7 (±0.8) vs. -0.2 (±0.9) 
CG: -2.0 (±0.8) vs. -0.7 (±1.1) 
Change after 60 months: +1.5* vs. +1.3* 
s.s. better improvement for IG, p=0.025 
(Modified) ICRS macroscopic 
score24, n (%) 
Diagnostic at 12 months: 
(18 vs. 24 pts.): 
Excellent: 4 (22.2) vs. 4 (16.7) 
Good: 8 (44.4) vs. 15 (62.5) 
Fair: 5 (27.8) vs. 5 (20.8) 
Poor: 1 (5.6) vs. 0 (0.0) 
Baseline vs. 24 months (subjective score): 
 s.s. for both treatment groups, p<0.0001 
 -s.s. better improvement in IG for month 24, 
p=0.03 
Baseline vs. 24 months (objective score): 
 s.s. for both treatment groups, p<0.0001 
 s.s. better improvement in IG for month 24, 
p=0.02 
NR 
Quality of life (QoL), scales: 
KOOS15 (QoL), mean (SD) 
Higher scores indicate  
better QoL. 
NR NR Baseline vs. 24 months: 
IG: 19.9 (±14.6) vs. 55.4 (±22.3) 
CG: 17.1 (±13.2) vs. 47.8 (±26.8) 
Change after 24 months: +35.5* vs. +30.7*, p=n/a 
Baseline vs. 60 months: 
IG: 19.9 (±14.6) vs. 59.8 (±24.6) 
CG: 17.1 (±13.2) vs. 52.4 (±26.6) 
Change after 60 months: +39.9* vs. +35.3*, p=n/a 
EQ-5D52, mean (SD) 
Higher scores indicate  
better QoL. 
NR NR Baseline vs. 24 months: 
IG: 60.3 (±21.1) vs. 76.5 (±15.2) 
CG: 54.7 (±21.7) vs. 74.1 (±18.5) 
Change after 24 months: +16.2* vs. +19.4*, p=n/a 
                                                             
52 The EQ-5D consists of a descriptive system and the EQ VAS and includes five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The five 
dimensions were rated via the VAS scale numbered from 0 to 100: 100 meaning the best health imaginable and 0 meaning the worst health. 
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Author, year [Reference] Bartlett, 2005 [22] Basad, 2010 [48] Brittberg43, 2018 [9] (Saris, 2014 [8]) 
EQ-5D52, mean (SD) 
Higher scores indicate  
better QoL. 
(continuation) 
  Baseline vs. 60 months: 
IG: 60.3 (±21.1) vs. 80.4 (±13.7) 
CG: 54.7 (±21.7) vs. 73.8 (±19.1) 
Change after 60 months: +20.1* vs. +19.1* 
s.s. better improvement for IG, p=0.043 
Short Form Health Survey 
(SF-36, SF-12, SF-8)23,  
mean (SD) 
Subscales: emotional role 
(ER), psychological well-
being (PS) 
Higher scores indicate  
better QoL. 
NR NR Baseline vs. 24 months: 
IG: 0.04 (±1.2) vs. 0.4 (±0.9) 
CG: -0.07 (±1.3) vs. 0.5 (±0.9) 
Change after 24 months: +0.4* vs. +0.6*, p= n/a 
Basline vs. 60 months: 
IG: 0.04 (±1.2) vs. 0.4 (±0.9) 
CG: -0.07 (±1.3) vs. 0.5 (±1.0) 
Change after 60 months: +0.4* vs. +0.5*, n.s., 
p=0.740 
Pain, scales: 
KOOS15 (pain), mean (SD) 
Higher scores indicate  
less pain. 
NR NR Baseline vs. 24 months: 
IG: 37.1 (±13.1) vs. 82.2 (±15.8) 
CG: 35.2 (±12.3) vs. 71.8 (±23.9) 
Change after 24 months: +45.1* vs. +36.6*, p=n/a 
Baseline vs. 60 months: 
IG: 37.1 (±13.1) vs. 82.2 (±20.1) 
CG: 35.2 (±12.3) vs. 74.8 (±21.7) 
Change after 60 months: +45.1* vs. +39.6*, p=n/a 
VAS25, mean (SD) 
Lower scores indicate  
less pain. 
Baseline vs. postoperative follow-up (n/a): 
IG: 6.0 vs. 4.1, s.s. p=0.003 
CG: 6.0 vs. 4.3, s.s., p=0.001 
Change after n/a: -1.9* vs. -1.7* 
n.s. difference between IG and CG 
NR NR 
WOMAC17 pain subscale, 
mean (%/SD) 
NR NR NR 
Short Form Health Survey 
(SF-36, SF-12, SF-8)23,  
mean (SD) 
Subscale: physical pain (PA) 
NR NR NR 
Necessity of total joint 
replacement, n (%) 
NR NR NR 
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5 
Author, year [Reference] Bartlett, 2005 [22] Basad, 2010 [48] Brittberg43, 2018 [9] (Saris, 2014 [8]) 
Activities of daily living, scales: 
KOOS15 (ADL) score/Return 
to activities, mean (SD) 
Higher scores indicate 
improved ADL. 
NR NR Baseline vs. 24 months: 
IG: 43.6 (±18.6) vs. 87.3 (±16.2) 
CG: 42.6 (±18.2) vs. 77.0 (±23.6) 
Change after 24 months: +43.7* vs. 34.4*, p=n/a 
Baseline vs. 60 months: 
IG: 43.6 (±18.6) vs. 86.4 (±17.6) 
CG: 42.6 (±18.2) vs. 80.0 (±21.2) 
Change after 60 months: +42.8* vs. +37.4*, 
s.s. better improvements for IG, p=0.007 
Tegner Activity Score 
(TAS)26, median 
Higher scores indicate 
improved ADL. 
NR Baseline vs. 12 and 24 months: 
IG: 2 vs. 4, s.s., p<0.0001 
CG: 2 vs. 3, s.s., p<0.0001 
s.s. better improvement for IG in month 24, p=0.04 
NR 
Complete defect filling 
(MRI/MRT imaging), n (%) 
NR NR NR 
MOCART score27 NR NR NR 
Safety 
Complications/ 
adverse events, n (%) 
N.s. general complications in any of the pts. Slight swelling and inflammation of the knee  
after partial weight-bearing (during early 
rehabilitation time period – 12 week): NR 
Total: 55 (76.4) vs. 60 (83.3)53,54: 
 Arthralgia: 37 (51.4) vs. 46 (63.9) 
 Headache: 13 (18.1) vs. 21 (29.2) 
 Nasopharyngitis: 10 (13.9) vs. 7 (9.7) 
 Back pain: 8 (11.1) vs. 7 (9.7) 
 Joint swelling: 7 (9.7) vs. 4 (5.6) 
 Joint effusion: 5 (6.9) vs. 4 (5.6) 
 Influenza: 4 (5.6) vs. 5 (6.9) 
 Pyrexia: 4 (5.6) vs. 2 (2.8) 
 Cartilage injury: 3 (4.2) vs. 9 (12.5) 
 Procedural pain: 3 (4.2) vs. 4 (5.6) 
 Ligament sprain: 2 (2.8) vs. 4 (5.6) 
 Abdominal pain: 0 (0.0) vs. 5 (6.9) 
Severe adverse events, n (%) 0 (0.0) vs. 0 (0.0) 0 (0.0) vs. 0 (0.0) Total: n/a (15.3) vs. n/a (26.4)53: 
Most common: treatment failure,  
cartilage injury, arthralgia 
                                                             
53 AEs were extracted from the original SUMMIT study (72 vs. 72 pts), as the extension study did not report any AEs, but reported that the frequency of AEs  
was consistent with the previous publication. 
54 Reported adverse events reported were treatment-emergent. 
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Author, year [Reference] Bartlett, 2005 [22] Basad, 2010 [48] Brittberg43, 2018 [9] (Saris, 2014 [8]) 
Procedure-related adverse 
events, n (%) 
NR NR Total: n/a (34.7) vs. n/a (38.9)53,55 
Most common adverse events: 
 Discontinuation due to treatment failure: 2* (1.4), 
 Discontinuation due to arthralgia: 2* (1.4), 
 Discontinuation due to joint swelling: 2* (1.4) 
Device-related AEs, n (%) Total: 6 (12.5*) vs. 4 (9.0*) 
At 6 months: 
Symptomatic hypertrophy: 1 (2.1*) vs. 0 (0.0) 
At 9 months: 
Painful catching: 0 (0.0) vs. 1 (2.3*) 
At 12 months: 
Symptomatic hypertrophy: 2 (4.3*) vs. 3 (6.8*) 
Superficial wound infection: 1 (2.1*) vs. 0 (0.0) 
Graft failure: 2 (4.3*) vs. 0 (0.0) 
NR NR 
Re-operation rate, n (%) Need for manipulation of the knee because  
of a restricted range of flexion:  
3 (6.4*) vs. 3 (6.8*) 
In IG 1 pt. (2.5*) persistent pain after 12 months 
due to persistent subchondral oedema  
 retrograde bone grafting  pain relief 
n/a (8.3) vs. n/a (9.7), n.s., p=0.42753 
Procedure-related mortality, 
n (%) 
NR NR At 24 months: 
0 (0.0) vs. 0 (0.0) 
Abbreviations: AMIC autologous matrix-induced chondrogenesis; ADL Activities of daily living; EQ-5D EuroQual-5D; ICRS International Cartilage Repair Society;  
IKDC International Knee Documentation Committee; KOOS Knee Injury and Osteoarthritis Outcome Score; n number; n/a data not available; NR not reported; n.s. not significant;  
MFx microfracture; MOCART Magnetic Resonance Observation of Cartilage Repair Tissue; MRI magnetic resonance imaging; pts. patients; RCT randomised controlled trial;  
s.s. statistically significant; TAS Tegner Activity Score; VAS Visual Analogue Pain Scale; WOMAC Western Ontario and McMaster Universities Osteoarthrisits Index; yrs years; 
* Own calculations. 
  
                                                             
55 Adverse events reported were treatment-emergent and related to the procedure. 
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7 
Table A-4: Matrix-induced autologous chondrocyte implantation (MACI) for cartilage repair of knee joints: Results from randomised controlled trials continued 
Author, year [Reference] Crawford, 2012 [49] Zeifang, 2010 [23] 
Country USA Germany 
Sponsor Histogenics Corporation, Waltham, Massachusetts Ministry of Science, Research and Arts, Baden-Württemberg, 
Germany 
Intervention/Product MACI (NeoCart, Histogenics, Waltham, Massachusetts): 
Bovine type-I collagen matrix scaffold with autogenous 
chondrocytes 
MACI (BioSeed-C, BioTissue Technologies Freiburg, Germany): 
20 Mio. autologous chondrocytes embedded in fibrin and  
combined with the rectangular resorbable scaffold of  
poyglactin 910 and poly-p-dioxanon 
Comparator MFx Two-step ACI56 
Study design Phase-II prospective, randomised clinical trial (RCT) Prospective randomised controlled trial (RCT) 
Number of pts, n 3057 (21 vs. 9) 21 (11 vs. 10) 
Location of lesion, n (%) Cartilage lesion of the femoral condyle: 
Medial or lateral femoral condyle (NR) 
Cartilage defects: 
Medial femoral condyle: 18 (85.7) 
Inclusion criteria For initial enrolment: 
 aged 18-55 yrs, 
 knee pain indicative of an articular cartilage injury, 
 medical ability to undergo arthroscopic MFx or biopsy and 
subsequent arthrotomy for NeoCart implantation, 
 availability of informed consent. 
For arthroscopy: 
 ≥1 treatable lesion(s) located on either medial or lateral femoral 
condyle that would be a candidate for MFx, 
 symptomatic ICRS grade-III cartilage lesion of femoral condyle, 
 lesions with max. linear dimension ≥1 cm and ≤3 cm to healthy 
cartilage border, 
 lesions with total areas less than area of NeoCart (7-8 cm²). 
 aged 16-50 yrs, 
 isolated cartilage defects between 2.5 and 6 cm2 detected by  
MRI and verified with arthroscopy, 
 localised at the medial or lateral femoral condyle. 
                                                             
56 In this study, the autologous chondrocyte implantation with periosteal flap (ACI-P, first generation) was used as the control intervention. 
57 30 pts for randomisation. 49 pts for initial enrolment and 35 pts before arthroscopy. 
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Author, year [Reference] Crawford, 2012 [49] Zeifang, 2010 [23] 
Exclusion criteria For initial enrolment: 
 any previous surgical treatment of lesion other than debridement, 
 BMI>35 kg/m², 
 joint space narrowing of >1/3 compared with normal knee or  
<3 mm of joint space measured on radiographs, 
 osteophytes, sclerosis, or degenerative conditions in treatment 
knee noted on radiographs, 
 malalignment >3° outside mechanical axis of other knee, or need 
for surgery to correct malalignment, 
 other symptomatic pathology of contralateral knee, 
 surgery on contralateral knee within 8 weeks prior to scheduled 
arthroscopy, 
 any form of inflammatory arthritis, ankylosing spondylitis, 
synovioma, hemangioma, pigmented villonodular synovitis,  
or neoplasms in knee, 
 chemotherapy, 
 pt. unable to undergo MRI, 
 pregnancy or intends to become pregnant during year following 
initial enrollment, 
 known history of allergy to bovine products or to collagen  
or more than a minimal reaction to an intradermal collagen 
injection challenge, 
 history of autoimmune disease, 
 evidence of HIV or chonric hepatitis-B or C viral infection, 
 known allergy to gentamicin, 
 current drug or alcohol abuse, 
 pt. deemed by investigator as unlikely to comply with protocol. 
For arthroscopy: 
 subchondral bone loss, 
 pt. requiring a concomitant procedure other than medial or 
lateral partial meniscectomy, 
 removal of loose bodies, 
 debridement of articular cartilage lesions other than that being 
treated and synovectomy, 
 untreated anterior cruciate ligament and/or posterior cruciate 
ligament deficiency or ligamentous instability in involved knee, 
 meniscus with rim <50% of normal thickness, 
 ICRS grade-III or IV kissing lesion, 
 more than slight anterior knee pain referable to patellofemoral 
joint and ICRS grade-III (B), III(C), or IV trochlear groove or 
patellar lesion. 
 extended cartilage erosion, 
 restricted mobility, 
 corresponding cartilage defects <grade II according  
to Outerbridge, 
 extended meniscal defect (meniscus resection >1/3), 
 untreated cruciate or collateral ligament laxity, 
 untreated varus/valgus alignment >5°, 
 obesity, 
 inflammation, 
 procedures in the respective knee (e.g. MFx or  
osteochondral autograft) <1 year ago, 
 hyaluronan injection <6 months ago, 
 corticosteroid injection <3 months ago. 
Prior surgery, n (%) None (exclusion criterion) 2.1 (1.2) vs. 1.9 (0.7) 
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Author, year [Reference] Crawford, 2012 [49] Zeifang, 2010 [23] 
Postoperative treatment(s) Standardised rehabilitation protocol Day after surgery: 
 6 weeks continuous passive motion and only partial weight-bearing, 
 2 weeks restricted range of motion to 90° of flexion,  
until week 12 no sports allowed 
Age of patients, mean, yrs (SD/range)  41.0 (±9.0) vs. 39.0 (±10.0) 29.1 (±7.5) vs. 29.5 (±11.0) 
Female sex, n (%) 2 (10.0) vs. 3 (33.0) 5 (45.5*) vs. 0 (0.0) 
Follow-up (months) 24 24 
Loss to follow-up, n (%) 12 months: 0 (0.0) vs. 0 (0.0) 
24 months: 2 (9.5*) vs. 0 (0.0) 
12 months: 4 (19.1) vs. n/a (n/a) 
24 months: 10 (47.6) vs. n/a (n/a) 
BMI, mean, kg/m² (SD/%) 29.0 (±3.0) vs. 25.0 (±4.0) 19.6 kg/m²: 1 (4.8) 
20.0-25.0 kg/m²: 10 (47.6) 
>25≤30 kg/m²: 9 (42.9) 
34.4 kg/m²: 1 (4.8) 
Defect size, mean, cm2 (SD) 2.9 (±1.4) vs. 2.5 (±1.4) 4.3 (±1.1) vs. 4.1 (±0.9) 
Clinical classification, n (%) ICRS grade-III cartilage lesion of the femoral condyle (all pts.) Outerbridge grade IV (all pts.) 
Primary endpoint(s) NR Postoperative change in subjective knee function assessed  
by the IKDC score at 12 months 
Outcomes 
Efficacy 
Mobility/joint functionality, scales 
KOOS15 (sports/rec) 
Higher scores indicate better function. 
At 12 months58: 
More improvements in IG vs. CG 
At 24 months: 
s.s. improvement in IG vs. CG, p<0.05 
NR 
IKDC score16, mean (SD) 
Higher scores indicate better function. 
At 12 months58: 
More improvements in IG vs. CG 
Baseline vs. 24 months: 
s.s. difference in IG vs. CG by +11.59 (95% CI 1.353-21.82, p=0.028) 
Baseline vs. 12 months: 
IG: 51.1 (±22.8) vs. 72.0 (±22.7) 
CG: 52.0 (±13.5) vs. 76.6 (±18.9) 
Change after 12 months: +20.9 (±20.9) vs. +24.6 (±19.3), 
n.s., p=0.5573 
Baseline vs. 24 months: 
IG: 51.1 (±22.8) vs. 70.1 (±28.6) 
CG: 52.0 (±13.5) vs. 77.1 (±22.7) 
Change after 24 months: +19.0 (±26.8) vs. +25.2 (±23.2), 
n.s., p=0.4994 
WOMAC17 stiffness subscale, mean (%/SD) NR NR 
                                                             
58 A responder was defined as having at least a 12-point improvement in the pain score of the KOOS and a 20-point improvement in the IKDC subjective score. 
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Author, year [Reference] Crawford, 2012 [49] Zeifang, 2010 [23] 
WOMAC17 physical function subscale,  
mean (%/SD) 
NR NR 
Modified Cincinnati Knee total score20, 
mean (SD) 
NR NR 
Lysholm score22, mean (SD) 
Higher scores indicate better function. 
NR Baseline vs. 12 months: 
IG: 71.4 (±23.8) vs. 76.3 (±27.5) 
CG: 61.3 (±14.3) vs. 86.3 (±17.0), s.s., p=0.0137 
Change after 12 months: +4.9 (±19.0) vs. +25.0 (±22.8), 
s.s. better improvement for CG vs. IG, p=0.0449 
Baseline vs. 24 months: 
IG: 71.4 (±23.8) vs. 72.5 (±28.0) 
CG: 61.3 (±14.3) vs. 84.0 (±21.9), s.s., p=0.0273 
Change after 24 months: +1.2 (±22.3) vs. +22.7 (±25.9), 
s.s. better improvements for CG vs. IG, p=0.0487 
Short Form Health Survey (SF-36, SF-12, 
SF-8)23, 59, mean (SD) 
Subscales: physical functioning (PF), 
physical role (PR), vitality (VI) 
Higher scores indicate better function. 
NR Change after 12/24 months for PR: 
IG: n/a, s.s., p=0.0156/p=0.0156 
Change after 12/24 months for PF: 
CG: n/a, s.s., p=0.0059/p=0.0156 
Change after 24 months for PF: 
IG: n/a, s.s., p=0.0020 
N.s. difference between IG vs. CG for 12 and 24 months 
ICRS macroscopic score24, n (%) NR NR 
Quality of life (QoL), scales 
KOOS15 (QoL), mean (SD) 
Higher scores indicate better QoL. 
At 24 months58: 
s.s. improvement in IG vs. CG, p<0.05 
NR 
EQ-5D NR NR 
Short Form Health Survey (SF-36, SF-12, 
SF-8)23,59, mean (SD) 
Subscales: emotional role (ER), 
psychological well-being (PS) 
Higher scores indicate better QoL. 
NR N.s. difference between IG vs. CG for 12 and 24 months 
Pain, scales: 
KOOS15 (pain), mean (SD) 
Higher scores indicate less pain. 
At 12 months58: 
more improvements in IG than in CG 
Baseline vs. 24 months: 
s.s. difference in IG vs. CG +12.06 (95% CI 2.388-21.74, p=0.016) 
NR 
                                                             
59 There were no significant differences between the study groups regarding the postoperative change of the eight sub-categories at 12 and 24 months (data not shown). 
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Author, year [Reference] Crawford, 2012 [49] Zeifang, 2010 [23] 
VAS25, mean (SD) 
Lower scores indicate less pain. 
At 12 months: 
more improvements in IG than in CG, p=n/a 
At 24 months: 
s.s. improvements in IG vs. CG, p<0.05 
NR 
WOMAC17 pain subscale, mean (SD) NR NR 
Short Form Health Survey (SF-36, SF-12, 
SF-8)23,59, mean (SD) 
Subscale: physical pain (PA) 
Higher scores indicate less pain. 
NR Change after 12 months: IG n/a, s.s., p=0.0391 
N.s. difference between IG vs. CG for 12 and 24 months 
Necessity of total joint replacement, n (%) 1 (4.8*)60 vs. 0 (0.0) NR 
Activities of daily living 
KOOS15 (ADL) score/Return to activities NR NR 
Tegner Activity Score (TAS)26, mean (SD) 
Higher scores indicate improved ADL. 
NR Baseline vs. 12 months: 
IG: 4.1 (±2.8) vs. 4.2 (±2.0), n.s., p=0.9141 
CG: 3.7 (±1.9) vs. 4.6 (±2.0), n.s., p=0.2500 
Change after 12 months: +0.1 (±2.1) vs. +0.9 (±2.5), n.s., p=0.4063 
Baseline vs. 24 months: 
IG: 4.1 (±2.8) vs. 4.7 (±2.9), n.s., p=0.7832 
CG: 3.7 (±1.9) vs. 5.3 (±1.9), n.s., p=0.0625 
Change after 24 months: +0.6 (±2.7) vs. +1.7 (±2.o), n.s., p=0.1043 
Complete defect filling (MRI/MRT 
imaging), n (%) 
NR At 6 months: 
4/8 pts. (50.0*) vs. 1/9 pts. (11.1*) 
MOCART score27, mean (SD) 
Higher scores indicate more complete 
defect filling. 
NR At 6 months: 
7.0 (±2.7) vs. 10.3 (±1.6), s.s. better improvements for IG, p=0.0123 
At 12 months: 
6.3 (±3.5) vs. 8.4 (±2.2), n.s. difference, p=0.2065 
At 24 months: 
6.3 (±3.0) vs. 6.8 (±4.7), n.s. difference, p=0.6926 
Safety 
Complications/adverse events, n (%) Total: 62 AEs in 21 pts. (295.2*) vs. 24 AEs in 9 pts. (266.7*) 
Most common: postoperative pain, stiffness, swelling, back pain, 
arm pain, peri-incisional numbness 
Other adverse events: 
 repeat arthroscopic biopsy due to loss of autologous cartilage 
tissue implant because of a contamination: 1 (n/a) 
At 6 months: 
 Osteochondral lesion: 1 (9.0*) vs. n/a 
 Effusion: 5 (45.5*) vs. 6 (60.0*) 
At 12 months: 
 Effusion: 5 (45.5*) vs. 5 (50.0*) 
 Development of an osseous spur: n/a vs. 1 (9.0*) 
                                                             
60 Also reported as a severe adverse event. 
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Author, year [Reference] Crawford, 2012 [49] Zeifang, 2010 [23] 
Complications/adverse events, n (%) 
(continuation) 
 arthroscopic MFx of a lesion in the ipsilateral knee: 1 (n/a) 
 arthroscopic anterior cruciate ligament (ACL) reconstruction  
of the contralateral knee: 1 (n/a) 
 
Severe adverse events, n (%) IG: 1 (4.8*): 
 Case of septic arthritis in the contralateral knee after 
meniscectomy 
 Following total knee arthroplasty 
CG:  
1 (11.1*):  Cancer of gynecologic origin61 
Inability to work due to persistent problems in IG: 1 (9.0*) 
Procedure-related adverse events, n (%) 0 (0.0) vs. 0 (0.0) NR 
Device-related adverse events, n (%) NR Total: 
4 (36.4*) vs. 14 (140*) 
At 6 months: 
 Transplant delamination after 6 months: 0 (0.0) vs. 1 (10.0*)62 
 Transplant hypertrophy: 1 (10.0*) vs. 7 (63.6*) 
At 12 months: 
 Transplant hypertrophy: 3 (27.3*) vs. 6 (60.0*) 
Re-operation rate, n (%) IG: 
 Total knee arthroplasty: 1 (4.8*)63 
 Arthroscopic MFx of a lesion in the ipsilateral knee63 
 Arthroscopic anterior cruciate ligament (ACL) reconstruction  
of the contralateral knee63 
 Revision arthroscopy: 3 (27.3*) vs. 1 (10.0*), n.s., p=0.5865 
Procedure-related mortality, n (%) NR NR 
Abbreviations: AMIC autologous matrix-induced chondrogenesis; ADL Activities of daily living; EQ-5D EuroQual-5D; ICRS International Cartilage Repair Society;  
IKDC International Knee Documentation Committee; KOOS Knee Injury and Osteoarthritis Outcome Score; n number; n/a data not available; NR not reported; n.s. not significant;  
MFx microfracture; MOCART Magnetic Resonance Observation of Cartilage Repair Tissue; MRI magnetic resonance imaging; pts. patients; RCT randomised controlled trial;  
s.s. statistically significant; TAS Tegner Activity Score; VAS Visual Analogue Pain Scale; WOMAC Western Ontario and McMaster Universities Osteoarthrisits Index; yrs years; 
*Own calculations. 
 
                                                             
61 None of the severe adverse events were considered to be related to the treatment of the cartilage defect. 
62 It was not clear whether it was an osteochondritis dissecans lesion or maybe a partial ossification and delamination of the graft that was mistaken  
for an osteochondritis dissecans lesion. 
63 See AEs (general). 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[53] and in the Guidelines of EUnetHTA [10, 51]. 
 
AMIC 
Table A-5: Risk of bias – study level (non–randomised controlled studies) [11] 
Study  
reference/ID 
Bias due to 
confounding 
Bias selection  
of participants 
into the study 
Bias in 
measurement  
of intervention 
Bias due to departures 
from intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement  
of outcomes 
Bias in selection  
of the reported 
results Overall bias Comments 
Sharma, 2013 [6] Serious64 Serious65 Low Moderate66 Moderate67 Serious68 Moderate69 Serious - 
 
  
                                                             
64 Relevant baseline characteristics not comprehensively provided or controlled for. 
65 Study protocol was switched from “randomised” to “non-randomised”. Furthermore, it is unclear whether patients were recruited consecutively or not.  
66 Adherence to concomitant treatment not reported. Concomitant medication (e.g. painkillers) not reported. 
67 Values for IKDC Score were not reported (only summarised in a figure of the publication). 
68 Subjective outcome measures, patients and trial personnel aware of intervention received. 
69 No study protocol available. 
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AMIC 
Table A-6: Risk of bias – study level (randomised studies), see [51] 
Trial 
Adequate generation  
of randomisation 
sequence 
Adequate 
allocation 
concealment 
Blinding Incomplete 
outcome data 
addressed 
Free of  
selective outcome 
reporting 
Free of  
other bias 
Risk of bias 
– study level Patient Treating physician 
Kon, 2018 [47] Yes Yes No (not possible)70 No (not possible)70 No71 Unclear72 No73,74 High 
Pipino, 2018 [46] Unclear75 Unclear76 No (not possible)77 No (not possible)77 Yes Unclear72 No73 High 
Shive, 2014 [3] 
(Stanish, 2013 [5])78 
Yes79 
(Yes) 
Unclear 
(Yes) 
No (not possible)80 
(No [not possible])80 
No (not possible)80 
(No [not possible])80 
No81 
(No81) 
Yes 
(Yes) 
No73,74,82 
(No73,74) 
High 
(High) 
Volz, 2017 [7] 
(Anders, 2013 [4]) 
Yes 
(Yes) 
Yes 
(Yes) 
No (not possible)83 
(No [not possible]) 
No (not possible)83 
(No [not possible]) 
No84 
(No81) 
No85 
(No86) 
No73,74 
(No73,87) 
High 
(High) 
 
                                                             
70 No information about the blinding of patients and study personnel. A blinded radiologist carried out the postoperative MRI assessments. A blinded statistician carried out  
the analysis. An external independent agency (Contract Research Organization, CRO) was involved to ensure data correctness and objectiveness of the study results. 
71 No statistical analyses of outcomes between groups for defect regeneration; missing confidence intervals and p-values. 
72 Insufficient information; no study protocol available. 
73 No adherence of possible effect of physiotherapy/rehabilitation or pain killers. 
74 Possible conflict of interests of the authors. 
75 Insufficient information; matched pair study. 
76 Insufficient information; no description of allocation concealment. 
77 No information about the blinding of patients and study personnel. 
78 Since data for 12 months follow-up were retrieved from Stanish 2013, the risk of bias of this study was also assessed. 
79 Assuming that the same randomisation method hold for the extension study. 
80 Investigators and patients were not blinded because of differences in incision size related to treatment. However, the independent third party carrying out the analyses  
of primary endpoints was unaware of patient treatment. 
81 Missing confidence intervals and p-values. 
82 Originally, planned follow-up was 12 months and after this period the follow-up was extended to 60 months. However, there was an extra screening and enrolment  
for the extension study. 
83 No blinding of patients and study personnel, due to the comparison of a total arthroscopic procedure (MFx) to an open procedure (AMIC). 
84 No statistical analyses of outcomes between groups for 60 months follow-up; missing confidence intervals and p-values partially missing. 
85 Unclear approach for assessing Modified ICRS; no study protocol available. 
86 No study protocol. Incomprehensive safety reporting, unclear approach for assessing Modified ICRS. 
87 Data from interim analysis of an open-label trial.  
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MACI 
Table A-7: Risk of bias – study level (randomised studies), see [51] 
Trial 
Adequate generation  
of randomisation 
sequence 
Adequate 
allocation 
concealment 
Blinding Incomplete 
outcome data 
addressed 
Selective 
outcome 
reporting unlikely 
No other aspects 
which increase the 
risk of bias 
Risk of bias – 
study level Patient Treating physician 
Bartlett, 2005 [22] Yes Yes No (not possible) No (not possible) No100 Unclear101 No97, 88 High 
Basad, 2010 [48] Yes No89 No (not possible)90 No (not possible)90 No91 Yes Unclear97,92 High 
Brittberg, 2018 [9] 
(Saris, 2014 [8]) 
Yes93 
(Yes) 
Unclear93 
(Yes)94 
No (not possible)95 
(No [not possible])95 
No (not possible)95 
(No [not possible])95 
No96 
(No96) 
Yes 
(Yes) 
No88,97 
(No)88,97 
High 
Crawford, 2012 [49] Yes98 Yes No (not possible) No (not possible)99 No100 Unclear101 No88,97 High 
Zeifang, 2010 [23] Yes Yes No (not possible) No (not possible)102 No100 Yes No97,88 High 
 
 
                                                             
  88 Possible conflict of interests of the authors. 
  89 Pts. were allocated consecutive numbers in the order of their study entry. 
  90 In the discussion of the study it is reported that blinding is practically impossible in some studies. 
  91 Partially missing statistical analyses of outcomes between groups; missing confidence intervals. 
  92 For pt. criteria no information about the cartilage defect size and the clinical classification was reported.  
Moreover, no information about potential conflicts of interest and about the sponsor of the study was reported. 
  93 Assuming that the same randomisation method hold for the extension study. 
  94 Randomisation using an interactive voice response system. 
  95 Given that the surgical techniques for MACI (two surgeries) and MFx (one surgery) are different, the study could not be blinded;  
however, histological and MRI evaluations were assessor blinded. 
  96 Missing confidence intervals and p-values partially missing. 
  97 No adherence of possible effect of physiotherapy/rehabilitation or pain killers. 
  98 A permuted block design, generated by a statistician independent of the study, was utilised to minimise the opportunity for guessing the next treatment assignment. 
  99 IKDC objective data reported by one physician (no author) blinded to the treatment or by clinicians (no authors) blinded to all patient-reported subjective data scores. 
100 Partially missing statistical analyses of outcomes between groups; missing confidence intervals and partially missing p-values. 
101 Insufficient information; no study protocol available. 
102 An independent musculoskeletal radiologist blinded to the treatment groups assessed the postoperative MRI scans.  
However, the biostatistician who performed the statistical analysis was not blinded to the treatment groups. 
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GRADE evidence profiles 
AMIC 
Table A-8: Evidence profile: efficacy and safety of AMIC compared to MFx for cartilage repair in the knee 
Certainty assessment № of patients Effect 
Certainty № of 
studies 
Study  
design 
Risk  
of bias 
Inconsistency Indirectness Imprecision Other considerations AMIC MFx or ACI Relative Absolute 
Mobility/joint functionality: improvement from baseline (follow-up: mean 24 months; assessed with: IKDC; Scale from: 0 to 100) 
1  randomised 
trials  
serious a not serious b not serious  not serious  None 51  49  -  MD 1 point 
higher d 
⨁⨁⨁◯ 
MODERATE 
Mobility/joint functionality: improvement from baseline (follow-up: mean 60 months; assessed with: WOMAC stiffness; Scale from: 0 to 8) 
1  randomised 
trials  
serious a not serious b  not serous not serious  None 46 23 - MD 3.5 points 
higher d 
⨁⨁⨁◯ 
MODERATE 
Mobility/joint functionality: reduction from baseline (follow-up: mean 12 months; assessed with: WOMAC stiffness; Scale from: 0 to 20) 
1 randomised 
trials 
serious a not serious b not serous not serious None 41 39 - MD 1.1 points 
lower d 
⨁⨁⨁◯ 
MODERATE 
Mobility/joint functionality: improvement from baseline (follow-up: mean 24 months; assessed with: WOMAC physical function; Scale from: 0 to 68) 
1 randomised 
trials  
serious a not serious b not serous not serious  None 46 23  -  MD 29.7 points 
higher d 
⨁⨁⨁◯ 
MODERATE 
Mobility/joint functionality: reduction from baseline (follow-up: mean 60 months; assessed with: WOMAC physical function; Scale from: 0 to 170) 
1 randomised 
trials 
serious a not serious b not serous not serous None 41 39 - MD 5.6 points 
lower d 
⨁⨁⨁◯ 
MODERATE 
Mobility/joint functionality: reduction from baseline (follow-up: mean 12 months; assessed with: Modified Cincinnati Knee Rating System; Scale from: 0 to 100) 
1  randomised 
trials  
serious a not serious b not serious  serious f None 34  13  -  MD 6 points 
higher d 
⨁⨁◯◯ 
LOW 
Mobility/joint functionality: reduction from baseline (follow-up: mean 60 months; assessed with: SF-36; Scale from: 0 to 100) 
1  randomised 
trials  
serious a not serious b not serious  not serious  None 41  39  -  MD 1.4 points 
higher d 
⨁⨁⨁◯ 
MODERATE 
Quality of life: improvement from baseline (follow-up: mean 60 months; assessed with: SF-36; Scale from: 0 to 100) 
1  randomised 
trials  
serious a not serious b not serious  not serious  None 41  39  -  MD 2.9 points 
higher d 
⨁⨁⨁◯ 
MODERATE 
Pain: reduction from baseline (follow-up: mean 24 months; assessed with: VAS; Scale from: 0 to 100) 
1  randomised 
trials  
serious a not serious b not serious  not serious  None 51  49  -  MD 6.3 points 
higher d 
⨁⨁⨁◯ 
MODERATE 
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Certainty assessment № of patients Effect 
Certainty № of 
studies 
Study  
design 
Risk  
of bias 
Inconsistency Indirectness Imprecision Other considerations AMIC MFx or ACI Relative Absolute 
Pain: improvements from baseline (follow-up: mean 24 months; assessed with: WOMAC pain; Scale from: 0 to 20) 
1 randomised 
trials  
serious a not serious  not serous not serous None 46 23  -  MD 12.0 points 
higher d 
⨁⨁⨁◯ 
MODERATE 
Pain: improvements from baseline (follow-up: mean 60 months; assessed with: WOMAC pain; Scale from: 0 to 50) 
1 randomised 
trials 
serious a not serious not serious not serious None 41 39 - MD 1.2 points 
lower d 
⨁⨁⨁◯ 
MODERATE 
Necessity of total joint replacement (assessed with: in % of pts.) 
1 randomised 
trials  
serious a not serious b not serious  not serious  None At 12 months: 1 total knee arthroplasty  
(study group n/a). 
⨁⨁⨁◯ 
MODERATE 
Safety: Severe adverse events (follow-up: range 24 months to 60 months; assessed with: in % of pts.) 
3 randomised 
trials  
serious a serious g not serious  serious h None 8/126 
(6.3%)  
3/101 
(3.0%)  
RR 2.1 d 33 more  
per 1,000 
⨁◯◯◯ 
VERY LOW 
Safety: Procedure-related adverse events (follow-up: range 24 months to 60 months; assessed with: in % of pts.) 
3 randomised 
trials  
serious a serious g not serious  serious h None 48/126 
(38.1%)  
35/101 
(34.7%)  
RR 1.1 d 35 more  
per 1,000  
⨁◯◯◯ 
VERY LOW 
Safety: Device-related adverse events (follow-up: range 24 months to 60 months; assessed with: in % of pts.) 
2 randomised 
trials  
serious a not serious  not serious  not serious  None 12/92 
(13.0%)  
0/88 
(0.0%)  
not 
estimable  
- ⨁⨁⨁◯ 
MODERATE 
Safety: Re-operation rate (follow-up: range 12 months to 60 months; assessed with: in % of pts.) 
2 randomised 
trials  
serious a not serious  not serious  serious h None 1/75  
(1.3%)  
2/52  
(3.8%)  
RR 0.34 d 25 fewer  
per 1,000 
⨁⨁◯◯ 
LOW 
Abbreviations: CI confidence interval; MD mean difference; RR risk ratio 
Comments 
a There was a serious risk of bias due to possible confounding, missing data,  
and the use of un-blinded patient-reported outcome measures.  
b Heterogeneity in reported cases across studies.  
d Based on self-calculated mean difference between study groups/relative risk.  
e Different age of pts. between studies.  
f Low incidence/pts. numbers.  
g Heterogeneity in reported cases across studies.  
h Low incidence/pts. numbers in one study. 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1) 
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MACI 
Table A-9: Evidence profile: efficacy and safety of MACI compared to MFx or ACI for cartilage repair in the knee 
Certainty assessment № of patients Effect 
Certainty № of 
studies 
Study  
design 
Risk  
of bias 
Inconsistency Indirectness Imprecision Other considerations MACI MFx or ACI Relative Absolute 
Mobility/joint functionality: improvement from baseline (follow-up: mean 60 months; assessed with: KOOS sport/rec; Scale from: 0 to 100) 
2  randomised 
trials  
serious a serious b serious c serious d None 86  72  - MD 8.1 points 
higher f,g 
⨁◯◯◯ 
VERY LOW  
Mobility/joint functionality: reduction from baseline (follow-up: mean 24 months; assessed with: IKDC; Scale from: 0 to 100) 
3  randomised 
trials  
serious a serious b serious c serious h None 97  82  - MD 2.4 points 
higher f 
⨁◯◯◯ 
VERY LOW  
Mobility/joint functionality: improvement from baseline (follow-up: range 12 months to 60 months; assessed with: Modified Cincinnati Knee Scoring System; Scale from: 0 to 100) 
2  randomised 
trials  
serious a serious b not serious  not serious  None 112  107  - MD 1.5 points 
higher f 
⨁⨁◯◯ 
LOW 
Mobility/joint functionality: improvement from baseline (follow-up: mean 24 months; assessed with: Lysholm scoring scale; Scale from: 0 to 100) 
2  randomised 
trials  
serious a serious b not serious  serious d None 51  30  - MD 2.3 points 
higher f 
⨁◯◯◯ 
VERY LOW 
Mobility/joint functionality: improvement from baseline (follow-up: mean 2 months; assessed with: SF-36; Scale from: 0 to 100) 
1 o randomised 
trials  
serious a not serious i not serious  serious d None At 12/24 months n.s. difference between study groups. ⨁⨁◯◯ 
LOW 
Quality of life: improvement from baseline (follow-up: mean 60 months; assessed with: KOOS QoL; Scale from: 0 to 100) 
2  randomised 
trials  
serious a serious b serious c serious d None 86  72  - MD 4.6 points 
higher f,g 
⨁◯◯◯ 
VERY LOW  
Quality of life: improvement from baseline (follow-up: mean 60 months; assessed with: EQ-5D; Scale from: 0 to 100) 
1  randomised 
trials  
serious a not serious i not serious  not serious  None 65  63  - MD 1 point 
higher f 
⨁⨁⨁◯ 
MODERATE 
Quality of life: reduction from baseline (follow-up: mean 24 months; assessed with: SF-36; Scale from: 0 to 100) 
1 0 randomised 
trials  
serious a not serious i not serious  serious d None At 12/24 months n.s. difference between study groups. ⨁⨁◯◯ 
LOW 
Pain: improvement from baseline (follow-up: mean 60 months; assessed with: KOOS pain; Scale from: 0 to 100) 
2  randomised 
trials  
serious a serious b serious c serious d None 86  72  - MD 5.5 points 
higher f,g 
⨁◯◯◯ 
VERY LOW  
Pain: improvement from baseline (follow-up: N/A; assessed with: VAS; Scale from: 0 to 100) 
2  randomised 
trials  
serious a serious b serious c serious d None 68  53  - MD 0.2 points 
higher f,j 
⨁◯◯◯ 
VERY LOW  
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Certainty assessment № of patients Effect 
Certainty № of 
studies 
Study  
design 
Risk  
of bias 
Inconsistency Indirectness Imprecision Other considerations MACI MFx or ACI Relative Absolute 
Pain: (follow-up: mean 24 months; assessed with: SF-12, SF-36) 
1  randomised 
trials  
serious a not serious i not serious  serious k None n.s. difference between IG vs. CG for 12 and 24 months. ⨁⨁◯◯ 
LOW 
Necessity of total joint replacement (assessed with: in % of pts.) 
1  randomised 
trials  
serious a not serious i not serious  serious k None 1/21  
(4.8%)  
0/9  
(0.0%)  
not 
estimable  
- ⨁⨁◯◯ 
LOW 
Safety: Severe adverse events (follow-up: range 24 months to 60 months) 
5  randomised 
trials  
serious a serious b serious c serious h None 2/184 
(1.1%)  
1/146 
(0.7%)  
RR 1.57 f 4 more  
per 1,000 
⨁◯◯◯ 
VERY LOW  
Safety: Procedure-related adverse events 
1 l randomised 
trials  
serious a not serious i not serious serious k None 0/21 
(0.0%)  
0/9  
(0.0%)  
not 
estimable  
- ⨁⨁◯◯ 
LOW 
Safety: Device-related adverse events (follow-up: range 6 months to 24 months) 
2p randomised 
trials  
serious a serious b serious c serious d None 10/58 
(17.2%)  
18/54 
(33.3%)  
RR 0.52 f 160 fewer  
per 1,000 m 
⨁◯◯◯ 
VERY LOW  
Safety: Re-operation rate (follow-up: mean 24 months) 
5  randomised 
trials  
serious a serious b serious c serious h None 8/184 
(4.3%)  
4/146 
(2.7%)  
RR 1.59 f 16 more  
per 1,000 n 
⨁◯◯◯ 
VERY LOW  
Abbreviations: CI confidence interval; RR risk ratio 
Comments: 
a There was a serious risk of bias due to possible confounding, missing data,  
and the use of un-blinded patient-reported outcome measures.  
b Heterogeneity in reported cases across studies.  
c Different defect size in pts. between studies.  
d Low incidence/pts. numbers in one study.  
f Based on self-calculated mean difference between study groups/relative risk. 
g Absolute effect based on one study (Brittberg 2018).  
h Low incidence/pts. numbers in two studies.  
i N/A (only one trial). 
j Absolute effect based on one study (Bartlett 2005).  
k Low incidence/pts. numbers.  
l Absolute numbers for adverse events given only in one study.  
m Absolute effect based on three studies.  
n Absolute effect based on four studies.  
o In one RCT [9], negative scores of the SF-12, which were not translated on a 0-100 score, were reported.  
Thus, the reported negative values could not be interpreted and this study could not be graded for this outcome. 
p For device-related adverse events only the studies with ACI as the comparator were considered. 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1) 
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Applicability table 
Table A-10: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population All studies included patients with (osteo)chondral defects in the knee. The patients had defects 
grades 3-4 of the Outerbridge Classification (stated in four studies) or grade-III of the ICRS 
classification (stated in one study). Across all studies, male patients were included more frequently. 
The mean age of patients was 35.9 years in the AMIC studies and 34.5 years in the MACI studies.  
One of the AMIC studies included patients with a slightly higher age (55.6 years), which is likely to 
have influenced the effects of the intervention. The studies included a total of 187 patients with the 
AMIC intervention vs. 127 with MFx and 184 patients with the MACI intervention vs. 92 with MFx or 
54 with ACI. The inclusion criteria and the population in the studies seem to be in accordance with 
the intended patient population for the technology. 
There was no study that included patients with (osteo)chondral defects in the talus. 
Intervention The implantations of the scaffolds, either single-step or two-step, were either performed  
by miniarthrotomy or by an arthroscopy. In all studies, it was stated that patients received 
postoperative physiotherapy or rehabilitation. 
AMIC studies: Patients in the included studies received Chondro-Gide®, MaioRegenTM, JointRepTM  
or BST-CarGel®. In one study, it was not stated which product was used; however, based on the 
compounds, it could have been GelrinC®. 
MACI studies: Patients in the included studies received NeoCart®, BioSeed®-C, ACI-MaixTM or 
MACITM. In one study, it was not stated which product was used. 
Comparators AMIC studies: In all studies, the control groups received microfracture alone. 
To date, there are no published studies in which the single-step scaffold-assisted treatment  
of cartilage defects in combination with microfracture has been compared with autologous 
chondrocyte implantation (ACI). 
MACI studies: In three studies the control groups received microfracture and in two studies the 
control groups received autologous chondrocyte implantation (ACI). 
Outcomes A range of clinically relevant outcome criteria was applied in the studies and have shown objective 
and/or subjective benefits from single-step scaffold-based cartilage repair (AMIC) or the two-step 
scaffold-based cartilage repair (MACI). The most reported outcomes for the assessment of the 
efficacy were mobility/joint functionality, pain and quality of life. For the assessment of safety, 
severe complications, procedure-, and/or device-related adverse events, as well as re-operation rates, 
were recorded. 
However, the presented data in the studies is limited, especially due to small study samples, partly 
short time horizons for follow-up, various scoring systems for efficacy outcomes between studies 
and obviously different approaches to the reporting/recording of complications (becoming apparent 
in a high variability in complication rates between studies). 
Setting AMIC studies: With two exceptions, the studies were carried out in Europe: Germany, Italy, and the 
Netherlands. Two studies were multi-centre studies carried out in (1) Canada, Spain and South Korea, 
and in (2) 9 European countries and South Africa. 
MACI studies: With one exception, the studies were carried out in Europe: Germany, England as well 
as 7 European countries (not specified). The latter was a multi-centre study. One study was carried 
out in the USA. 
Patients were recruited and the operations were performed at orthopaedic centres. Study centres 
had experience in the technology used, as well as in clinical research in general. 
The settings of the studies reflect the clinical setting in which the technology is intended to be used 
in an appropriate way. No applicability issues are expected from the geographical setting. 
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List of ongoing randomised controlled trials 
Table A-11: List of ongoing randomised controlled trials 
Identifier/ 
Trial name Patient population Intervention Comparison 
Primary  
Outcome 
Primary  
completion date Sponsor 
NCT01656902103 Pts. with localised articular cartilage 
defect of the femoral condyle or the 
trochlea of the knee 
NOVOCART® 3D plus 
(MACI) 
Microfracture Subjective IKDC score baseline  
vs. 36 months follow-up 
May 2019 Tetec – Tissue 
Engineering 
Technologies – AG 
EUCTR2011-
005798-22-DE103 
Pts. with localised, full-thickness 
cartilage defects of the femoral 
condyle (medial, lateral or trochlea) 
NOVOCART® 3D plus 
(MACI) 
Microfracture Safety and Effectiveness NR TETEC – Tissue 
Engineering 
Technologies – AG 
NCT02659215 
FastTRACK 
Pts. with symptomatic lesion  
of the femoral condyle  
(medial and/or lateral) or femoral 
trochlea images confirmed 
Hyalofast® 
(AMIC) 
Microfracture % change in Knee injury and 
Osteoarthritis Outcome (KOOS) 
Pain Score for 2-year follow-up 
December 2020 Anika Therapeutics, 
Inc. 
NCT01957722 Pts. with isolated articular cartilage 
lesions on the femoral condyle 
NOVOCART® 3D 
(AMIC) 
Microfracture Pain and function change  
from baseline to 24 months with 
KOOS score 
July 2019 Aesculap Biologics, LLC 
NCT03307668 Pts. with diagnosed isolated knee 
cartilage defects in condyles of femur 
by arthroscopy 
CaReS®-1S 
(AMIC) 
Microfracture Difference of Magnetic resonance 
observation of cartilage repair 
tissue (MOCART) score between 
two groups after 12 months 
December 2019 Arthro-Anda Tianjin 
Biologic Technology 
Co., Ltd. 
NCT01222559 Pts. with isolated ICRS grade III or IV 
single defect chondral lesions on 
femoral condyles 
co.don 
chondrosphere® 
(AMIC) 
Microfracture Change of overall KOOS after  
24 months 
September 2017 co.don AG 
EUCTR2017-
002601-35-CZ 
Pts. with symptomatic knee articular 
cartilage defects 
Chondrograft® 
(AMIC) 
Microfracture Effectiveness and Safety NR PrimeCell Advanced 
Therapy a.s. 
 
 
                                                             
103 These studies may be connected and may represent the same results. 
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Literature search strategies 
Search strategy for Cochrane 
Search date: 07/12/2018 
ID Search 
#1 MeSH descriptor: [Cartilage Diseases] explode all trees 
#2 cartilage near (damage* or disorder* or defect* or lesion* or disease*) (Word variations have been searched) 
#3 MeSH descriptor: [Cartilage, Articular] explode all trees and with qualifier(s):  
[abnormalities – AB, injuries – IN, pathology – PA, physiology – PH, physiopathology – PP] 
#4 #1 or #2 or #3 
#5 MeSH descriptor: [Knee Joint] explode all trees 
#6 Knee* (Word variations have been searched) 
#7 MeSH descriptor: [Ankle Joint] explode all trees 
#8 Ankle* 
#9 MeSH descriptor: [Knee Injuries] explode all trees 
#10 MeSH descriptor: [Ankle Injuries] explode all trees 
#11 MeSH descriptor: [Knee] explode all trees 
#12 MeSH descriptor: [Ankle] explode all trees 
#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 
#14 #4 and #13 
#15 MeSH descriptor: [Osteochondritis Dissecans] explode all trees 
#16 osteochondritis dissecans (Word variations have been searched) 
#17 OCD:ti,ab,kw (Word variations have been searched) 
#18 osteochondr* near (damage* or disorder* or defect* or lesion* or disease*)  
(Word variations have been searched) 
#19 #15 or #16 or #17 or #18 
#20 #14 or #19 
#21 MeSH descriptor: [Chondrogenesis] explode all trees 
#22 autologous near chondrogenes* (Word variations have been searched) 
#23 (Matri* NEAR (Chondrogenes* OR Chondrocyte*)) (Word variations have been searched) 
#24 AMIC (Word variations have been searched) 
#25 osteochondral regeneration* (Word variations have been searched) 
#26 OCD regeneration (Word variations have been searched) 
#27 MeSH descriptor: [Transplantation, Autologous] explode all trees 
#28 (Matri*) (Word variations have been searched) 
#29 (#27 AND #28) (Word variations have been searched) 
#30 (Matri* NEAR (autologous chondrocyte* NEAR (implant* or transplant*)))  
(Word variations have been searched) 
#31 (MACI):ti,ab,kw (Word variations have been searched) 
#32 (MACT):ti,ab,kw (Word variations have been searched) 
#33 Chondro-Gide (Word variations have been searched) 
#34 Chondrotissue (Word variations have been searched) 
#35 Chondro-Tissue (Word variations have been searched) 
#36 Hyalofast (Word variations have been searched) 
#37 MaioRegen (Word variations have been searched) 
#38 (CaRes-1S) (Word variations have been searched) 
#39 (Gelrin*) (Word variations have been searched) 
#40 (BST-Car*) (Word variations have been searched) 
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#41 (Novocart*) (Word variations have been searched) 
#42 (MeRG) 
#43 (Chondrofiller*) (Word variations have been searched) 
#44 (JointRep*) (Word variations have been searched) 
#45 (Spherox*) (Word variations have been searched) 
#46 (BioSeed*) (Word variations have been searched) 
#47 #21 or #22 or #23 or #24 or #25 or #26 or #29 #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 
OR 39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 (Word variations have been searched) 
#48 #20 and #47 in Trials 
#31 (MACI):ti,ab,kw (Word variations have been searched) 
#32 (MACT):ti,ab,kw (Word variations have been searched) 
#33 Chondro-Gide (Word variations have been searched) 
#34 Chondrotissue (Word variations have been searched) 
#35 Chondro-Tissue (Word variations have been searched) 
#36 Hyalofast (Word variations have been searched) 
#37 MaioRegen (Word variations have been searched) 
#38 (CaRes-1S) (Word variations have been searched) 
#39 (Gelrin*) (Word variations have been searched) 
#40 (BST-Car*) (Word variations have been searched) 
#41 (Novocart*) (Word variations have been searched) 
#42 (MeRG) 
#43 (Chondrofiller*) (Word variations have been searched) 
#44 (JointRep*) (Word variations have been searched) 
#45 (Spherox*) (Word variations have been searched) 
#46 (BioSeed*) (Word variations have been searched) 
#47 #21 or #22 or #23 or #24 or #25 or #26 or #29 #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 
OR 39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 (Word variations have been searched) 
#48 #20 and #47 in Trials 
Total: 165 Hits 
 
Search strategy for CRD 
Search Date: 10/12/2018 
#1 (Chondrogenesis) 
#2 (autologous NEAR chondrogenes*) 
#3 (Matrix-Induced Chondrogenesis) 
#4 (AMIC) 
#5 (osteochondral regeneration*) 
#6 (OCD regeneration) 
#7 (Chondro-Gide) 
#8 (Chondrotissue) 
#9 (Chondro-Tissue) 
#10 (Hyalofast) 
#11 (MaioRegen) 
#12 (CaRes-1) 
#13 (BST-Car*) 
#14 (Gelrin*) 
#15 (Novocart*) 
#16 (MeRG) 
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#17 (Chondrofiller*) 
#18 (JointRep*) 
#19 (Spherox*) 
#20 (BioSeed*) 
#21 MeSH DESCRIPTOR Transplantation, Autologous EXPLODE ALL TREES 
#22 (Matri*) 
#23 #21 AND #22 
#24 (Matri* NEAR (autologous OR chondrocyte* OR implant* OR transplant*)) 
#25 (MACI) 
#26 (MACT) 
#27 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR 
#16 OR #17 OR #18 OR #19 OR #20 OR #23 OR #24 OR #25 OR #26 
Total: 25 Hits 
 
Search strategy for Embase 
No. Query Results Results Date 
#57. #54 OR #56 102 7 Dec 2018 
#56. #53 AND #55 96 7 Dec 2018 
#55. 'crossover procedure':de OR 'double-blind procedure':de OR 'randomized controlled 
trial':de OR 'single-blind procedure':de OR random*:de,ab,ti OR factorial*:de,ab,ti 
OR crossover*:de,ab,ti OR ((cross NEXT/1 over*):de,ab,ti) OR placebo*:de,ab,ti OR 
((doubl* NEAR/1 blind*):de,ab,ti) OR ((singl* NEAR/1 blind*):de,ab,ti) OR 
assign*:de,ab,ti OR allocat*:de,ab,ti OR volunteer*:de,ab,ti 
2,328,003 7 Dec 2018 
#54. #18 AND #52 AND ([controlled clinical trial]/lim OR [randomized controlled 
trial]/lim) 
26 7 Dec 2018 
#53. #18 AND #52 598 7 Dec 2018 
#52. #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #31 OR #32 OR #33 OR #34 OR 
#35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR 
#45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 
2,331 7 Dec 2018 
#51. bioseed* 80 7 Dec 2018 
#50. 'spherox*' 7 7 Dec 2018 
#49. 'joint rep*':dn,df 9 7 Dec 2018 
#48. chondrofiller* 3 7 Dec 2018 
#47. merg:ti,ab 140 7 Dec 2018 
#46. novocart* 39 7 Dec 2018 
#45. 'gelrin*' 10 7 Dec 2018 
#44. 'bstcar*' 7 7 Dec 2018 
#43. 'bst car*' 50 7 Dec 2018 
#42. cares:df 1 7 Dec 2018 
#41. cares:dn 32 7 Dec 2018 
#40. maioregen* 27 7 Dec 2018 
#39. hyalofast* 11 7 Dec 2018 
#38. 'chondro tissue*' 3 7 Dec 2018 
#37. chondrotissue* 20 7 Dec 2018 
#36. 'chondrogide*' 29 7 Dec 2018 
#35. 'chondro-gide*' 77 7 Dec 2018 
#34. mact:ti,ab 222 7 Dec 2018 
#33. maci:ti,ab 298 7 Dec 2018 
#32. (('matri*-induc*' OR 'matri*-appli*' OR 'matri*-associat*' OR 'matri*-assist*') 
NEAR/5 ('autologous chondrocyte*' OR implant* OR transplant*)):ti,ab,de 
563 7 Dec 2018 
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#31. #29 AND #30 790 7 Dec 2018 
#30. matri*:ti,ab,de 517,666 7 Dec 2018 
#29. 'autotransplantation'/exp 30,282 7 Dec 2018 
#28. 'ocd regeneration' 2 7 Dec 2018 
#27. 'osteochondral regeneration':ti,ab,de 118 7 Dec 2018 
#26. amic:ti,ab 312 7 Dec 2018 
#25. (('matri*-induc*' OR 'matri*-appli*' OR 'matri*-associat*' OR 'matri*-assist*') 
NEAR/5 (chondrogenes* OR chondrocyte*)):ti,ab,de 
491 7 Dec 2018 
#24. (autologous NEAR/5 chondrogenes*):ti,ab,de 146 7 Dec 2018 
#23. #19 AND #22 9 7 Dec 2018 
#22. #20 OR #21 2,613 7 Dec 2018 
#21. 'collagen'/exp/dd_dt,dd_ad 2,613 7 Dec 2018 
#20. 'collagen'/exp/dm_dt,dm_th 2,200 7 Dec 2018 
#19. 'chondrogenesis'/exp 9,461 7 Dec 2018 
#18. #12 OR #17 34,253 7 Dec 2018 
#17. #13 OR #14 OR #15 OR #16 20,292 7 Dec 2018 
#16. (osteochondr* NEAR/5 (damage* OR disorder* OR defect* OR lesion* OR 
disease*)):ti,ab,de 
6,718 7 Dec 2018 
#15. ocd:ti,ab 12,197 7 Dec 2018 
#14. 'osteochondritis dissecans':ti,ab,de 3,062 7 Dec 2018 
#13. 'osteochondritis dissecans'/exp 2,541 7 Dec 2018 
#12. #4 AND #11 16,356 7 Dec 2018 
#11. #5 OR #6 OR #7 OR #8 OR #9 OR #10 284,302 7 Dec 2018 
#10. 'ankle injury'/exp 12,986 7 Dec 2018 
#9. 'knee injury'/exp 30,570 7 Dec 2018 
#8. ankle*:ti,ab,de 87,803 7 Dec 2018 
#7. 'ankle'/exp 31,394 7 Dec 2018 
#6. knee*:ti,ab,de 213,273 7 Dec 2018 
#5. 'knee'/exp 63,468 7 Dec 2018 
#4. #1 OR #2 OR #3 67,853 7 Dec 2018 
#3. 'articular cartilage'/mj 11,920 7 Dec 2018 
#2. (cartilage NEAR/5 (damage* OR disorder* OR 24,645 7 Dec 2018 
#1. 'chondropathy'/exp/mj 39,431 7 Dec 2018 
 
Search strategy for Medline via OVID 
Database: Ovid MEDLINE(R) <1946 to November Week 5 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<December 06, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 06, 2018>,  
Ovid MEDLINE(R) Daily Update <December 06, 2018> 
Search Strategy: 
1 exp Cartilage Diseases/ (12449) 
2 (cartilage adj5 (damage* or disorder* or defect* or lesion* or disease*)).mp. (16307) 
3 exp *Cartilage, Articular/ab, in, pa, ph, pp [Abnormalities, Injuries, Pathology, Physiology, Physiopathology] 
(7539) 
4 1 or 2 or 3 (28870) 
5 exp Knee Joint/ (55377) 
6 Knee*.mp. (154628) 
7 exp Ankle Joint/ (14535) 
8 Ankle*.mp. (61360) 
9 exp Knee Injuries/ (23319) 
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10 exp Ankle Injuries/ (9262) 
11 5 or 6 or 7 or 8 or 9 or 10 (205925) 
12 4 and 11 (9203) 
13 exp Osteochondritis Dissecans/ (1518) 
14 osteochondritis dissecans.mp. (2255) 
15 OCD.mp. (8547) 
16 (osteochondr* adj5 (damage* or disorder* or defect* or lesion* or disease*)).mp. (4829) 
17 13 or 14 or 15 or 16 (14337) 
18 12 or 17 (22175) 
19 exp Chondrogenesis/ (4544) 
20 exp *Collagen/ad, tu [Administration & Dosage, Therapeutic Use] (2867) 
21 19 and 20 (12) 
22 (autologous adj10 chondrogenes*).mp. (115) 
23 ((Matri*-Induc* or Matri*-appli* or Matri*-associat* or Matri*-assist*) adj10 (Chondrogenes* or 
Chondrocyte*)).mp. (378) 
24 AMIC.mp. (255) 
25 osteochondral regeneration*.mp. (100) 
26 OCD regeneration.mp. (2) 
27 exp Transplantation, Autologous/ (47796) 
28 Matri*.mp. (441072) 
29 27 and 28 (1025) 
30 ((Matri*-induc* or Matri*-appli* or Matri*-associat* or Matri*-assist*) adj5 autologous chondrocyte* adj5 
(implant* or transplant*)).mp. (245) 
31 MACI.ti,ab. (203) 
32 MACT.ti,ab. (168) 
33 Chondro?Gide*.mp. (9) 
34 Chondrotissue*.mp. (5) 
35 Chondro-Tissue*.mp. (1) 
36 Hyalofast*.mp. (1) 
37 MaioRegen*.ti,ab. (10) 
38 CaRes-1S.mp. (3) 
39 BST-Car*.mp. (17) 
40 Gelrin*.mp. (2) 
41 Novocart*.mp. (16) 
42 MeRG.mp. (92) 
43 Chondro?filler*.mp. (1) 
44 JointRep*.mp. (1) 
45 Spherox*.mp. (3) 
46 BioSeed*.mp. (22) 
47 21 or 22 or 23 or 24 or 25 or 26 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 
or 43 or 44 or 45 or 46 (1895) 
48 18 and 47 (466) 
49 limit 48 to clinical trial, all (40) 
50 ((randomized controlled trial or controlled clinical trial).pt. or randomi#ed.ab. or placebo.ab. or drug 
therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.) (3757380) 
51 48 and 50 (92) 
52 49 or 51 (111) 
53 remove duplicates from 52 (111) 
Search date: 07/12/2018 
 

  
 
